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Post-epidemic surveillance is a necessary component in the process by which areas having ex¬
perienced epidemic or endemic animal disease gain a 'disease-free' status. Whilst it is useful
to rapidly and surely regain this status, surveillance uses expensive resources and imposes a
time delay on regaining disease-freedom. It is beneficial to design and analyse surveillance to
maximise efficiency and use data effectively. This thesis addresses issues of surveillance design
and analysis in the context of demonstration of disease freedom after foot-and-mouth disease
(FMD) epidemics or outbreaks. International regulations require the process of demonstrating
disease freedom to include a serological survey of livestock after the epidemic has apparently
ended. Currently, animal holdings are sampled from randomly to achieve a defined probability
of detecting disease, if present in the region. Using a risk model applied to demographic and
epidemic data from the Devon UK 2001 FMD outbreak, I estimate the efficiency gains of risk
based sampling compared to random sampling. With this technique farms at a high risk of har¬
bouring undiscovered infection are selectively targeted for sampling. This approach is robust to
model errors and reduces the number of farms to be sampled from 1083 to 225 to achieve a 95%
level of confidence that the area is disease free. Additionally, using the risk model to order the
sampling of farms will reduce delays to declaration of disease-freedom by approximately 11 days
on average. The Thrace region of Turkey is a buffer zone between the rest of Europe, which
is generally FMD free, and Anatolian Turkey, which has endemic FMD. A EU/FAO funded
project vaccinates and serologically tests Thrace's livestock. This provides a data set for the
exploration of survey analysis techniques. The testing is for the purpose of demonstrating dis¬
ease freedom so Turkey may join the European Union. Using a stochastic model simulating
different disease scenarios and diagnostic test performances I evaluate the current sampling
strategy. It generally satisfies the sensitivity requirement to detect disease in the area. However
the initial specificity is low, resulting in a high rate of false positive classifications of villages,
requiring the use of confirmatory tests. I describe the results from three surveys in 2005-2006
and adjust for an apparent shift in test result datum over the period. The results are then used
to parameterise a multilevel, mixture model of FMD in Thrace. Estimates from this model sug¬
gest a high village-level prevalence of disease with high variability of within-village prevalence.
The temporal changes are compatible with the reported FMD outbreaks though the absolute
estimates are much higher than expected from outbreak data. I suggest that there may be
relatively few truly exposed villages with the large number of apparently exposed villages the
consequence of imperfect diagnostic test specificity in the vaccinated population. Post-epidemic
surveillance relies on serological and clinical surveillance. I develop a simulation model based
on a within-group stochastic model and models of stockholder observation and diagnostic test
response to estimate the time varying results of clinical surveillance and the additional benefits
of serological surveillance. This quantifies current belief that serological surveillance should be
focused on more extensive production systems. The additional benefits of serological surveil¬
lance are greatest in poorly observed, sparse outbreaks allowing, in the simulated scenarios,
disease freedom to be declared in animal groups 15-33 days sooner than by clinical observation
alone.
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This thesis considers elements of the design and analysis of post-epidemic surveillance
in the context of foot-and-mouth disease. This chapter provides a background on
general issues of disease surveillance and the specific issues pertaining to post-epidemic
foot-and-mouth disease surveillance.
Chapter 2 considers a risk model based approach to post-epidemic serological surveil¬
lance for foot-and-mouth disease. In this I propose that the aims of post-epidemic
surveillance may be more economically and more quickly met by applying risk based
rather than random selection based criteria to the surveillance of a previously diseased
region.
The Thrace region of Turkey is a buffer between the, foot-and-mouth disease endemic,
Anatolian region of Turkey and, foot-and-mouth disease-free, Europe. There is an
ongoing vaccination and serological testing programme in Thrace to control foot-and-
mouth disease incursions and to monitor foot-and-mouth disease control. In chapter
3, I use a simulation model to evaluate the probable efficacy of the ongoing testing
programme. Data are available from three region-wide serological surveys. In chapter
4, I explore these data and apply a calibration to the diagnostic test results and in
chapter 5, I use a Bayesian, multilevel, mixture model to make inferences about the
epidemiology of foot-and-mouth disease in Thrace. I also discuss the limitations of
using data from disease-freedom surveillance for more general inference.
1
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Alongside serological surveillance there will always be implicit clinical surveillance of
livestock after a disease outbreak or epidemic. In chapter 6, I combine individually
based stochastic models of within herd epidemiology with simulation models of clinical
and serological surveillance to examine the relative performance of these systems.
Chapter 7, the general discussion, collates the major findings of the thesis and considers




Foot-and-mouth disease was first described in 1546 by a monk, Hieronymous Fracasto-
rius, in his observations of an epidemic in the cattle near Verona, Italy [Mahy, 2005].
The causative agent, foot-and-mouth disease virus was discovered in the late nine¬
teenth century by Friedrich Loeffler and Paul Frosch [Mahy, 2005]. They observed that
fluid from infected animals remained infectious when passed through sub-bacteria sized
filters. This was the first recorded description of a viral disease of animals. Foot-and-
mouth disease occurs throughout much of the world, including parts of Europe, Africa,
Asia, and South America. In the UK it was first recorded in 1839 where it remained
endemic until the 1880s. After a period of absence, foot-and-mouth disease returned to
the UK in the year 1900 with a total of 21 outbreaks followed by a further 12 outbreaks
in 1901 and a single case in 1902. There was then a period of disease-freedom until
1908, with a major epidemic in 1922-24. Foot-and-mouth disease remained present in
the UK until 1962. During this period, investigation of transmission of the foot-and-
mouth disease virus informed a number of control policies including restriction of meat
imports from endemic countries and regulations to require the boiling of food waste fed
as swill to pigs. These strategies, in combination with control measures in neighbour¬
ing countries, eliminated foot-and-mouth disease from the UK by 1962 [DEFRA, 2009].
Since then there have been two major UK epidemics; one in 1967-68, thought have
arisen from the feeding of Argentinean lamb bones to pigs, involving the slaughter of
400,000 animals [Anon, 1969]. And more recently an epidemic in 2001, thought to have
arisen from feeding of catering waste (possibly derived from illegally imported meat) to
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pigs, with 2030 farms classified as infected and involving the culling of approximately
4 million animals [Anderson, 2002], The estimated direct costs to agriculture and food
production were £ 3.1 billion. The indirect losses to tourism and other industries were
estimated at £ 2.7 - 3.2 billion [Francis et ah, 2002].
In August 2007 the accidental release of foot-and-mouth disease contaminated material
from a research laboratory and vaccine manufacturing plant in Surrey caused the UK's
most recent foot-and-mouth disease outbreak. A total of 8 infected premises were
identified between the 2nd of August and the 30t/l of September. After widespread
serological testing of stock the EU permitted trade from 31 st December and the World
Animal Health Organisation (OIE) declared the UK as once more free of foot-and-
mouth disease on the 22nd of February [Anderson, 2008].
1.2.2 Virology
Foot-and-mouth disease is a highly contagious, usually non-fatal disease of cloven-
hoofed animals. The disease is caused by a non-enveloped virus of the family Pi-
cornaviridae. These are single-stranded, positive sense, RNA viruses, about 30nm
diameter. It is of the Apthovirus genus as it is acid labile. It exists in seven distinct
serotypes: O, A, C, South African Territories (SAT) 1, SAT 2, SAT 3 and Asia 1, most
of them with many subtypes [Kitching et ah, 1989]. It is also subdivided into topo-types
e.g. foot-and-mouth disease virus Type O has eight topo-types. As an RNA virus foot-
and-mouth disease virus mutates rapidly. A study of the UK 2001 epidemic estimated
a mean 4.3 nucleotide base changes between each separate infected farm [Cottam et ah,
2008a]. This property has been exploited in the molecular epidemiology of the disease
whereby a substitution history can be used to connect sampled virus in an epidemic
tree [Bastos et ah, 2003; Bronsvoort et ah, 2004; Cottam et ah, 2008a,b]. Infection or
vaccination with one serotype, or in some cases even a different sub-type of the same
serotype, does not confer immunity against another [Mahy, 2005]. The different foot-
and-mouth disease serotypes/topo-types have differing transmission characteristics and
host susceptibilities; the widely distributed, Pan Asian O topo-types responsible for the
UK 2001 epidemic being considered 'aggressive' and difficult to control by vaccination
[Mahy, 2005].
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1.2.2.1 Virus Properties
The foot-and-mouth disease virus is relatively temperature and pH sensitive. It survives
for up to one year at 4°C but only for 10 days at 37°C. It is rapidly inactivated by pH of
less than 6 or above 9 making disinfection with citric acid or caustic soda convenient and
economical bio-security measures [AVIS Consortium, 2002]. Foot-and-mouth disease
virus is resistant to iodophores, quaternary ammonium compounds, hypo-chlorite and
phenol, especially in the presence of organic matter. Survival times in the environment
are largely dependant on moisture content of the medium; the virus will survive in
slurry for up to 6 months but only for 14 days in dry faeces. Survival times in soil
range from 3 days in the summer to 28 in the winter [Alexandersen et al., 2003].
1.2.3 Hosts
Foot-and-mouth disease infects a wide range of domesticated and wild species. Eco¬
nomically important domestic species include cattle, sheep, goats, pigs and buffalo.
Wildlife species include deer, hedgehogs and rats. A complete list is available from the
AVIS Consortium website [AVIS Consortium, 2002]. Additionally there are anecdotal
reports of a very small number of reported cases of foot-and-mouth disease infecting
humans with claims that two people died from the disease in the UK in 1884 [Jeffery,
2001]. Generally the disease is considered to be of minor direct consequence to human
health [National Health Service, 2008].
1.2.4 Clinical Illness
The incubation period is 2-14 days from inoculation to first appearance of clinical signs.
These signs vary in severity between species and with serotype of virus [Alexandersen
et al., 2003] and [Mahy, 2005]:
Signs in Cattle
Foot-and-mouth disease in cattle is normally clinically overt. Signs include pyrexia,
anorexia, in-appetence, shivering, reduced milk production for 2-3 days, then smacking
of the lips, grinding of the teeth, drooling, lameness, stamping or kicking of the feet
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caused by vesicles on buccal and nasal mucous membranes and/or between the claws and
coronary band. After 24 hours, these vesicles rupture leaving erosive lesions. Vesicles
may also appear on the udder. Recovery from clinical signs is normally within 8-
15 days. Complications include tongue erosions, secondary infection of lesions, hoof
deformation, mastitis and permanent reduction of milk production, permanent weight-
loss and abortion. Young animals may die due to myocarditis with mortality rates as
high as 30%.
Signs in Sheep and goats
Clinical signs in sheep are more subtle than in pigs and cattle. Vesicular lesions are
less pronounced. Foot lesions may even go unrecognised. Lesions may be evident in the
dental pad. Milk yields may be reduced and in a milking flock this may be identified
by stockmen. Foot-and-mouth disease may present as sudden death in lambs or as a
reduction in fertility rate or fecundity.
Signs in Pigs
Vesicles may be seen on the snout, lips gums and tongue. Vesicles on the feet rupture
after 1-2 days leaving eroded lesion and pronounced lameness. Lesions may also be seen
on other pressure points such as the knees and hocks. Digits may also slough exposing
the laminae underneath. In breeding herds there may be a high mortality rate in piglets
with postmortem identification of multi-focal cardiac lesions.
1.2.5 Clinical diagnosis of foot-and-mouth disease
Clinical diagnosis of foot and mouth disease will be based on an exclusion of possible
differential diagnoses (see table 1.1 for differential diagnoses [OIE, 2002]) combined with
clinical pathology on either blood, milk or lesion samples. In a normally disease-free
region, such as the UK, the primary clinician examining an animal presenting with
foot-and-mouth disease signs is required to promptly contact the government animal
health service in order to expedite diagnosis and application of control measures.
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1.2.6 Epidemiology
1.2.6.1 Transmission
Virus can be isolated in all excretions and secretions from an infected animal. These
include: Saliva, nasal discharge, vesicular fluid from the mouth and feet, samples of
exhaled breath, milk, semen, urine, faeces, vaginal discharge and aborted foetuses.
Virus excretion rates vary by species and route. Excretion rates in exhaled breath have
been measured at up to 160 virus particles per minute in cattle and sheep and up to
250,000 particles per minute in pigs. Virus excretion is estimated to last from 5 to 11
days with the salivary route of greatest duration [AVIS Consortium, 2002], Beyond the
11 days, there are reports of virus being isolated from oesophageal (probang) samples
for considerable periods after infection of 9 months in sheep, 2.5 years in cattle and
more than 5 years in buffalo [Alexandersen et al., 2002a].
1.2.6.2 Animals and Animal Products
Foot-and-mouth disease may be introduced into a previously disease-free region by
import of infected or carrier animals [Martinez-Lupez et ah, 2008]. It may also be
transmitted by animal products; meat from viraemic animals can contain virus particles
and be infectious. The increase in pH in meat during the rigor mortis process will
normally be sufficient to inactivate the virus. However, this change does not occur in
lymph nodes and bone marrow which can remain infectious for several months post¬
mortem.










Table 1.1: Diseases with a similar clinical appearance to foot-and-mouth disease
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1.2.6.3 Transmission by Personnel, Equipment and Vehicles
Foot-and-mouth disease virus remains infectious in faecal fomites and fluid droplets
that may become attached to personnel, vehicles or equipment. This is particularly
relevant in the case of veterinary surgeons, farm workers and delivery services that
may travel from farm to farm unwittingly transmitting infection. These routes pose
particular problems during disease epidemic control as in the absence of detailed records
they are difficult to trace. Thrusfield et al. [2005b] documents putative sources of
infection for farms in the Dumfries and Galloway region during the UK 2001 foot-
and-mouth disease epidemic, with personnel movements estimated to be the dominant
cause of transmission events. These estimates were based on collated data of potential
epidemiological links and timings of infection on associated premises.
1.2.6.4 Airborne Spread
Foot-and-mouth disease virus exhaled by animals may be spread as an aerosolised viral
plume from one group of animals to another. Depending on the virus serotype and the
immediate meteorological conditions viral plumes may be tens of kilometres long. In
1981 an outbreak of foot-and-mouth disease in cattle on the Isle ofWight was attributed
to airborne transmission from a pig unit in Henansal, Brittany [Gloster et ah, 1982].
Optimal temperature conditions with high relative humidity and a 7 m/sec southerly
wind were thought to result in a long viral plume and hence successful transmission.
This and other airborne transmission events have been modelled by Sorensen et al.
[2000]. Airborne transmission was also considered to be the cause of the rapid initial
escalation of the 1967 epidemic and also the route from the index case pig farm in 2001
to a neighbouring sheep unit from which movement of animals seeded large areas of the
UK [AVIS Consortium, 2002; DEFRA, 2008].
1.2.6.5 Transmission by Wild Birds and mammals
The Northumberland Report on the 1967/68 epidemic reported evidence that birds
may carry foot-and-mouth disease virus for up to 91 hours [Anon, 1969] although there
are no epidemiological studies available to assess the importance of this transmission
mode.
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Species TCID50 respiratory TCID50 oral Excretion (estimated virus units day *)
Cattle 10 - 1000 3 xlO6 105
Sheep 15 - 100 Not known 105
Pigs 400 105 108
Table 1.2: Foot-and-mouth disease virus susceptibility (Tissue Culture Infectious Dose
causing infection in 50% of individuals - TCID50) and airborne excretion
1.2.6.6 Susceptibility
Foot-and-mouth disease can be acquired by inhalation, ingestion or through damaged
epithelium. Approximate infectious doses vary by route and by species; they are shown
in table 1.2 alongside estimates of airborne excretion. These figures are approximate
as they are experimental and vary by serotype [AVIS Consortium, 2002].
1.2.7 Carriers
A foot-and-mouth disease carrier is defined as an animal from which foot-and-mouth dis¬
ease virus can be recovered from the oropharynx at 28 days or later, post-infection[Sutmoller
et ah, 1968]. Virus has been found after this period in the saliva of cattle with the site
of virus persistence identified as the dorsal surface of the soft palate [Murphy et ah,
1994]. In sheep the virus persists in the tonsillar area [Burrows, 1968]. Although virus
persistence in these areas is a normal feature of infection the probability of an animal
being a carrier decreases with time and was also related to the severity of the original
challenge infection [Hedger, 1970; Moonen et ah, 2004]. The significance of carrier an¬
imals in the transmission of foot-and-mouth disease and implications in its control is
contentious. Definitive transmission from carriers to cattle has been demonstrated in
buffalo [Dawe et ah, 1994], has been anecdotally reported in cattle and is considered
unlikely in sheep [Alexandersen et ah, 2002a].
1.2.8 Vaccination
The first attempts to develop a foot-and-mouth disease vaccine were in the 1920's
with work concentrating on attenuating the virus to produce a live, non-pathogenic
vaccine. Much later, in the 1960's, this work was continued but virulence of the resulting
vaccine rendered the vaccines practically unusable. Live vaccines may be produced
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using current vaccine technology however they would have the disadvantage, compared
with inactivated vaccines, that vaccinated animals would be hard to differentiate from
infected animals. The first effective vaccines were developed by Waldermann et al
[Desmettre, 1995] and were inactivated vaccines manufactured by extracting fluid from
epithelium and tongue vesicles from deliberately infected cattle and inactivating it
with formaldehyde and using an aluminium hydroxide adjuvant [Doel, 2003]. The
inconvenience of using an infected animal host was removed by Frenkel in 1947 who
grew foot-and-mouth disease virus in a culture medium derived from tongue epithelium
of healthy, slaughtered cattle. This method was used to manufacture foot-and-mouth
disease vaccine until 1962 when immortalised cell line culture methods were developed
by various researchers using hamster kidney cells as a growth medium [Capstick et ah,
1965; Doel, 2003]. These immortalised cell line methods reduce logistic and sterility-
testing problems compared to culture in epithelia media. Vaccine quality was further
improved by the introduction of more effective inactivation technologies including use
of aziridine acetylethyleneimine [Brown and Crick, 1959] and now binary ethyleneimine
(BEI) [Bahnemann, 1975]. BEI inactivation is now required by regulatory authorities
to achieve active virus particle contamination rates less than one per 10,000 litres of
product [OIE, 2009a]. The inactivated products are currently concentrated and purified
by ultrafiltration. As the vaccine is inactivated, an adjuvant is required to stimulate the
immune response. Saponin is now added to the aluminium hydroxide adjuvant for use in
ruminants. Oil based adjuvants are typically used in pig vaccines [Intervet, 2005]. The
OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals contains detailed
specifications regarding the manufacture, efficacy, safety and testing of foot-and-mouth
disease vaccines [OIE, 2009a]
1.2.9 Geographical Distribution
Foot-and-mouth disease is endemic in parts of Asia, Africa, the Middle East and South
America with sporadic outbreaks in many disease-free areas. North America has been
disease-free since 1929 when the last outbreak occurred in California [Segarra and Raw-
son, 2001], Australia has been free since 1872 [Cannon and Garner, 1999] and New
Zealand has no history of any foot-and-mouth disease outbreaks [Thomson, 2009]. See
figure 1.1 for world distribution of foot-and-mouth disease outbreaks and endemic areas
in August 2009 [OIE-WAHID, 2008],
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Geographical distribution is serotype related with O and A serotypes of foot-and-mouth
disease widely distributed and the SAT serotypes found mainly in Africa. Asia 1
serotype is found only in Asia and the C serotype is extinct.
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Figure 1.1: Distribution of foot-and-mouth disease outbreaks and endemic areas from
OIE WAHID reporting system to August 2009.
1.2.10 Diagnosis
The initial diagnosis of foot-and-mouth disease will normally be based on clinical signs.
This is the main mechanism used for initial detection of an outbreak. It relies on
examination by stockholders, clinical veterinarians, animal haulers, abattoir staff and
official veterinary surgeons at abattoirs and ports of entry. Clinical diagnosis is inexact
and its performance varies with species. Sheep and goats, particularly, may harbour
foot-and-mouth disease without showing overt clinical signs [Mahy, 2005]. To confirm
clinical diagnosis or as part of control and surveillance operation laboratory based
tests will be used as they will generally increase the sensitivity and specificity of the
overall diagnostic process. Laboratory tests for foot-and-mouth disease are carried
out at approved laboratories with biological security precautions in place owing to the
potential for release of infectious material from submitted samples. The UK laboratory
for such diagnosis is the Institute of Animal Health at Pirbright.
Tests can be based on detection of either virus antigen or antibodies raised to the virus
by the host animal and are summarised here:
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Antigen Based Tests
Virus isolation in tissue culture Samples are cultured in a cellular growth medium
and cytopathic effects observed directly.
ELISA antigen test Samples are incubated with anti-foot-and-mouth disease virus
antibodies which may be directly or indirectly labelled with an enzyme which is
then used to promote a reaction with a conjugate. The change in conjugate is
normally detected colourimetrically.
PCR - polymerase chain reaction Viral RNA is amplified using primers and poly¬
merase enzymes. Results of the amplification process are normally detected using
electrophoresis.
Antibody based structural protein serological tests
Virus Neutralisation Test Serum is incubated with a known sample of tissue pathogenic
foot-and-mouth disease virus. The result is then tested using tissue culture to de¬
termine if neutralising antibodies in the serum have prevented cytopathic activity
in the virus.
Antibody ELISA Similar to the ELISA antigen tests, a known foot-and-mouth dis¬
ease virus antigen is used to bind potential foot-and-mouth disease antibodies in
the sample and detected using an antibody linked enzyme / conjugate system.
Non-Structural Protein Serological Tests — for NSPs
These tests identify antibodies to non-structural proteins (discussed later) that are
present in animals in which foot-and-mouth disease virus has replicated but are not
present in non-exposed, foot-and-mouth disease vaccinated animals.
ELISA A number of ELISA based assays have been developed using some or all of the
non-structural 3ABC proteins. These test are reviewed by Brocchi et al. [2006]
Enzyme linked immuno-transfer blotting Also called Western blotting, is an elec¬
trophoresis based technique where proteins from the sample are separated on a gel
under an electric field. They are then transferred to a membrane and identified
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using specific linked antigen/antibodies. The EITB technique is claimed to have
high specificity and be suitable as a confirmatory test for foot-and-mouth disease
virus non-structural proteins [Bergmann et ah, 1996].
1.2.11 Diagnostic tests in post epidemic surveillance
Post-epidemic serological surveillance for foot-and-mouth disease is currently focused on
the use of enzyme linked immunosorbent assays (ELISAs [Lequin, 2005]). These tests
can identify antigen or antibody to foot-and-mouth disease. The overall methodology
relies on coated wells in which antigen or antibody is trapped. An enzyme labelled
antibody then promotes the conversion of a substrate to an optically detectable product
(either by optical absorbance or fluorescence). The methodology may be modified, for
example, by having foot-and-mouth disease virus antibodies in the sample compete with
labelled antibodies where a sample low in antibody will result in higher proportions of
bound, labelled antibodies and hence a higher optical absorbance reading.
The standard ELISA test used in the UK 2001 foot-and-mouth disease epidemic for the
detection of foot-and-mouth disease antibodies in unvaccinated cattle is the cELISA
described in detail in Paiba et al. [2004], In this test, foot-and-mouth disease antigen is
fixed to antibody coated wells. Then the test serum is added together with a competing
guinea pig anti-foot-and-mouth disease antibody. After incubation the wells are washed
and depending on the relative concentrations of antibodies in the test and competitive
sera there will be a similar proportion of antibodies bound to the antigen in the wells.
The proportion of test antibody bound is assayed by using an horseradish peroxidase
labelled anti-guinea pig immunoglobulin. This binds to the competitive antibodies and
is measured by final incubation with a substrate. The resulting optical density is related
to the proportion of bound competitive antibody i.e. the greater the optical density
the lower the antibody concentration in the test serum. The optical density result is
corrected by calculation of a percentage inhibition (PI) using the following formula :
PI = 100 — (~>^>samPle ODconjugate x
ODcontro[
where OD is the optical density of the test well and ODcontroi is the optical density of
the control wells with no test serum and ODconjugate is the optical density of the control
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wells with no test serum or competitive serum (i.e. background conjugate effect), (note:
formulae for PI will vary from test to test in detail e.g. some methods do not subtract
ODconjUgatg from the ODsample)
The cELISA test is serotype specific and also has the disadvantage that it cannot be
used in vaccinated animals as foot-and-mouth disease vaccination elicits an antibody
response against the structural proteins detected by the cELISA. More recent test
developments have produced ELISA tests that detect non-structural proteins (NSPs)
of foot-and-mouth disease virus. Non-structural proteins are proteins that are coded
for by the foot-and-mouth disease virus but are not part of the virus capsid. They are
classified as protein products from the genes 3A, 3B, 3C and 3D (see figure 1.2). Hence
it is possible to develop an inactivated vaccine that will elicit immunity to the surface
capsid proteins of the virus but will not elicit antibodies to NSPs since there will have
been no viral replication in the host animal. However if an animal becomes infected
with foot-and-mouth disease NSPs will be produced during virus multiplication and are
released during cell lysis. These NSPs elicit an immune response with the formation
of antibodies to NSP. Thus previously foot-and-mouth disease infected animals can be
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Figure 1.2: Foot-and-mouth disease genome (from Information System for the OIE/-
FAO FMD Reference Laboratories Network)
The major NSP specific ELISA tests are reviewed and evaluated in Brocchi et al. [2006].
Here I will describe the outline protocol for the CEDITEST NSP test as this is the main
test used in the Turkish sero-surveillance presented in chapters 3, 4 and 5. The assay
is described in detail in Sorensen et al. [2005]. In summary:
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Plain ELISA plates are coated with a monoclonal IgG antibody against NSPs 3ABC.
These plates are then incubated with 3ABC antigen (manufactured in baculovirus) to
give a plate coated with IgG antibody with a bound layer of 3ABC antigen. Serum or
control samples are then added and the plates are incubated. Test serum containing
3ABC antibodies will bind to the antigen layer forming an antibody-antigen-antibody
sandwich. Then horseradish peroxidase labelled monoclonal IgG antibody is incubated
with the plates. This antibody will bind with otherwise unbound antigen. After final
washing the amount of bound, labelled antibody is assessed by addition of a substrate
and colorimetery at 450nm. The percentage inhibition result is calculated from a cor¬
rected optical density using ODj^ir — a non-inhibited reference with buffer substituted
for test samples. A high percentage inhibition signifies low optical density i.e. greater
binding of serum IgG and hence a positive result. The manufacturer recommended
cut-off is a PI of 50%.
PI = ioO-^=^xioo^Dcontrol
1.3 Economics of foot-and-mouth disease
Foot-and-mouth disease is considered to be of high economic importance in the agricul¬
tural systems of the developed world [Prempeh et ah, 2001]. This arises from its effects
on animal production at an individual level and, depending on consequences to trade
and control, from its contagious nature, high infectivity and significant morbidity.
1.3.0.1 Economics at a Local Level
Foot-and-mouth disease has an impact at a local farm or producer level influencing the
productivity of agricultural enterprises [Doel, 2003]. It has an impact on many aspects
of livestock production systems as listed below causing ...
• an average 25% reduction in annual milk yield of dairy cows.
• meat production to be reduced with some reports estimating a 10-20% increase in
time to maturity and a 20% reduction in annual pig meat production in infected
animals.
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• animal draught power to be reduced by 60-70% in the first month after infection.
• fertility rate to be reduced by up to 10% due to increased abortion rate.
• very high mortality losses in young animals of up to 30%.
• culling loss of chronically infected animals
• gross disruption of farming practices
A further local economic loss is that of missed selection opportunity. It is unlikely that
the performance of a chronically infected animal will exactly correlate to its performance
if it were healthy. Hence selective breeding pressures applied to an animal population
with transiently endemic foot-and-mouth disease will results in a herd that may not
perform optimally if foot-and-mouth disease were not present. This difference is termed
the "lost selection benefit" and represents an opportunity cost of disease.
1.3.0.2 Effects at a National Level
The national and international economic consequences of foot-and-mouth disease arise
from control measures generally enacted by statutory disease control regulations, emer¬
gency control legislation and self-imposed control and bio-security measures. The highly
infectious nature of the disease makes movement restriction of livestock and temporary
closure of livestock markets prime components of control strategy [Doel, 2003, page
133]. However, these restrictions effectively cease livestock trade for the duration of
the control period. These regulations and compensation systems for farmers' losses
during an outbreak will shift the costs of foot-and-mouth disease losses from the farms
experiencing the loss to the general agricultural economy, other sectors and the state.
This can make accurate estimation of the economic consequences of an foot-and-mouth
disease outbreak difficult.
1.3.1 Economic Consequences of 2001 foot-and-mouth disease Epidemic
The state costs to the UK exchequer of controlling the 2001 foot-and-mouth disease epi¬
demic are estimated within the National Audit Office (NAO) 2002 report [National Au¬
dit Office, 2002] as £3.1 billion in total. This is represented by £1.4 billion in compen¬
sation to farmers for culled stock and £ 1.7 billion as other disease control measures.
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The report estimates the total loss to the rural economy as more than £ 5 billion arising
mainly from tourism losses. £355 million of this is uncompensated losses by agricul¬
tural producers (about 20% of 2001 farming income). The NAO report that the food
industry cost, downstream of agriculture, was around £ 115 million. The NAO report
estimates that the overall impact on the UK economy was modest due to substitute
expenditure by consumers; the epidemic reducing UK GDP by 0.2% (of total GDP
which is approximately £1.8 trillion i.e. a £3.6 billion cost) [DEFRA, 2008; Francis
et ah, 2002].
DEFRA report the medium-term effects of the 2001 foot-and-mouth disease epidemic
on UK agriculture [Francis et ah, 2002]. In summary: It was found that a small pro¬
portion of farmers from infected premises (6%) intended to leave agriculture. Farmers
expected a further reduction in number of people employed - this continued the pre-
epidemic trend. A 2% increase in the use of contractors and share farming was expected.
Restocking was planned in about 70% of culled premises but to lower, on average, lev¬
els than before the epidemic. The number of cattle in the dairy sector was expected
to fall but with production levels maintained due to increased efficiency. There was
also evidence of an increasing diversification of farming enterprise into organic and
environmental management schemes.
1.3.1.1 Foot-and-mouth disease Control
The definition of under control was one of the contentious issues surrounding the 2001
UK foot-and-mouth disease epidemic [BBC News Online, 2001]. For the purposes of
this section, disease control is considered to be any intervention that is enacted with
the intention to reduce epidemic size, duration or severity in its broadest sense. Foot-
and-mouth disease control can adopt two, non-exclusive approaches; either to reduce
the probability that units become infected or to reduce the probability that infected
units transmit disease. These actions can be applied within the context of the unit
being an individual, an animal group/farm or a region/nation.
1.3.1.2 Import Control and Stock Movement
Following the first recorded appearance of foot-and-mouth disease in the UK in 1839
the disease was assumed to be un-preventable and there is no record of specific control
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measures [Anderson, 2002; DEFRA, 2008; Woods, 2004]. In fact, prior to 1841 animal
importation was prohibited but this restriction was removed in 1842 subject to payment
of the requisite, per head, duty. This duty was later removed in 1846 by Sir Robert
Peel, once more permitting free trade. However, a UK Rinderpest epidemic 1864-66
motivated widespread movement and import control legislation. In addition to this, a
weekly report was published in the London Gazette detailing contagious disease out¬
breaks. These controls were viewed as important in the elimination of Rinderpest and
were legislatively fine-tuned to help control foot-and-mouth disease. Import restrictions
persist to date with a balance being sought between the desires to maintain interna¬
tional free trade and the wish to protect the health of the national herd. The need to
recognise this balance is encapsulated in the World Trade Organisation Agreement on
the Application of Sanitary and Phyto-sanitary Measures [World Trade Organisation,
2008]. This outlines a basis by which nations can protect their animal (and human)
populations against disease whilst aiming to prevent the use of disease control argu¬
ments as a mechanism to disrupt free trade [World Trade Organisation, 2008]. The
EU maintains a list of countries outside the community which are permitted to export
animal products into the EU. This list will be revised from time to time with changes in
the international disease status and changes in animal disease science [European Com¬
mission, 2006]. Such imports have to pass through approved Border Inspection Posts.
In the UK these are maintained by the State Veterinary Service [Anderson, 2002].
1.4 Surveillance for disease-freedom
Surveillance in the context of animal disease is a process where individuals and/or
the population are observed in order to assess disease status with an intention to take
action if the status changes [Salmon, 2003]. In the specific case of surveillance to
demonstrate disease-free status the methodology and consequences of such surveillance
will be informed by national and international codes and regulations.
1.4.1 Definitions of Disease-Freedom
The OIE in the Terrestrial Animal Health Code - 2005 [OIE, 2005b] define a disease-free
zone as:
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... a zone in which the absence of the disease under consideration has
been demonstrated by the requirements specified in this Terrestrial Code
for free status being met. Within the zone and at its borders, appropri¬
ate official veterinary control is effectively applied for animals and animal
products, and their transportation.[OIE, 2005a]
The OIE Terrestrial Code lays down requirements for disease-free status for countries
and zones within countries for control with and without vaccination. The requirements
for a country to obtain disease-free status require the following requirements to be met
depending on the class of disease-free status required as follows:
Disease-freedom in the absence of vaccination
Foot-and-mouth disease may be controlled without vaccination by application of strict
import and biosecurity measures. To be classified as foot-and-mouth disease-free with¬
out vaccination a country will need to provide evidence to the OIE of regular and
prompt disease reporting and a declaration of:
1. No outbreak in the previous 12 months.
2. No evidence of infection in the previous 12 months.
3. No vaccination in the previous 12 months.
4. Supply evidence of surveillance for foot-and-mouth disease and virus in accordance
with OIE codes.
5. No importation of foot-and-mouth disease vaccinated animals since the country's
own cessation of vaccination.
Disease-freedom with vaccination
Where importation controls are difficult it is possible for a country to maintain a lower
standard of freedom with vaccination included as a control measure. Achieving this
status requires:
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1. Evidence of regular and prompt disease reporting.
2. Declaration of no outbreak in the previous 2 years and no evidence of foot-and-
mouth disease circulation in the previous 12 months.
3. Documented evidence that:
(a) Surveillance for FMD and FMDV circulation in accordance with OIE codes
is in operation, and that regulatory measures for the prevention and control
of FMD have been implemented;
(b) Routine vaccination is carried out for the purpose of the prevention of foot-
and-mouth disease;
(c) With a vaccine that complies with the standards described in the OIE man¬
ual.
If a foot-and-mouth disease-free country, where vaccination is practised, wishes to
change its status to a foot-and-mouth disease-free country where vaccination is not
practised, the country should wait for 12 months after vaccination has ceased and pro¬
vide evidence showing that foot-and-mouth disease virus circulation has not occurred
during that period. The OIE provide further definitions referring to foot-and-mouth
disease-free zones with and without vaccination control. These parallel the foot-and-
mouth disease-free country regulations with additional requirements for physical, geo¬
graphical or buffer zone areas to separate disease-free areas from other areas. After a
foot-and-mouth disease epidemic, specific OIE regulations refer to the process by which
a formally disease-free country may regain its disease-free status of either free with or
without vaccination [OIE, 2009b].
1.4.2 History of freedom from disease surveillance design
Freedom from disease surveys are part of the mechanism by which a zone is demon¬
strated to be free of a nominated disease. Their most common application is after an
outbreak or epidemic. A number of samples are taken from animals in the zone, they
are biologically tested for evidence of disease and after suitable statistical analysis the
survey result will be reported. Classically, a successful result is of the form:
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The survey has found no evidence of disease. If disease were present in at
least x% of epidemiological units and within those infected epidemiological
units if it were present in at least y% of animals the survey would detect
disease with a z% confidence.
Where x, y and z define the statistical performance and epidemiological design criteria
of the survey.
Hence these surveys take the form of a frequentist statistical test with a null hypothesis
of, say, disease being present and a size or Type I error of, for example, (1 — z) i.e.
a = (1 — 2:) [Cameron and Baldock, 1998b]. The development of the design and analysis
of these surveys is reviewed in Cameron [1997] and in Baldock [1998]. The following
represents a summary together with outlines of more recent issues and developments.
The design of such surveys regarding sample sizes has undergone a process of improve¬
ment using increasingly sophisticated models for the disease, survey and diagnostic
test process. The original sample size calculations assumed sampling from an infinite
population using a perfect diagnostic test with a disease that was reliably present at
a design prevalence [Cameron, 1997]. Sophistication in survey design now includes fi¬
nite population models (using hypergeometric models of within herd sampling) and
imperfect knowledge of imperfect diagnostic tests [Hanson et ah, 2003; Audige et ah,
2001]. Generally this will increase the required sample size to declare disease-freedom
with a given confidence level. The later approaches are also not solvable analytically
so require numerical solutions to determine approximate sample sizes. Public domain
software exists to provide these solutions such as FreeCalc 2 [Cameron and Baldock,
1998b].
Further work by Donald et al. [1994] challenges the regulatory standards and surveil¬
lance designs that make the assumption that if disease is present within a herd that it
will be present at a minimum within-herd prevalence. In reality a herd may contain
as few as one diseased animal if the herd has only recently become infected, if there is
limited susceptibility as in the case of vaccination or if there were segregation between
herd members. Even if the mean prevalence across all infected herds meets some design
level, heterogeneity across herds will reduce the overall efficacy of the surveillance pro¬
cess so it may fall below the design level. Donald et al. [1994] discusses and models this
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although the results are not extended to demonstrate the consequences in a real-world,
two stage disease survey.
A particular problem of survey design and analysis occurs in small animal groups. Many
regulatory codes require a survey to be able to detect disease in an epidemiological
group (i.e. herd or flock) at a certain confidence if it is present at a certain prevalence
as described above. With moderately insensitive diagnostic tests this can be achieved in
most groups by sampling sufficient animals. However in small groups even sampling all
the animals may not provide the required group level sensitivity/confidence. This issue
has been discussed by Martin et al. [1992] and in detail by Greiner and Dekker [2005]
who offer models to estimate survey performance in small herds and possible solutions
including consideration of all small herds as infected or the alternative suggestion that
small herds pose a less important disease threat and may be considered uninfected.
An alternative to regulation-informed design is presented by Hohle and Jorgensen [2003]
regarding prevalence estimates of disease in a herd. Their study uses a loss function for
sensitivity and specificity to develop an analytic function for utility and hence explore
sensitivity to uncertainty in test parameters. The analysis does not extend to multi-herd
scenarios and does not consider explicitly the disease-freedom issue.
1.4.2.1 Bayesian approaches to survey analysis and design
Most previous work addresses the issue of survey design and analysis as a frequentist
hypothesis test. A Bayesian approach views probability as a measure of subjective belief
allowing epidemiologists and stake-holders to refer to "probabilities of disease-freedom".
Johnson et al. [2004] discuss a Bayesian approach to sample size calculation within a sin¬
gle stage (herd/flock) survey framework and illustrate it using foot-and-mouth disease
screening within a herd. Suess et al. [2002] derive a Bayesian model for disease-freedom
estimation illustrated with examples using Newcastle Disease and Porcine Reproductive
and Respiratory Syndrome. In a further extension of this approach Choi et al. [2006]
describe a Bayesian approach to use the full continuous information from diagnostic
tests rather than dichotomising the results with a cut-off (positive/negative) value for
each animal. The study illustrates the estimation of probability of infection for each
individual in a sampled group. Bayesian approaches have the advantage that they
allow the incorporation of prior information into the analysis, often provide a natural¬
istic framework for specifying the problem and produce probabilistic statements about
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the estimated quantities. In the context of testing for disease-freedom these proba¬
bilistic outputs can be used to provide direct input into economic and utility based
models. Critics of Bayesian approaches highlight the need for, potentially subjective,
prior information arguing that this makes the whole process subjective. Another issue
is that Bayesian approaches will often require large amount of numerical computation
increasing costs and delaying results.
1.4.2.2 Serial and parallel testing
Many disease-freedom surveys will use an initial, screening, test on each sampled animal.
These tests are selected considering diagnostic performance but also speed and economy.
Often the diagnostic test will have an imperfect specificity - it will give false positive
results. To reduce the impact of these results, further tests can be done on animals
testing positive using a more specific, confirmatory, test. Alternatively, in situations
where no single test is sufficiently sensitive, another test can be done in parallel to
increase the probability of detecting diseased animals. Gardner et al. [2000] discuss
these approaches with reference to disease-freedom estimation and considers the impact
of conditional dependence between tests, where co-varying tests may give less additional
information than conditionally independent tests.
1.4.2.3 Retrospective evaluation of surveillance designs
The performance of a given survey design may be retrospectively assessed in simple
cases by analytic methods. In more complex settings, with uncertainty of diagnostic
test performance and epidemiological parameters, simulation models will be required.
In Tsutsui et al. [2003] a stochastic model was used for evaluation of the foot-and-mouth
disease surveillance in Miyazaki, Japan after the outbreak in 2000. The study models
within herd prevalence using Reed-Frost model [Carpenter, 1984]. It incorporates un¬
certainty in diagnostic test performance and estimated herd level sensitivity at 71 to
76.5%. Similarly, Carpenter and Gardner [1996] use simulation modelling to explore
interpretation of a serologic survey for porcine parvovirus. The effects of diagnostic
test performance and number of animals tested are investigated demonstrating that
extrapolation from animal-level test performance to herd level survey performance is
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complex and non-linear. The study did not explicitly consider disease-freedom as such
but classified herds into sero-prevalence bands.
1.4.2.4 Use of multiple information sources — scenario trees
In practical applications, disease-freedom surveys using serological methods will not
be used in isolation; the results of serological surveillance will be interpreted in the
light of previous surveys and clinical information. In a review of disease-freedom ap¬
proaches this is discussed by Cannon [2002]. His work also highlights that most studies
consider the technical issues of surveys to demonstrate disease-freedom rather than
standing back and considering what these surveys could most usefully estimate or de¬
tect. Cannon [2002] introduces a points system for scoring tests performed in the face of
estimated disease prevalence incorporating test sensitivity, number of tests performed
and expected disease prevalence and discusses combination of prevalence from multiple
surveys. The approach appears to be based on point estimates and probability theory
and does not consider the correlation of survey estimates. The use of multiple surveys
is further expanded in Martin et al. [2007b,a] where the "scenario tree" methodology is
described. This uses Bayes theorem (see later) to update a probabilistic inference from
one surveillance activity with the results of another [Salmon, 2003, page 172-174].
1.4.2.5 The influence of vaccination on surveillance
Paton et al. [2004] reports EU Council Directive 203/85/EC which gives provision
for vaccination control of foot-and-mouth disease and defines post-vaccination sero-
surveillance requirements. They discuss issues of test sensitivity and specificity in a
vaccinated population. Sutmoller and Gaggero [1965] (cited by Paton et al. [2004])
observed a 50% within herd prevalence four months after a vaccine trial failure in
Brazil. Paton et al. [2004] also reports a recent trial where 45% of 20 vaccinates
became infected 21 days after exposure in a research setting. The issues of herd false
positives and small herds are further discussed with reference to the work of Greiner
and Dekker [2005] with the suggestion that positive herds are re-sampled and re-tested
to demonstrate absence of circulation rather than infection. Later, Arnold et al. [2007]
developed a model to estimate the residual carrier population after a foot-and-mouth
disease outbreak to assess the efficacy of non-structural protein based testing. Their
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study estimated that only 0.2% of herds in the UK would contain carrier animals after
an outbreak and that, within these herds, the number of carriers would be low. On this
basis they suggest testing of all vaccinated herds and culling of just the test positive
animals. This approach assumes that the animal-level tests are adequate in terms of
both sensitivity and specificity to avoid missing carrier animals and excessive culling of
healthy stock.
1.4.2.6 Risk based surveillance
Recently attention has been paid to development of risk based strategies for the es¬
timation of population parameters and demonstration of disease freedom. Williams
et al. [2009b] discusses targeted techniques for estimation of population parameters
and Williams et al. [2009a] introduces Poisson sampling to demonstrate freedom from
disease within a flock of animals and allow estimation of population parameters based
on a measurable covariate that is associated with risk of disease. Cannon [2009] dis¬
cusses the theory behind quarantine inspection and disease surveillance with limited
resources proposing analytical expressions to be optimised under different objective cri¬
teria for optimisation. In chapter 2 I use a simulation based approach to this problem
to estimate the performance of a risk based targeting approach estimating risk from an
epidemiological model.
1.5 Bayesian inference
In chapter 5 I use a Bayesian model to estimate prevalences and diagnostic test perfor¬
mance measures based on sero-surveillance data from the Thrace region of Turkey. The
Bayesian approach to statistical inference is described in detail elsewhere (Lee [1997]
and others). Here I will provide a brief outline.
Bayesian inference derives from Bayes theorem and considers probability to be a mea¬
sure of subjective belief. The theorem states that the probability of an event, given
some observed data, can be calculated from the probability of the event before the data
is considered; the likelihood of the event given the data and the probability that the
data will be observed:
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Promx)= MiiyE)
Where E is the event and X the data.
For a multi-variable model with continuous parameters this extends to:
,f(,mmx) ~ —
Where 9 is a vector of parameters and /() represents the probability distribution func¬
tion.
Although it is frequently straightforward to write down an expression for f(9\X) only
simple problems have closed solutions to allow description of the posterior distribution
and summary statistics of 6. Normally, numerical methods are required to sample from
the posterior distribution for 6. The JAGS [Plummer, 2003] software used in the Thrace
analysis in chapter 5 uses Gibbs Sampling [Lee, 1997, page 259] where draws of values
are made randomly from distributions based on only the immediate previous parameter
values. This is referred to as Markov chain Monte Carlo (MCMC) methodology as the
system has Markov Chain properties (a series where the next value is conditional only
on the immediate previous value) and is random hence 'Monte Carlo' after the Monte
Carlo Casino in Monaco.
Gibbs sampling is a numerical method for drawing samples from a multivariate distribu¬
tion. It requires a distribution for each parameter conditional on the other parameters
in the posterior. From a starting set of parameter values, samples are drawn sequen¬
tially for each parameter conditionally on the remaining current parameter set. Each
new draw is then substituted into the current parameter set. In the long term as the
number of draws tends to infinity the distribution of drawn values will tend to the
posterior distribution of the parameter. For example in a three parameter model of 9
at iteration i draws of 6 are made sequentially from the conditional distributions:
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The posterior distribution values simulated by this method are only asymptotically
distributed as if from the true posterior distribution, i.e. only after an infinite number
of samples has been drawn. There will be a finite period during which the samples
are highly unrepresentative of the posterior distribution. Identification of the point at
which samples can be reasonably considered to approximate the posterior distribution
poses a continuing problem for numerical Bayesian inference. A number of approaches
exist as discussed in chapter 5 which permit identification of simulation series that have
not adequately converged on the posterior distribution. However these methods can
only identify failure to converge; there are no formal mechanisms by which convergence
can be proven. In practical application, examination of multiple long simulation runs,
predictions from the model, visual examination of convergence behaviour and absences
of non-convergence diagnostics are used to validate MCMC estimation. For a brief,
light hearted but enlightening opinion about MCMC diagnostics and their 'bogosity'
see Geyer [2005].
The major advantages of Bayesian inference for disease surveillance problems are that
the methodology permits complex, naturalistic formulation of models that describe
the observed data conditionally on epidemiological and diagnostic test parameters and
produces results that capture the uncertainty of the parameter estimates considering
the data, model and prior assumptions.
Chapter 2
Risk based surveillance design
2.1 Summary
Post epidemic surveillance will be more efficient if sample selection uses spatial disease
models to select farms for sampling and to order their sampling i.e. a higher system
sensitivity of infection detection can be achieved for a given sample size.
Current post epidemic sero-surveillance will normally be carried out within the appro¬
priate surveillance zone (10 Km radius for foot-and-mouth disease) and will involve
sampling of either all farms (if vaccinated) or a probability sample of farms (if not vac¬
cinated). It is unlikely that an arbitrary sampling strategy will be optimally efficient.
A better strategy is to estimate the benefits gained by sampling each farm in the re¬
stricted area. This allows the estimation of incremental benefit of sampling each farm
and hence allows farms to be sampled in order of decreasing benefit, until the sam¬
pling budget is exhausted or surveillance performance targets are met. Furthermore, if
farms are sampled in order of decreasing estimated risk of latent infection the time to
declaration of disease freedom may be reduced.
In this chapter I adapt a previously published model of the UK 2001 farm foot-and-
mouth disease infection risk [Diggle, 2006] to estimate the probability that the farms
in Devon had been infected during the outbreak in that region. I then add a model
estimating the probability that these farms would have been identified as infected during
the epidemic. This allows estimation of the post-epidemic probability of each farm
harbouring an undiscovered infection. Adjustment of this result by the individual farm
27
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level diagnostic sensitivity of surveillance estimates the probability that a given farm,
if sampled and tested, will result in the detection of a previously undiscovered (latent)
foot-and-mouth disease infection. Aggregation of these results for a given sample set of
farms allows estimation of the system sensitivity of that set of farms as a tool to detect
post-epidemic infection in the region.
The two methods of selecting this sample set of farms are compared across a full range
of sampling budgets (from one farm to the entire farm population). This allows com¬
parison of the system sensitivity (ability to detect infection in the area) of random farm
selection versus risk model based selection.
Additionally, assuming that samples take a finite time to process from collection to re¬
sult, the effect of ordering samples by risk is also explored. This estimates the potential
of risk-ordered sampling to detect any infected farms earlier than randomly ordered
sampling and hence expedite subsequent disease control activities and restoration of
disease-free status.
The study showed that it was possible to achieve a system sensitivity (probability of
detecting infection in the area if present) of 95% by sampling, on average, 1083 farms
with random sampling and 225 farms with risk based sampling. Risk ordering the
sampling process resulted in detection of positive farms, if present, 15.6 days sooner
than with randomly ordered sampling, assuming 50 farms were tested per day. This
would potentially allow declaration of disease freedom and resumption of international
trade 15.6 days earlier.
2.2 Introduction
After the apparent end of an animal disease epidemic a country will normally benefit
from demonstrating that infection is no longer present in its livestock. This is both
to satisfy international trade requirements [OIE, 2009b] and also to identify previously
undiscovered infection to prevent recrudescence. Demonstration that disease has been
controlled also has domestic societal and political advantages. The process is described
as demonstration of disease freedom [Cameron, 1997; OIE, 2009b]. With many diseases
this process includes a prescribed sampling of livestock in the vicinity of the previously
infected premises. Appropriate diagnostic tests are used to determine the infection
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status of sampled animals and hence infer the infection status of the whole region.
Unless all animals are sampled with a perfect diagnostic test there will be uncertainty
in the subsequent estimate of the region's infection status. Much work has been done
to determine optimal sample sizes and performance limits of such surveys [Cannon,
2002; Branscum et ah, 2006; Cameron and Baldock, 1998a,b; Humphry et ah, 2004;
Johnson et ah, 2004], All these studies assume a probability based sampling of animal
holdings, usually, within a defined surveillance zone which would normally surround the
previously infected premises. Current disease control and surveillance policies generally
involve the definition of a surveillance zone as a buffer zone a defined radius around
previously detected, infected premises. In the case of foot-and-mouth disease in the
United Kingdom this is a 10 Km radius zone around any previously infected premises.
For the purposes of illustration and discussion the remainder of this chapter will focus
on the design of post-foot-and-mouth disease epidemic surveys although the approach
may be generalised to other diseases.
The World Organisation for Animal Health (OIE) have previously set prescriptive
guidelines regarding the sampling strategy to be adopted for post-epidemic demon¬
stration of freedom from foot-and-mouth disease. Recent changes in OIE guidelines
introduce considerable freedom in how disease freedom surveys may be designed, allow¬
ing a more pragmatic approach to design, provided that the survey adequately supports
a claim of disease freedom [OIE, 2009b],
Traditionally, farms are sampled from within the surveillance zone on a random basis
to achieve an expected survey system performance (e.g. to have a 95% confidence
of detecting an infected farm if infection is present at some predetermined, design
value, such as 2%). Within each selected farm, samples will be taken from animals to
achieve a within-farm expected survey performance - typically to detect infection on
the farm with a 95% probability if it were present at some previously defined, within-
group design prevalence (often 5%). More recently, in the case of disease control by
vaccination, current procedures may require testing of all vaccinated animals on all
vaccinated farms [TAIEX, 2007]. This more rigorous testing is aimed to overcome the
possibility that vaccinated animals may have subtle clinical signs if infected and may
have a higher likelihood of becoming carrier animals [Arnold et ah, 2007; Paton et ah,
2006],
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This chapter examines the traditional approach for post epidemic surveillance using
random selection of farms within the surveillance zone and suggests a more efficient
methodology. This involves sample selection from wider areas using a latent infection
risk model to choose which farms to sample and when to sample them. This approach
is expected to reduce sampling costs by requiring fewer farms to be tested and to
expedite the return to disease-free status by finding infected farms, if they are present,
more quickly.
2.3 Methodology
The mathematical nomenclature and symbols used in this chapter are listed in table
2.1.
Variable Symbol
A positive test result for farm/region
A diseased farm/region
Number of farms in restricted zone
Probability of farm i being latently infected on day t
Probability of farm i being latently infected ever
Farm level sensitivity (farm i)
System sensitivity
Probability that a sampled farm ultimately tests positive
Sampling cost of ith farm
Sample size













Table 2.1: Nomenclature used for terms in this chapter
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2.3.1 Theory
2.3.1.1 Surveillance system sensitivity
The purpose of post-epidemic sero-surveillance is to inform a decision about the disease
status of an area under consideration, normally the restricted area. Return to interna¬
tional trade and removal of disease control measures are likely to be contingent on this
decision. The area will be considered free of disease if it is contains no infected animals
or evidence of circulating infection. Hence the performance of a survey to demonstrate
disease freedom can be assessed by its ability to detect infection in an area if present.
Martin et al. [2007b] call this the system sensitivity (SSe). For this analysis I assume
that an optimally efficient survey design either:
1. Maximises the probability of detecting any previously undetected infected animals
in the area (SSe), if present, for a given budget or,
2. Minimises the sampling cost of a survey that achieves a desired probability of
detecting previously undetected infected animalsS'S'e, if present, in the area
The system sensitivity SSe is defined:
SSe = Prob(T+\D+)
Where Prob(T+) is the probability of at least one farm testing positive in the region,
Prob(D+) is the probability of at least one farm being infected. 1 — SSe is effectively
the probability that a surveillance system will fail to detect infection in an infected
region.
I assume perfect system specificity as discussed by Martin et al. [2007a]. Any initially
test-positive farms are retested until they are demonstrated to be genuine positive or
cannot be shown to be negative. Effectively the case definition for a positive farm is a
farm that tests positive after confirmatory and follow-up retesting i.e.
Prob(T~\D~) = 1
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In order to estimate SSe:
Prob(T+) = Prob(T+\D+) x Prob(D+) + Prob{T+\D ) x Prob(D )
but since
Prob{T+\D~) = 1 - Prob{T~\D~) = 0




If the probability that each farm is latently infected (i.e. was infected but the infection
is not detected during the epidemic) can be estimated, the system sensitivity (SSe)
of different post epidemic sampling strategies can then be calculated using 2.1. It is
assumed that any previously detected and infected farms have been removed from the
sampling frame. If Pi is the probability that farm i is latently infected, si..n are the
indices of a sampled set of n farms from the population of N farms and pi is the farm
level sensitivity on farm i (i.e. the probability of a positive farm result if an infected
farm is selected, sampled and tested). For this analysis I have assumed that Pi and
pi are independent, i.e. the sensitivity with which infection is detected on a farm is
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2.3.1.2 Risk based versus random farm selection
If all farms have an equal probability of being latently infected, the designed survey
has a constant farm level sensitivity across all farms and the cost of sampling farms is
constant there will be no advantage in selecting farms for sampling. However if latency
probability P; or farm sensitivity pi vary then maximum system sensitivity within a
sampling or cost constraint will be obtained by selecting a sample set Sj=i..n of n farms
to maximise Prob(T+):
i- n (! - px Pi)
£>i=l. .n
As pi x Pi is always positive this is maximised by maximising (Pi x Pi) given the
constraint of a number of farms to be sampled.
If the sampling constraint is simply a number of farms n to be sampled this gives a
sample set of the first n farms when they are ordered by decreasing {pi x Pi).
If the sampling constraint is a fixed sampling cost budget C and it is assumed that all
farms have an equal sampling cost c* (cost of visiting the farm plus cost of sampling on
the farm) then the most efficient sample will be the first n farms ordered by increasing
{1 — Pi x Pi] where n is at a maximum but satisfies nc* < C.
2.3.1.3 Efficiency gains from risk based sampling
For risk based sampling to give an increased system performance (with a sampling/cost
constraint) there needs to be both a variation in P, x pi and a predictive model that
allows a survey design to select farms with a comparatively high Pi x pi compared to
random selection. In the following section I adapt a previously published model for
risk of infection and use it to estimate potential gains in surveillance system efficiency
resulting from application of risk-based as opposed to random sampling in a post-
epidemic surveillance scenario.
Chapter 2. Risk based surveillance design 34
2.3.2 Application to post-epidemic surveillance
2.3.2.1 Study scenario - Devon, UK 2001 foot-and-mouth disease epidemic
The foot-and-mouth disease outbreak in Devon 2001 was estimated to start on the 17th
February and end with animals on the last known infected premises culled on 19th June
2001. Sero-surveillance during and after the epidemic identified 15 farms in this area
as previously infected (recorded in the DEFRA submission to the OIE to substantiate
freedom from disease and recorded in the disease control system database [DEFRA,
2002] and [Gibbens and Wilesmith, 2002]).
I adapt a model of the UK 2001 foot-and-mouth disease epidemic from Keeling et al.
[2001] using parameter estimates from Diggle [2006] to estimate the probability of
infection for each animal holding in Devon. From the model the probability that an
uninfected farm i becomes infected on day t of the epidemic is estimated using the
formula:
Pi,t = 1 - exp J - ^2 X(t)rj(dij)AjBi
jeinfected farms at time t
Where:
A — i 49/v0-13 -i- /V013A] — cattle T ^sheep
Bt = 36.2N^le +N^p
Aj represents the transmission potential of an infected farm j, B{ the susceptibility of
farm i. Ncattie and Nsheep are the stocking numbers of cattle and sheep respectively.
The parameter A(t) is a baseline hazard.
The distance kernel r)(d), representing the decreased risk of transmission between farms
with increasing straight-line separation, dij is modelled:
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77(d) = exp j- | + 1.3 x 10 4
This gives a declining relative probability of transmission with distance as shown in
figure 2.1
distance (d) Km
Figure 2.1: The distance Kernel used in the model [Diggle, 2006]. d is the distance sep¬
arating an infectious and a susceptible farm, 77(d) is the relative probability
of transmission.
2.3.2.2 Model parameters
Model parameters (see table 2.2) were as used in [Diggle, 2006]. The baseline hazard
(A(t)) represented the overall risk of transmission occurring in the Devon area, varying
with time, during the epidemic. In Diggle [2006]'s study this was estimated from the
daily case report data using a survival analysis technique (approximately 4.88 e-05
with slight variation over the course of the epidemic). This baseline hazard would
be dependent on stocking densities, husbandry practices, foot-and-mouth disease virus
serotype, time of year and other factors. For the Devon region the baseline hazard was
relatively constant with time so was kept fixed in my model for simulation purposes.
To assess the robustness of my estimates of risk based surveillance the baseline hazard
parameter lambda was varied between simulation sets from 1 x 10~5 to 5 x 10~4.
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Variable Value
Relative susceptibility in cattle
Relative susceptibility in sheep
Relative transmissibility in cattle
Relative transmissibility in sheep
Power correction 0.13






Table 2.2: Parameters for model to predict infection probability
The modified Diggle [2006] model is used to estimate the probability of infection in each
of the 4856 premises with sheep recorded in Devon in the 2001 UK agricultural census
[DEFRA, 2000] using the 172 infected premises from the DCS database [Gibbens and
Wilesmith, 2002] as sources of infection. The results from this model are shown in
section 2.4.1
In the study I need to predict the probability that farm i will become infected and that
infection will not be clinically discovered (or serologically discovered during routine sero-
surveillance prior to formal post epidemic sero-surveillance). There are two scenarios
by which an infected farm will become a latent (undiscovered) infected farm by failure
to observe clinical disease: one is if infection on the farm is not clinically detectable i.e.
disease is effectively sub-clinical; the other is if clinical signs are present but are not
observed. The latter scenario is partially time dependent, there being a limited period
during which infection may be clinically detected (of up to several weeks duration).
As serological surveillance will normally start several weeks after the last clinically
observed case and the frequency of cases in the tail end of the epidemic is low the
time dependent effects may be disregarded and the two modes by which a farm may be
missed considered as one probability. Hence in order to use the model [Diggle, 2006]
it is necessary to estimate a non-discovery multiplier to allow for the probability that
an infected farm is not clinically detected during the first few weeks post-infection and
then goes on to become a latently infected farm. This probability may be different for
every farm and is likely to change over the course of the epidemic and post-epidemic
period as surveillance efforts vary. Unfortunately only limited data are available to
estimate this parameter for each farm.
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2.3.2.3 Estimation of probability of discovery of infection
Serosurveillance in Devon, after the 2001 epidemic, involved sampling and testing of
some 4,407 farms out of the estimated 5,000 remaining sheep farms [DEFRA, 2002].
For the purposes of this analysis I assume that all farms that could be serologically dis¬
covered were discovered. The sero-surveillance identified ten holdings as seropositive in
Devon after the slaughter date of the last infected premises (I have not considered the
five serologically detected premises prior to this date as representative of latent infec¬
tions). 172 holdings were identified as infected premises during the epidemic in Devon
having been detected either clinically or by in-epidemic sero-surveillance. Exploratory
data analysis suggests that farms that were discovered during the epidemic were more
likely to have cattle present and more likely to be close to other infected premises. A
logistic regression model estimated in a Bayesian framework was used to model the
heterogeneity of discovery probability across farms whilst capturing the uncertainty in
these parameter estimates resulting from the limited data. Given the limited number of
serologically discovered farms in the data set I elected to use binary predictor variables
of cattle presence (i.e. cattle numbers greater than zero) and adjacency to the nearest
IP (less than 3 Km) to reduce the model parameter count. The 3 Km adjacency cut¬
off was selected as regulations require there to be a heightened surveillance during an
epidemic in the area within 3 Km of infected premises and hence likely to be a higher
probability that an infected farm is discovered. The probability of detection is assumed
to remain fixed for each farm over the course of the epidemic in the absence of sufficient
data to estimate a time dependent effect.
The probability of discovery of an infected farm was modelled:
cz
Prob (discovery) = —
Z = A) T PcattleXcattle T PnearXnear
Where exp(/3o) is the baseline odds of discovery, exp(/3cattie) the odds ratio for discovery
if cattle are present and exp(f3near) the odds ratio for discovery if the farm is within
3 Km of an IP. Xcattie and Xnear are indicator variables for presence of cattle and
adjacency to an IP.
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The parameters of the logistic regression model were estimated from the sero-surveillance
results for Devon in 2001 using the JAGS software [Plummer, 2003] to produce 5000
sets of samples from the posterior distribution of the parameters after a burn-in of 5000
simulations. Alternative parameterisation and the inclusion of different predictors were
compared using the Deviance information Criterion [MRC Cambridge]. Chain conver¬
gence was assessed using the Brooks, Gelman and Rubin statistic [Brooks and Gelman,
1998].
Draws from these posterior distributions were then used with demographic data from
the 2001 Agricultural census (as a sampling frame and source of stock/location data)
to estimate the mean probability of discovery, if infected, for each sheep farm in Devon.
The discovery model does not account for farms that were infected, not discovered dur¬
ing the epidemic but subsequently culled as part of the disease control process (where
farms contiguous or otherwise associated with infected farms where pre-emptively culled).
If a future epidemic used a similar control process the results from this study would
be valid as such undiscovered farms would face a similar risk of being culled. Different
future disease control processes would bias the performance estimates based on this
study.
Probability of infection from a published model [Diggle, 2006] and probability of dis¬
covery if infected from the above model are combined to estimate the daily probability
for each sheep farm that the farm has become infected and that the infection has not
been detected. This assumes that the probability of discovery and probability of infec¬
tion are independent, conditional on the risk factors used in the infection and discovery
models.
The resulting daily probability of farm i becoming infected yet not clinically detected
is converted to a probability that farm i has become infected yet not clinically detected
at any point during the epidemic, Pi, assuming Pi(t) is independent (see section 2.5.5)
using:
pi = 1 - 11 (! - Pi,t)
te(T)
Where if the probability of latent infection on farm i on day t from the Diggle [2006]
and discovery models and T duration of the epidemic.
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2.3.3 System sensitivity versus number of farms sampled
The system sensitivity (SSe) of risk based surveys is estimated using a range of farm
sample sizes (n) from just one farm to the whole population, by preferentially selecting
the n farms with the highest probability of latent infection. This result assumes that the
within-farm sensitivity is 100% i.e. if a latently infected farm is selected and sampled
that infection, if present, will be detected with certainty. The results are shown in
section 2.4.3.
2.3.4 System sensitivity of random sampling
For comparison the expected system sensitivity for randomly selected samples is esti¬
mated by simulation. The sampling is assumed to take place from within the 3 Km
protection and 10 Km surveillance zones. For each sample size (n) of farms from 1 to
the remaining, post-epidemic, population of 3526 sheep farms, within the protection
and surveillance zones, 1000 random samples of size n were drawn (without replace¬
ment). The system sensitivity of each sample was calculated using equation 2.2 and
the mean for each sample size stored. Additionally the worst case results are estimated
by simulation of selection of farms in order of increasing risk of latent infection. This
gives a lower bound of system sensitivity for a given farm sample size. The results are
shown in section 2.4.3.
2.3.5 Zonal location of sampled farms
Conventionally farms are sampled from within the surveillance and protection zones.
This may not be the most efficient approach; it is possible that farms outside these zones
may be at higher risk of latent infection and hence should be sampled with priority. To
investigate this I classify farms by decreasing probability of latent infection according to
their location within their zones. The zones used are the current 3 Km protection and
10 Km surveillance zones constructed using the respective buffers around the 172 source
infected premises from the Devon 2001 epidemic. The results are shown in section 2.4.4.
Chapter 2. Risk based surveillance design 40
2.3.6 Consequences of imperfect information / robustness analysis
The above methodology makes the strong assumption that the model used to estimate
each farm's probability of latent infection is correct. It does not assume perfect infor¬
mation about each farm's latent infection status but perfect information about each
farm's probability of latent infection. In reality any model estimating the probability
of infection in a farm will have error. In this section I investigate the sensitivity of
the performance gains of risk based sampling to uncertainty in the performance of the
predictive model.
With risk based sampling it is the rank of estimated probabilities and their heterogeneity
that determines the choice and expected benefits of farm selection. A model that
estimates the probabilities as a monotonic increasing function of the true probabilities
will still be able to perfectly inform selection of an optimal sampling set (though give an
incorrect estimate of its system sensitivity) for a given sample size. Sub-optimal farm
selection will only occur when the model causes incorrect selection of lower probability
farms for inclusion in the sample. Imperfect models that correctly rank the farms' risk
of undiscovered infection will still, however, incorrectly estimate the system sensitivity
achieved by a survey.
To investigate the effect of model uncertainty I have used two sets of models which have
an error component. One modifies the estimated probability of infection for each farm
using a transformed normal error component. The other set randomises a proportion of
the estimated probabilities so that only a proportion of the farms' have an accurately
estimated risk of infection. These models are then used to select farms and with the
original, error-free model to estimate the system sensitivity performance of the resulting
sample sets:
2.3.6.1 Transformed normal error approach
The Diggle [2006] model and discovery model are used to estimate the probability of
latent infection Pi for each farm i. This value is then transformed to the log-odds scale
and a normally distributed error component is added. The result is then re-transformed
to the probability scale:
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P\ = invLogit (logit(Pi) + N(0, a))
Where Pf is the transformed probability of latent infection on farm i, logit is the
logistic transformation logit(x) = log(1/(1—x)) and invLogit the inverse invLogit[x) =
1/(1 + exp(-x)). For o greater than zero this will add an error component to the
model's predictions. For a range of a from 0 to 25 the estimated probabilities with error
were used to select farms for sampling and the probabilities from the original [Diggle,
2006] model were used to estimate the resulting system sensitivity (performance). This
estimation was repeated 1000 times to provide an estimate of the mean performance
with each level of model error. The results are described in 2.4.5.
2.3.6.2 An alternative partial knowledge approach
Rather than simulating errors in the estimation of each farm's risk I also estimate
the performance of risk based sampling if I can only correctly estimate the risk for a
proportion of all farms. This was done for proportions from 1 (i.e. perfect knowledge)
to 0 (i.e. no information on risk - random selection). The results are shown in section
2.4.6.
2.3.7 Effect of risk based sampling on delay to declaration of disease free¬
dom
Given a selected set of farms for sero-surveillance sampling (whether by the above
model-driven method or by another, e.g. random or a veterinary expert directed
method) there may be flexibility to choose the order with which farms are visited
and sampled. Sampling and subsequent sample handling, analysis and recording may
introduce delays of several days between sampling and result. If a sampled farm tests
positive for infection and virus is subsequently isolated on a farm it may be classified
as a new outbreak and consequently disease freedom may not be declared until a fixed
period has elapsed after the culling of stock on this farm. Hence it is desirable to order
sampling such that farms that are most likely to be latently infected will be visited,
sampled and analysed first.
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To estimate the potential benefits of ordered sampling I estimate time from start of
sampling to identification (on average) of the last positive farm for sero-surveillance in
Devon. A sample set of farms of a given size are selected either at random from the
whole population or by decreasing risk of latent infection using the model, sampling
from these farms is then simulated over a surveillance period assuming that 50 farms
can be sampled each day. In the risk based approach high risk farms are sampled
first. In the random approach the farms are sampled in a random order. Then over
repeated simulations the status of sampled farms is simulated (using a bernoulli process
with probability equal to the farm's probability of latent infection). For all farms this
status is combined with their simulated sample timing data to give the time that each
positive farm was sampled. Hence the maximum of this allows estimation, for each
sampling approach, of the time of sampling of the last positive farm. Repeated over
the simulation set this gives an estimate of the time from start of sampling to the
sampling of the last positive farm for each approach (d).
d = max {sampleDatej x 6ern(Pl)}lGfarms to sample
Where d is the date of sampling of last positive farm, sampleDatej the sampling date
for farm i and bern(Pi) a bernoulli random variable with probability Pi. I assume that
50 farms are sampled and tested each day.
The simulation was repeated 5000 times for a range of sample sizes and the mean of
the latest dates stored. The results are described in section 2.4.7.
2.4 Results
2.4.1 Results from latent infection model
The model, with the base baseline-risk parameter (Ao = 4.88 x 10~5), estimated an
expected 11.2 latent farms in Devon with 7.8 within the protection zone (0-3 Km
from the nearest IP), 3.0 within the surveillance zone (3 - 10 Km from the nearest IP)
zones and an expected 0.4 farms outside these zones. The spatial distribution of risk of
latent infection is shown in Figure 2.2. Farms with a high probability of harbouring a
previously undiscovered infection are spatially associated with the premises that were
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identified as infected during the epidemic. The spatial component of risk of latent in¬
fection will be a combination of the increased risk of farms near to detected infected
premises and the increased probability of undiscovered farms being further from de¬
tected infected premises. The results suggest that the modelled risk overwhelms the
discovery effect such that overall farms near to detected infected farms are more likely
to be latently infected.
Table 2.3 gives the mean result of 500 simulations for the 3 km protection zone, the
10 km surveillance zone and the whole region. Results are given for each zone and
cumulatively across zones. They are the number of farms, the expected number of
latently infected farms and the system sensitivity if all farms in the zone were sampled
with an on-farm survey of 100% sensitivity.
Figure 2.2: Estimated risk that individual sheep/mixed farms may be latently infected
. holding
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with foot-and-mouth disease at the end of the epidemic. The ten farms
found to be sero-positive in 2001 after the epidemic are also shown (blue
dots)
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2.4.2 Results from discovery model
The results of the latent infection discovery model are shown in table 2.4. Farms with
cattle present were much more likely to be detected, if infected, during the epidemic as
were farms within 3 kilometres of a previously infected farm. The magnitude of these
estimates has a large uncertainty.
2.4.3 Performance of risk based sampling
The comparative results of risk based sampling are shown in Figure 2.3. Risk based
sampling gives a markedly better performance than random sampling for the same
sample size (number of farms visited); for example, assuming the model provides perfect
information about a farm's probability of latent infection, only 225 farms need to be
sampled to give a 95% system sensitivity as compared to 1083 farms if random sampling
is used. The system sensitivity performance gains relative to sample size would either
increase the probability that the survey system detects disease, if present, or reduce
the cost of surveillance to attain a required (95%) system performance. The gains of
employing risk based sampling decrease as the sample size increases until approximately
2000 farms are sampled when both risk based and random sampling converge onto a
system sensitivity of 1. Figure 2.3 also shows the worst case for sample design where
farms were sampled in order of increasing probability of detecting latent infection, i.e.
the lowest risk farms are selected with priority. This identifies a lower limit for the
performance of the surveillance system, i.e. a worst case if farm selection was based on
a model that ordered the risk of infection in farms as the complete inverse of the true
risk.
Zone Total Expected latent SSe Cumulative
farms farms (all farms sampled) Farms
Protection zone 1439 7.79 0.976 1439
Surveillance zone 2087 3.01 0.821 3526
Other 1330 0.381 0.337 4856
Table 2.3: Sheep farm distribution and model predictions
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Mean SD Odds
Cattle present 3.11 0.97 22.5
Near IP (<3 Km) 2.67 0.87 14.4
Table 2.4: Results from Bayesian discovery model - mean and SD of coefficients of
logistic model (and odds ratio) predicting discovery of an infected farm.
0 1000 2000 3000 4000 5000
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Figure 2.3: Comparison of system sensitivity of random (blue line) and risk based (red
line) sampling. Horizontal dashed line is at 95% system sensitivity (the
conventional target for farm level post-epidemic surveillance) with vertical
lines showing corresponding sample sizes. (Worst case performance shown
with an orange dotted line)
2.4.4 Zonal sampling
Conventionally, sampling has drawn samples, unless veterinary judgement suggests oth¬
erwise, from the 10 Km surveillance zone. Figure 2.4 shows the zone that samples would
be taken from when risk based sampling is used with the potential to draw from any
farm in the restricted area. As sample size increases to 1476 farms the first farm out¬
side the protection and surveillance zones will be selected. By a sample size of 2254
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1% of farms will be selected from the area outside the surveillance zone. These sample
sizes represent system sensitivities of virtually 100% and as such would be unlikely to
be required for regulatory purposes. Hence this suggests, given the risk model used in
this study, that the conventional approach of sampling within the surveillance zone is
rational if random selection within a geographical zone were a regulatory requirement.
i 1 1 1 1—
0 1000 2000 3000 4000




1 % of non PZ/SZ selected
Figure 2.4: Source zone of farms when the farms are allocated in decreasing probability
of latent infection. Vertical dotted lines showing points at which first and
1% of farms outside surveillance zone and protection zone will be selected.
The red line shows the estimates system sensitivity (SSe) using risk based
selection for the range of sample sizes.
2.4.5 Consequences of imperfect information - logistic error model
Imperfect models of farm risk will give a reduced performance for risk based selection
for surveillance. In this section error was added to the model's estimated probability
that each farm is latently infected. The error component was drawn from normal dis¬
tributions with different variances. The error was added in the logistic domain. Figure
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2.5 shows the effect of this error on the model estimates with increasing variance. The
fitted regression lines show that, as expected, even with high added error the noisy data
still retains the overall trend of the noise free estimates. Figure 2.6 shows estimated
system performance loss of using risk based selection of farms with error introduced to
the risk model. The performance versus sample size of risk-based selection is compared
to the performance of random selection of farms from within the 10 Km surveillance
zone. The uncertain models with high error will (when bad enough) perform worse,
on average, when selecting from the whole region than random selection from protec¬
tion/surveillance as these traditional zones do contain the majority of risk. A logistic
noise standard deviation of 10 downgraded the risk based selection to have similar
performance to random, surveillance zone based selection.
Figure 2.6: System sensitivity versus sample size (number of farms selected) for error-
free, uncertain and worst case models versus random selection. Error-free
model shown in red and blue line shows random selection from protection
and surveillance zones) - uncertain model results shown in grey annotated
with standard deviation of additive error component (N(0,a)) on the log
odds scale (a from 1-25).
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(c) a = 5 (d) cr = 10
Figure 2.5: Probability of latent infection in farms in Devon (in ascending order - x-
axis) plotted against this probability with an added logistic normal error
component (P with error — P?) ( invLogit(Logit(Pi) + 7V(0,cr)) ) for dif¬
ferent cr. The red dotted line is a fitted linear model (form Pf = a+ bx Pi).
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2.4.6 Consequences of imperfect information - proportion known model
An alternative exploration of the impact of imperfect models is shown in figure 2.7.
The method estimates the system sensitivity when only a given proportion of the farms
have their risk known. Risk based sampling will perform more efficiently than random
sampling from the 10 Km surveillance and 3 Km protection zones until the proportion
of accurately known farm-risks of latent infection drops below approximately 20%.
0 250 500 750 1000 1250 1500
Number of farms sampled
Figure 2.7: System sensitivity versus sample size (number of farms selected) for error-
free and partial knowledge models versus random selection. Error-free risk
based model shown in red. Blue line shows random selection from pro¬
tection and surveillance zones) - partial knowledge model results, with se¬
lection from whole region, shown in grey labelled with percentage of farm
where risk is known. The models range from 0% to 100% of farms' risk
known in 10% increments.
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2.4.7 Effect of ordering on delays to disease freedom
The time to last positive sample is plotted against the system sensitivity for a risk-
ordered and randomly ordered approach to farm sampling in figure 2.8. The result
demonstrates that risk based sampling and ordering, given a desired system sensitivity,
will result in any farms that turn out to be test positive being selected and sampled
markedly sooner than if ordering is not used. For a target system sensitivity of 95%
risk based selection and ordering will, on average, mean that the last positive farm
is sampled at 2.8 days after sampling commences whereas random selection will mean
that the last positive farm is sampled at 18.4 days. Detection of a test positive farm will
result in follow up confirmatory tests and possible disease control consequences such
as further investigation of contact farms and animal culling. Hence risk based ordering
may decrease delays to ultimate declaration of disease freedom in the region.
2.4.8 Sensitivity analysis with respect to baseline risk on infection
The previous results use a baseline hazard (A = 4.88 x 10~5). Changes in the baseline
hazard will shift the estimated latent probabilities for all farms in the area with con¬
sequent effects on the estimates of system sensitivity for different sample sizes. This
effect is illustrated in figure 2.9 where the system sensitivity of risk based and ran¬
dom selection is shown against sample size for three different baseline hazards. As the
baseline risk decreases the relative benefits of choosing farms with a high probability of
latent infection increase. Or alternatively, as risk increases it becomes less important to
focus surveillance — intuitively, infection is more likely to be present on any randomly
selected farm so it matters less where you look.
Table 2.5 shows this quantitatively. As baseline hazard decreases there are fewer, on
average, latent farms in the region. More samples are required to achieve a target
system sensitivity and hence the relative benefits of risk based surveillance increase.
Additionally the time saved in delay to sampling the last positive farm compared to
random selection increases as baseline risk decreases; i.e. risk based selection and
ordering becomes increasingly beneficial to both performance and timing as baseline
hazard decreases.
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Figure 2.8: Expected time to last positive farm for randomly selected/ordered and risk
model selected/ordered sampling.
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(a) A = 10 X 10~5
0 1000 2000 3000 4000 5000
Number of farms sampled
(b) A = 5 x 10"5
0 1000 2000 3000 4000 5000
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(c) A = 1 x 10-5
Figure 2.9: Effect of decreasing baseline risk of farm infection on the performance of
surveys with increasing sample size. System sensitivity (SSe) of risk based
selection is shown in red and random selection is shown in blue.
Chapter 2. Risk based surveillance design 53
A Latent farms Samples Samples PZSZ ADelay
(in region) (Risk based) (Random)
5e-04 111.1 13 103 12.1
le-04 24.0 75 478 22.6
5e-05 12.0 184 945 26.9
base 11.0 225 1083 27.0
le-05 2.0 1934 3337 25.8
Table 2.5: Effect of baseline risk. The table shows the effect of decreasing baseline
hazard (reference value was 4.88 x 10" 5) on the number of latent farms in
the region, the number of samples required to achieve 95% system sensitiv¬
ity for risk based and random selection (from the surveillance zone) and the
reduction in delay (ADelay) to finding the last positive farm (if all farms
are sampled using risk based compared to random ordering). The (ADelay)
measures how targeted sampling will speed up detection of any positive
farms — a higher number represents a greater benefit to risk targeted sam¬
pling.
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2.5 Discussion
This study shows that a suitable model of infection risk can be used to target and
order sero-surveillance sampling to increase efficiency and reduce delays to declaring
disease freedom after an foot-and-mouth disease outbreak. Historically, post-epidemic
surveillance for foot-and-mouth disease has targeted sampling to farms within the 3
kilometre protection zone and 10 kilometre surveillance zone, presumably on the basis
that any undetected infected farms are most likely to be in these areas. This involves
an implicit spatial assumption about disease transmission which may be derived from
veterinary assessment. Risk based selection refines this to target specific farms with
the vicinity of the outbreak/epidemic . The benefits of this technique are shown to be
potentially large with an 80% reduction in sample sizes for the same system performance
(95% SSe) and reduction in timing to last positive case of 15 days.
2.5.1 Model uncertainty
The realisation of these potential benefits is dependent on the accuracy with which a
predictive risk model can order farms by infection risk. I have used simple approaches
to model uncertainty to explore the consequences of imperfect knowledge of farm infec¬
tion risk. This shows that the benefits of targeted sampling were reasonably robust to
the introduction of noise/uncertainty into model estimates; knowledge of only 20% of
farms' infection risk will provide a system of better performance than surveillance-zone
targeted sampling. As one would intuitively expect, as long as a model has some infor¬
mation value it will increase efficiency and reduce delays to declaring disease freedom.
However, if a predictive model of farm infection risk is particularly poor its application
could result in a survey that's efficiency and timing would be worse than a randomly
sampled and ordered survey that draws from the traditional (overall high risk) surveil¬
lance and protection zones. Whilst such a scenario is unlikely it means that the risk
based sampling and ordering approach should be used cautiously, especially with models
that are potentially over-fitted, unstable or otherwise suspect.
Bias in the model estimating risk may result in expected gains of sampling to be under
or over estimated as the quantitative benefits will depend on the degree of heterogeneity
in the farm infection risk probabilities. As previously discussed, a flat risk distribution
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will give no benefits to risk based surveillance whereas a risk distribution with a small
proportion of very high risk farms will give great rewards to risk based surveillance. In
the case of a biased risk model, whilst the risk-based technique may still propose an
optimal set of farms for sampling the actual estimated benefits from my analysis are
contingent on the distribution of risk of infection in both the region and the sample set.
The study assumes knowledge of the probability that infection is discovered on infected
farms. In the analysis this uses data obtained from post-epidemic sero-surveillance. In
real application these data would not be available. Available options are to assume that
discovery probability is constant across all farms or to use historical data to estimate
discovery probability under the assumption that this probability is similar for similar
farming systems and diseases. These assumptions may reduce the estimated benefits
of the targeted surveillance techniques.
2.5.2 Fixed cost assumption
The study approach assumes that the marginal cost of visiting a particular farm for
sampling is constant. In reality the cost of sampling a particular farm will be conditional
on which other farms have been sampled due to travelling costs and deployment of
sampling teams. Hence it may be more efficient to use a sub-optimal sampling set and
ordering if the consequent increase in required farm numbers and delays to freedom
were outweighed by the reduced costs of sampling adjacent or convenient farms. This
point does not negate the concepts raised in the study but suggests that in application it
may be appropriate to extend the models to include sampling/travelling logistics. The
cost of farm sampling is potentially more variable than latent infection risk depending
on available resources, overall epidemic extent and geographical location.
Regarding the extension to our approach to include variable cost data: I have assumed
that the unit cost of visiting a farm is equal for all farms. The optimisation is then one
of benefit maximisation (in this case for system sensitivity) for a given cost budget. In
reality sampling costs may vary from farm to farm and hence designing a survey that
gives highest sensitivity for a fixed budget becomes more challenging. With a fixed
cost, choosing farms in decreasing order of risk until a budget limit is exhausted will
give the best expected performance for a budget.
When costs are allowed to vary it is necessary to maximise:
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1 - EI (1 - -Pi x pi)
i=Si ..n
1 - n n - Pi)
i=l..N
for a given cost budget such that
i=Si ..n
Where Pi x pi is the product of risk of undiscovered infection and farm sensitivity on
the ith farm, si..n is a sample of n farms, N is the number of farms in the area and Cj
is the cost of sampling /testing on the ith farm and C is the cost budget. Removing
elements from 2.3 that are independent of the selected sample this means maximising:
(2.3)
I I Pi * Pi
i=S\..n
given the cost constraint.
There is no simple rule to select farms for inclusion in a sample given their estimated
risks (Pi) and costs (cj). With several thousand farms as candidates for a survey which
may be cost limited to roughly hundreds of farms there are too many combinations of
possible sample sets to allow an exhaustive search. This search is further complicated
as the costs of visiting a particular farm will be conditional on which other farms are
being visited. An optimal sampling strategy if cost data were available would require
carefully designed models and search algorithms to determine most cost-efficient sample
sets.
2.5.3 Assumption of 95% farm sensitivity
For the graphical comparisons of performance I have assumed that all farms' livestock
are sampled and tested to give a farm level diagnostic sensitivity of 95% in accordance
with previous OIE codes [OIE, 2005b]. Depending on the size of the farm and the
available diagnostic tests the cost of reaching this performance will vary from farm
to farm and may even be unobtainable when the individual animal diagnostic test
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sensitivity is lower than the farm level performance target and the farm size is small
[Greiner and Dekker, 2005]. If this constraint is removed then a survey design would
have freedom to choose not only which farms in the region to sample but rather which
animals in the region to sample and indeed which diagnostic test to use and how to
interpret the results for each sample. Although the removal of these constraints would
give a potentially lower cost method of achieving a required regional performance it is
a high dimension optimisation problem that is computationally difficult. Furthermore,
the resulting varying farm by farm performance and sampling requirements may be
politically harder to justify to both farmers and decision makers.
2.5.4 Spatial correlation — disease clustering
This analysis has used a spatial model to estimate the probability that farms are latently
infected after an epidemic. However the interpretation of surveillance results disregards
any spatial correlations between farms' risks. Foot-and-mouth disease infection at a
farm level tends to be spatially clustered, i.e. a farm near an infected farm is more
likely to be infected than a random farm. Thus by sampling and testing a farm more
information is gained about the infection status of nearby farms than about distant
farms. A risk based approach will tend to focus surveillance around high risk areas,
such as previous infected premises. Given two farms of equal risk of latent infection
more information would be gained, if disease is spatially clustered, by sampling a farm
distant from a previous sample site than the one near to it. In the Devon scenario the
infected premises that were identified during the epidemic were relatively dispersed and
the risk based sampling model generates a dispersed sampling field. Hence estimates of
performance benefits in this setting are likely to be reasonable estimates of true gains.
A strategy to explore the issue could consider the explicit spatial correlation of risk in
sampled farms. However, as the spatial correlation information of a farm to add to the
sample set is contingent on the existing members of the sample set it would be necessary
to use an iterative approach to pick sample sets, testing sets which do not necessarily
contain the highest risks of latent infection but that may give more information through
spatial correlation. Such an analysis would be numerically complex, potentially taking
a factorial, TV!, computational steps where N is the desired sample size. These problems
can be computationally intractable [Harel, 1987].
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2.5.5 Assumption that the non-discovery probability residual error is con¬
ditionally independent of residual in disease risk model
To estimate the probability that a farm is infected but has not been detected I have
used a model that estimated probability of infection and detection and a model of non-
discovery probability. The calculation of probability of undiscovered infection using
the simple product of probabilities from these two models assumes that the residuals
or error in these two models are independent. If the errors are correlated the final risk
estimate will be biased.
2.5.6 Combination of multiple risk models
As already mentioned the risk-based strategy is, in effect, a development of the existing
strategy that focuses surveillance on farms within the surveillance and protection zones.
The existing strategy implies a 10 Km radially based model of infection risk. It is
possible that there are other models of infection risk, which may be mathematical,
empirical or conceptual, that one may wish to employ to inform sampling. These may
be combined to design a sampling strategy by using appropriately weighted combination
of the models' estimates to give a synthesis of their risks and using this to select and
order sampling.
2.5.7 Effect of testing and control during the epidemic
To simplify the analysis I have not attempted to model the ongoing culling and test¬
ing that would normally occur during an outbreak; none of the at-risk population are
considered to have been declared as infected premises during the outbreak. In a real
outbreak farms would be culled, neighbouring farms would be subject to ongoing clin¬
ical and serological surveillance and latent disease may thus be discovered before the
post-epidemic surveillance period. Nonetheless, although these discoveries may alter
the estimates of the benefits of risk based and ordered sampling the risk based sam¬
pling approach will remain more efficient and bring an, on average, faster return to
declaration of disease freedom than randomised sampling. However the estimates of
benefits from the current study may over or under estimate the benefits under different
control strategies.
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2.5.8 Assumption that farm level sensitivity and probability of latent infec¬
tion are independent
Risk of infection and probability of discovery of infection during an epidemic were
estimated in this analysis on a farm by farm basis. However the sensitivity of on
farm detection, given a farm was selected for investigation was fixed at 95%. This is
the target on farm value based on previous OIE recommendations [OIE, 2005b] that
individual animals be sampled within each selected epidemiological unit to give a 95%
probability that an infected unit would be detected if 5% of animals on that unit were
infected. Even if each farm survey is designed to meet this criteria there will be farm
by farm variation in the true farm level sensitivity. Probabilities of latent infection on a
farm by farm basis varied (as estimated by the model) from approximately 2 x 10 to
2 x 10~2 whereas on farm sensitivity is unlikely to vary beyond 20-100%. For example,
a sensitive test applied to all animals in a group will give a farm level sensitivity
approaching 100%, a poor (50% sensitive test applied to a minimum sample size of 40
animals out of a group of 100 with only one animal infected would still give a farm
level sensitivity of 20%). So variation in latent risk probabilities is likely to overwhelm
variations in on farm sensitivity. Hence any dependence of latent probability and farm
level sensitivity will not affect the first order magnitude of the estimates of performance
gains.
2.5.9 Concluding remarks
Current, random sample based surveillance is likely to be inefficient requiring more
farms to be visited and more animals to be sampled than necessary to achieve a given
performance target. Risk based selection of farms for post epidemic surveillance is more
efficient and will also expedite the process of declaration of disease freedom. Prompt
detection of latently infected farms may also reduce the risk of onwards transmission
and recrudescence of the outbreak. Whilst risk based selection is robust, to give the
best and most reliable gains, risk models also need to be robust and precise hence







The next three chapters examine the application of serology based surveillance for foot-
and-mouth disease in the Thrace region of Turkey. Thrace is an important region as
it lies between the Asian region of Turkey, subject to repeated foot-and-mouth disease
incursions and Europe that remains generally free from foot-and-mouth disease without
vaccination [OIE-WAHID, 2008]. A foot-and-mouth disease vaccination program in
Thrace is currently in use to provide a buffer for disease control. Annual or biannual
surveys are conducted in Thrace to monitor the disease status of livestock with an
eventual aim to demonstrate freedom from foot-and-mouth disease .
In this chapter I estimate, using a stochastic simulation model, the performance of the
current Thrace serological surveys. The surveys are designed under a set of assumptions;
in the analysis I relax these with regard to the animal-level diagnostic test performance
and underlying epidemiology of foot-and-mouth disease. The result is an estimation
of the village-level performance of the surveys. The results show that under most
circumstances the surveys have sufficient sensitivity to detect disease unless present
at a very low prevalence (which may not represent an important onwards transmission
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threat). However the surveys' initial specificity is very poor at a village-level potentially
resulting in many villages being declared as exposed to disease when they are not.
3.2 Introduction
3.2.1 Foot-and-mouth disease in Thrace
Thrace is the European region of Turkey covering 3% of the land mass and 10% of
the population (see figure 3.1). Thrace borders Bulgaria and Greece to the West and
Eastern (Anatolian) Turkey to the South and East. It acts as a buffer zone between the
foot-and-mouth disease endemic Anatolian region of Turkey and remainder of Europe.
A European Union funded project (EUFMD Commission) assists the Turkish veterinary
services with vaccination of Thrace's 403,000 cattle and 516,000 small ruminants using
a trivalent foot-and-mouth disease vaccine against foot-and-mouth disease serotypes O,
A and Asia 1 [DEFRA, 2005]. The short term aim of the EUFMD project is to monitor
and reduce foot-and-mouth disease incursions within the area. The long term goal is
permanent eradication of foot-and-mouth disease within the Thrace region and official
declaration of disease freedom. Declaration of disease freedom and satisfactory disease
control and monitoring systems are required as Chapter 12 of Turkey's accession to EU
membership [European Council, 2008].
100 Km
Figure 3.1: Map of North-Western Turkey with Thrace provinces named
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Movement of cattle from the foot-and-mouth disease endemic region of Anatolia into
Thrace is legally banned although an annual religious festival (The Kurban Festival held
on dates set according to the Islamic Calendar) results in large movements of animals
into Istanbul during the festival period. Unsold animals are then allegedly moved,
illegally, into Thrace maintaining a regular disease threat to the region's livestock.
Foot-and-mouth disease is endemic in Anatolia (Asian Turkey) with 61 to 177 outbreaks
reported each year since 2000 [DEFRA, 2005]. Two serotypes of foot-and-mouth disease
are commonly found in Anatolian Turkey; Type O and Type A. Although a trivalent
vaccine is used in the region, control is challenging as invasion of new subtypes mean
that vaccine protection is not complete. This is a particular challenge with serotype-A
which has a high antigenic diversity [Klein et ah, 2006]. Some of the recent outbreaks in
Anatolia have been identified as serotype-A subtype Iran 05. These may have occurred
due to poor vaccination coverage or reduced cross protection with the A Iran 96 subtype
on which the trivalent vaccination is based. The distribution of serotypes until 2006 in
Turkey and the neighbouring Middle Eastern countries is illustrated in figure 3.2.
mn FAO w<«ui l t.i FM::
Figure 3.2: Isolates of foot-and-mouth disease from Turkey and neighbouring countries,
2004 to 2006, as identified by IAH Pirbright. (Figure from DEFRA [2007b])
Thrace has been apparently free of foot-and-mouth disease since a serotype-0 outbreak
in 2001 (see figure 3.3). However in early 2006 there were 16 foot-and-mouth disease
outbreaks due to serotype A-22 like virus [DEFRA, 2006b]. These were thought to
be the consequence of illegal movements from the Anatolia region. The outbreaks
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occurred from the 11th January to 26s' March 2006. Spring sero-surveillance samples
were taken from 19th February to 6th March 2006. A further solitary outbreak of
serotype-A Iran 22 foot-and-mouth disease occurred on the 14th June 2006. Previous
trivalent vaccination did not include the A-22 serotype so emergency vaccination with
A-22 vaccine was carried out from IIth February to 14'ft April 2006. The estimated
coverage for this campaign was 92% [EUFMD advisory group, 2006]. Outbreaks are
recorded in DEFRA reports [DEFRA, 2007b,c,a, 2005, 2006a,b] (see table 3.1 for a
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International guidelines require declarations of disease freedom to be supported by a 24
month period with no foot-and-mouth disease outbreaks and a 12 month period of sero-
surveillance demonstrating no circulating disease [OIE, 2009b]. To monitor effectiveness
of the foot-and-mouth disease control program and eventually help demonstrate disease
freedom the EUFMD Commission co-ordinate an annual (and occasionally biannual)
sero-surveillance campaign aiming to detect circulating foot-and-mouth disease virus in
the Thrace region.
3.2.2 Historical Surveillance Design
Currently, sero-surveillance in the Thrace region is conducted one or two times a year
and has been based on OIE guidelines to substantiate freedom from disease. The
surveillance uses a two-staged design with villages considered to be the epidemiological
group and animals the individual unit. From a sampling frame of all the villages in
Thrace, sufficient villages are sampled such that if disease were present in 2% of the
villages there would be a 95% confidence that at least one infected village would be
detected given the surveillance has a village-level sensitivity of 95%. Animals (cattle)
are sampled from within each chosen village such that if 5% of animals within the
village were infected at least one animal would test positive with a 95% confidence
given a stated diagnostic test sensitivity and specificity. Currently, sero-surveillance in
Thrace has uses the CEDITEST [Sorensen et al., 2005; Wen-Bin Chung et al., 2002] as
the primary screening test and it has been assumed, for survey design, that this test
has a sensitivity of 90% and a specificity of 100% in the Turkish cattle population.
The sero-surveys have been designed using 'Freecalc' software [Cameron and Baldock,
1998a,b] that determines a two-stage sampling design considering finite population sizes
and imperfect diagnostic tests. In 2005 there were 927 villages recorded in the sam¬
pling frame. Using a herd-level sensitivity of 95% aiming for a system sensitivity or
confidence of 95% a survey would need to sample from 142 villages. The current survey
designs have specified 152 villages to be sampled. This permits a degree of purpo¬
sive sampling of perceived higher risk areas such as Istanbul (EUFMD research group,
personal communication 2006).
If two stage disease freedom surveillance, as described in Cameron and Baldock [1998b],
is used as the design methodology the population of each selected village would be used
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to calculate the optimal sample size for that village. However in Thrace, to avoid
complicating the survey design in the field, a fixed sample size has been used within
each village. This has been set to 64 animals from each village. This sample size
corresponds to the 'Freecalc' optimal sample size for a population of 1000 animals with
a test of 90% sensitivity and 100% specificity aiming to detect 5% prevalence with 95%
confidence. With village cattle sizes below 1000 head this sample size will, theoretically,
be greater than required. With larger village cattle populations the sample size may
be too small although this effect will be insignificant.
Any animals testing positive with the initial CEDITEST NSP test are re-tested with a
repeated CEDITEST NSP test and a BOMMELI CHEKIT NSP test [Intervet, 2008]
and any animals testing negative on the second and third tests are considered negative
for the purposes of substantiation of disease freedom. This strategy aims to remove
false positive test results that are the consequence of diagnostic test repeatability errors.
However this policy will cause a slight reduction in the overall sensitivity of the diagnosis
at an animal and hence village and system level due to variance of test results in truly
infected animals [Cannon, 2001].
Surveys are designed to fulfil their design criteria under a set of assumptions including
disease epidemiology, livestock demography and diagnostic test performance. In this
chapter I use a stochastic simulation model of the epidemiology, sampling and diagnosis
of disease in the Thrace region to estimate how well the designed surveys will perform
as their design assumptions are relaxed.
The epidemiological parameters describing the prevalence of disease need to be estimat¬
ed/stated to evaluate serological surveillance performance. From a regulatory perspec¬
tive if the rules state a design prevalence (e.g. 5% within an epidemiological group) the
survey simply needs to achieve the stated confidence of detecting this prevalence. Since
2005, OIE guidelines have become less prescriptive and treat sero-surveillance as part of
a portfolio of evidence to substantiate disease freedom [OIE, 2009b]. This suggests that
measuring the survey systems performance against an arbitrary design prevalence/epi¬
demiology may not be sufficient and that surveys should be assessed in their ability
to detect disease present at a realistic prevalence. The challenge here is that there are
limited data to estimate a realistic prevalence. The epidemiology of foot-and-mouth
disease is dependent on demography, husbandry practice, environmental variables and
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evolution of viral strains [Grubman and Baxt, 2004]. For the stochastic evaluation the
surveillance performance will be assessed against both the design prevalence and a set
of relatively simple but more realistic epidemiological models.
3.3 Methodology
3.3.1 Overview
Several approaches may be used to estimate the diagnostic performance of a sero-
surveillance system. With simple surveys, models of foot-and-mouth disease epidemiol¬
ogy and test performance the overall system performance can sometimes be determined
analytically [Cameron, 1997]. However for more complex survey systems and/or when
it is required to model uncertainty in the knowledge of the epidemiological and diagnos¬
tic systems stochastic simulation models are normally necessary to estimate the overall
diagnostic performance of the system [Tsutsui et al., 2003].
In this study a stochastic model generates simulated sets of exposed and unexposed
cattle populations in villages using a set of candidate foot-and-mouth disease epidemi¬
ologies and the available cattle demography data for Thrace. Then simulated samples
are drawn using the current survey designs and the analysis and interpretation of these
is simulated using plausible diagnostic performance data from recent diagnostic test
evaluations (see figure 3.4).
3.3.2 Demography and epidemiology
A sampling frame is available for sero-surveillance in Thrace in 2005 listing 927 villages
in the region with an estimate of their cattle population (with the exception of one
missing value which was excluded). The distribution of village cattle populations is
shown in figure 3.5. For the simulation model, village cattle populations are randomly
drawn with replacement from this empirical distribution.
A previously exposed village is modelled as having one or more exposed animals. A
number of simple models can be used to describe this within-village infection distribu¬
tion:








Brocchi 2006 (laboratory evaluation)
Engel 2008 (Bayesian evidence synthesis)
unvaccinated
Figure 3.4: Schematic showing the components and outline structure of the stochastic
evaluation model
Single individual - worst case: A single individual animal in an infected village rep¬
resents the worst case from the perspective of detection of disease. Obviously this
may not, necessarily, be the worst case from a disease control perspective as a
single individual, especially in the generally vaccinated population of Thrace may
be considered to represent a low threat of onwards transmission. However, it
is appropriate to use this model as one of the scenarios for the evaluation as it
sets a lower bound for the sensitivity of the village surveillance performance with
respect to within-village epidemiology.
Design prevalence - deterministic: Surveillance has been historically designed in
Thrace to detect infection within a village if it is present within 5% or more
animals. Under this assumption 5% of each village's population is modelled as
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Figure 3.5: The distribution of cattle populations in Thrace villages in 2005
infected. If this value is not an integer the number of infected animals is rounded
up to the next integer.
Design prevalence - binomial process: Under this assumption rather than 5% of
animals in a village being infected the model assumes that the probability that
an individual is infected is 5% and models the infection process in the village as
a binomial process. This will tend to capture some of the variation in epidemic
sizes between infected villages that would be seen in real outbreaks.
Design prevalence - beta-binomial process: The infection process is modelled as
a binomial process within each village with a binomial probability drawn from a
beta distribution for each village. The parameters of this beta distribution are set
to give an overall probability of infection for an individual of 5% with an addition
parameter determining the dispersion or variation in prevalence between villages
[Suess et ah, 2002].
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The distribution of prevalence resulting from these models is shown in 3.6. These
distributions represent the result of applying the above four epidemiology models to all
village sizes (of greater than 64 animals — see later) and then averaging the resulting
prevalence.
Prevalence
Figure 3.6: Epidemiology scenarios used in the stochastic evaluation (sampled over all
herd sizes greater than 64 then smoothed)
3.3.3 Sampling strategy
Sampling in the Thrace surveillance studies has been fixed to 64 animals per village as
previously discussed. In 2005, 52 of the 925 villages had a recorded cattle population
of less than 64. Examination of sero-surveillance reports suggests that if a randomly
selected village has a cattle population less than 64 the field veterinarians will sample
animals from villages in the same district to attain the desired sample size. There
are no records of the actual strategy for selecting these additional villages. For this
stochastic evaluation of village-level sensitivity and specificity only villages with a cattle
population of 64 or greater are considered eligible for sampling.
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3.3.4 Diagnostic test performance parameters
The primary screening test is the CEDITEST ELISA test for non-structural proteins
[Sorensen et al., 2005; Wen-Bin Chung et ah, 2002]. For surveillance design this has
been assumed to have a sensitivity of 90% and a specificity of 100%. Whilst these are
convenient figures for calculation purposes the survey performance needs to be evalu¬
ated under a realistic range of diagnostic test performance parameter values. For the
evaluation of survey performance I have used several models of test performance. Three
derive directly from the studies by Paton et al. [2006] and Brocchi et al. [2006] where
diagnostic test evaluations using animals assumed to have a known disease status are
used to estimate the test's sensitivity and specificity. These evaluations will normally
report a trial size (n) and the number of animals with correct diagnostic test results
(r). A maximum likelihood point estimate will normally be calculated as r/n. So if 100
assumed diseased animals were tested and 98 tested positive the maximum likelihood
estimate for test sensitivity would be 98%. For the stochastic evaluation an uncertainty
distribution is required. For this I have used the Bayesian posterior for sensitivity and
specificity assuming a Bayes prior distribution of Beta( 1,1) [Lee, 1997, page 83] . This
assumes that prior to the evaluation in question the belief about the test performance
was uniform over 0-100%.
Design performance: A base case using 90% sensitivity and 100% specificity with¬
out modelling any uncertainty in these parameters.
Uncertain performance based on evaluations Sensitivity and specificity are con¬
sidered to be uncertain and hence are sampled from distributions informed by
diagnostic test evaluations in known healthy and infected animals. Uses data
from Paton et al. [2006]; Brocchi et al. [2006] shown in table 3.2
Serial testing: In Thrace any animals testing positive with the initial CEDITEST
screening test are then retested with a repeated CEDITEST. Paton et al. [2006]
estimates the combined sensitivity and specificity of serial diagnostic test use
allowing the evaluation to be extended to model the effect of this strategy. Esti¬
mates are also shown in table 3.2.
Detection of carriers: A foot-and-mouth disease carrier is defined as an animal
that has an infection persistent 28 days after initial infection with virus recovered
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from the oropharynx by probang sampling [Zhang and Alexandersen, 2003]. The
CEDITEST has been evaluated in its ability to detect animals in the carrier state
[Paton et ah, 2006].
Vaccination Days Infection P r n Posterior
Status post infection Status mean
N 28-100 Y 1.000 26 26 96.4%
N 100+ Y 0.500 1 2 50.0%
Y 28-100 Y 0.681 62 91 67.7%
Y 100+ Y 0.745 35 47 73.5%
Y 28-100 carrierf 0.864 57 66 85.3%
Y 100+ carrierf 0.892 33 37 87.2%
Y 28-100 carrier! (serial tests) 0.818 54 66 80.8%
N - N 0.998 656 675 97.0%
Y - N 0.995 423 425 99.3%
Y N N (serial tests) 0.995 423 425 99.3%
Table 3.2: Parameter estimates of CEDITEST performance for single testing strategy
(from [Brocchi et ah, 2006; Paton et ah, 2006]) (p is reported sensitivity or
specificity, n is reported sample size and r is inferred number of test positive
(or negative) animals for infected (or uninfected) subjects), (f animals from
which virus is isolated more than 28 days after infection)
A further two models use the diagnostic test performance estimates of Engel et al.
[2008]; this evaluation relaxes the assumption that the disease status of the sampled
animals is known and use the joint test results of six different NSP diagnostic tests to
jointly estimate the sensitivity and specificity of the tests and the prevalence of disease
in the test subject groups. This approach derives from the Hui-Walters methodology
of assessing diagnostic tests without having a gold-standard and, potentially, provides
less biased estimates of test performance with more accurate estimates of the uncer¬
tainty of the performance estimates [Hui and Walter, 1980]. The results of Engel et ah
[2008]'s study are distributions for the sensitivity and specificity of the diagnostic tests.
In a fully Bayesian analysis it would be possible to repeat Engel et ah [2008]'s model
to produce samples from the joint posterior distributions of sensitivity and specificity
for the CEDITEST. This approach does have high computational requirements so as
an alternative I have used beta distributions to approximate the results from Engel
et ah [2008]'s study. Their paper records means and 0.025 and 0.975 quantiles for
each diagnostic test performance measure. I estimated Beta distribution parameters to
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approximate these results using a Nelder-Mead optimiser ('optim' function [R Devel¬
opment Core Team, 2007]) to minimise the sum of squared differences between three
statistics of the reported and candidate distributions:
Y [(* ~ c)2 + (<70.0254 - <?0.025c)2 + (<70.9754 ~ 90.975c)2]
where qn is the nth quantile, t is the statistic from the study and c is the statistics from
the approximating distribution. Estimates for the beta parameters are shown in table
3.3.
Vaccination Status Age Infection Status a b mean
N N 738.7 22.2 97
N Y 52.3 1.7 97
Y N 593.9 6.6 99
Y Y 141.3 25.3 85
Table 3.3: Parameter estimates of CEDITEST performance for single testing strategy
(from Engel et al. [2008]) parameters a and b from fitted Beta(a,b)
In Brocchi et al. [2006] diagnostic sensitivity was assessed at a number of periods after
infection. For my evaluation the periods of 28-100 and greater than 100 days were used;
the former as it reflects likely post epidemic surveillance timing and the latter to cover
the possibility that surveillance (which is annually to twice annually) may take place
more than 100 days after exposure/infection events.
Since 2000 EUFMD [1999] cattle in Thrace have been vaccinated, biannually against
foot-and-mouth disease. Both the epidemiology of disease within an infected group
of animals and the performance of a diagnostic test will vary in response to vaccina¬
tion. Hence the survey evaluation needs to model the influence of vaccination on these
parameters and therefore an estimate of vaccination coverage is required. There are
limited data available to estimate coverage. A survey dated March 2006 [Bulut, 2006]
reports an overall vaccination coverage for Thrace of approximately 90%. There is a
wide variation in estimated coverage across the districts with some districts apparently
having received no vaccinations and others with coverage exceeding 100% (in one case
20% more cattle were vaccinated than were thought to be in the district). Hence these
data can only be used to approximate coverage levels. For this evaluation of survey
performance village-level sensitivity and specificity will be assessed using diagnostic test
evaluation results from studies in unvaccinated and vaccinated cattle.
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3.3.5 Detailed model Structure
The model estimates the herd-level performance of the survey system. This is estimated
by simulating the testing and interpretation of results for a large number of exposed (to
estimate village-level sensitivity) and unexposed (to estimate village-level specificity)
villages. The village sizes are drawn from the 2005 census data so that the performance
estimates are representative of the performance of the survey in a randomly selected
village.
For exposed villages the number of infected animals in each simulated village will be
drawn from one of the four candidate epidemiologies:
Single animal nexposed = 1 animal infected in each village
Design prevalence - deterministic 5% of animals infected in each village nexposed =
ceiling(h x 0.05)
Design prevalence - stochastic nexposed ~ Binomial(h, 0.05) + 1 animals infected
where h, is the village size
Beta binomial distribution nexposed ~ Binomial(h, Beta(2.9, 58.1)) + 1 animals in¬
fected where h is the village size
Where h is the village cattle population and ceiling(x) is a function returning the lowest
integer greater than x
In the beta-binomial model the beta parameters were selected to give a mean prevalence
within the 2005 herd size distribution of 5% (i.e. identical to the design prevalence) but
to introduce over-dispersion compared to a binomial distribution with a 95% probability
interval of approximately 0.01 to 0.1.
For each simulation for each exposed village 64 samples are drawn without replacement
so the number of exposed animals is given by:
®exposed ~ Hyper(nexpose(h h n>eXposedi 64)
Chapter 3. Thrace Introduction and survey performance 75
Where Hyper (n, m, k) is the hypergeometric distribution function of number of exposed
animals drawn for a sample (without replacement) of size k from a group of animals
where n are exposed and k are not.
The number of unexposed animals in each sample is simply:
Sunexposed ~ 64 Sexposed
The model then simulates the testing of each sample with a potentially imperfect di¬
agnostic test so that the number of test positive samples is given by:
tpositive ~ Binomial(sexposed, Se) + Binomial(sunexposed, (1 - Sp))
and test negative samples by:
inegative — 64 tposjf/lve
Where Se and Sp are the test sensitivity and specificity of the CEDITEST ELISA test
respectively. Values for these two parameters are draw from the relevant distributions
for each village sampling/testing simulation as listed in section 3.3.4
To simulate sampling and testing of an unexposed herd the number of test positives is
simply:
^positive ~ Binomial(64, (1 - Sp))
Thus the model gives the number of test positive and test negative animals for each
simulation of either an exposed or unexposed herd under the different epidemiological
and diagnostic test scenarios. In traditional sero-surveillance to demonstrate disease
freedom the result of testing a village would then be considered with respect to a village
cut-point such that observation of more test-positive animals than this cut-point would
result in the village being classified as exposed. In this analysis I use a cut-point of
zero as this is will maximise village-level specificity. Hence any village with one or more
test positive animals is regarded as exposed. Over the full set of simulations for each
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combination of epidemiology and diagnostic test scenarios the village-level sensitivity






Where V+ is an indicator variable which is 1 if a village is classified as exposed and 0
if it is not and nSim is the total number of simulations for the exposed or unexposed
simulation sets.
The simulation model estimates the sensitivity and specificity of the surveillance system
at a village-level. There are several considerations that need to be applied to the
interpretation of these results:
3.3.6 Single test analysis as an upper bound of group and system level
performance
In a practical testing situation any animals testing positive may be subsequently retested
with a confirmatory test. Serial testing strategies then require this second test to be
positive for the animal and hence village to be classified as infected. The upper bound
of the sensitivity of such surveys at village-level is defined by the application of the
first test i.e. subsequent tests to rule out false positive animals will only reduce the
overall sensitivity of the system at village-level. Thus for this analysis the estimated
sensitivity results from single test applications can be considered an upper bound for
the village-level sensitivity.
3.3.7 The effect of imperfect specificity on group level sensitivity
At a village or regional level the sensitivity of a survey to substantiate disease freedom
will be increased if the animal-level test is not perfectly specific. A test with less than
100% specificity may result in some animals being classified as infected when they are
not. This will then result in the classification of some infected villages of animals as
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infected even though no infected animals were sampled and classified as infected by the
diagnostic test. Although this anomaly apparently increases the village-level sensitivity
of the survey it is problematic. Villages found to be infected on the first survey will
normally be subject to follow up investigation involving re-testing of the submitted
samples. A more specific test would correctly identify these samples as from uninfected
animals and thus the village would be finally reclassified as uninfected.
To remove this effect to allow assessment of the sensitivity of the surveillance systems
arising solely as a consequence of the diagnostic test's sensitivity all my evaluations
include an analysis where the the diagnostic test specificity is set to 100%.
3.4 Results
Results of the stochastic simulation model are shown in tables 3.4 - 3.13
Using test performance assumed for current survey design
Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.22 0.22 1.00
2 Design 5% prevalence 0.96 0.96 1.00
3 Binomial 5% probability 0.95 0.95 1.00
4 Beta-binomial ~5% probability 0.89 0.89 1.00
Table 3.4: Estimation of village-level performance of surveillance Design test per¬
formance Village-level sensitivity (HSe), village-level sensitivity assuming
perfect specificity (HSe2) and village-level specificity (HSp)
The estimated survey village-level performance with the design test performance of
90% sensitivity and 100% specificity is shown in table 3.4. The surveys are designed
to have a target of 95% village-level performance; the estimated performance using a
5% binomial model for infection of 95% sensitivity is as expected. If a fixed village by
village prevalence of 5% is used (rounding up to the next highest integer) the village
performance is slightly higher at 96%. If prevalence is allowed to vary between villages,
though still averaging 5% the average sensitivity performance is 89%, markedly worse
than the target performance. Effectively, the improved performance in villages having
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higher prevalence is not sufficient to compensate for the degraded performance in vil¬
lages having a lower prevalence. This is a consequence of the village-level performance
being a non-linear function of the prevalence as shown in figure 3.7. In the worst case
scenario - where only a single individual in each village is infected, the village-level
performance is drastically worse than the target performance with a sensitivity of 20%.
Prevalence
Figure 3.7: The non-linear effect of animal-level prevalence of disease on village-level
sensitivity. The curves show the estimated village-level sensitivity of disease
detection for a range of prevalence using tests of 50%, 70% and 90% animal-
level diagnostic sensitivity. The curves were generated using simulated
sampling of 64 animals from a village of 500 animals. A binomial model of
infection was used within the village.
The village-level specificity is 100% as expected as the diagnostic test is modelled to
have perfect specificity.
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Vaccinated cattle using estimates from Brocchi 2006 study
Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.45 0.16 0.66
2 Design 5% prevalence 0.94 0.91 0.66
3 Binomial 5% probability 0.93 0.89 0.66
4 Beta-binomial ~5% probability 0.89 0.83 0.65
Table 3.5: Estimation of village-level performance of surveillance in vaccinated cattle
at 28-100 days post infection. Village-level sensitivity (HSe), village-
level sensitivity assuming perfect specificity (HSe2) and village-level speci¬
ficity (HSp)
Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.47 0.17 0.65
2 Design 5% prevalence 0.95 0.93 0.66
3 Binomial 5% probability 0.94 0.91 0.66
4 Beta-binomial ~5% probability 0.90 0.85 0.65
Table 3.6: Estimation of village-level performance of surveillance in vaccinated cattle
at 100+ days post infection. Village-level sensitivity (HSe), village-level
sensitivity assuming perfect specificity (HSe2) and village-level specificity
(HSp)
Tables 3.5 and 3.6 show the estimated performance using diagnostic test performance
data from Brocchi et al. [2006] in animals 28-100 and 100+ days post infection. These
post infection timings represent the likely post infection times of disease surveillance
testing so the real world village-level performance is likely to lie somewhere between
the estimates in these two tables.
In practice the results for 28-100 and 100+ days post infection are similar. This is a
consequence of similar estimates of diagnostic test performance. Using the village-level
sensitivity estimates assuming perfect diagnostic test specificity the village sensitivity
is less than 95% for all epidemiology scenarios. With the fixed and binomial models
the village-level sensitivity is 90% but this drops to 85% if the prevalence is allowed to
vary between villages (but has a mean value of 5%). In the extreme case of a single
exposed animal in a village the sensitivity is 16-17%.
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The village-level specificity is about 65% in both diagnostic test scenarios. This means
that on average about one in three disease free villages tested will initially have at least
one test positive animal and will require further follow up testing.
Unvaccinated cattle using estimates from Brocchi 2006 study
Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.88 0.24 0.16
2 Design 5% prevalence 1.00 0.97 0.16
3 Binomial 5% probability 0.99 0.96 0.16
4 Beta-binomial ~5% probability 0.99 0.90 0.16
Table 3.7: Estimation of village-level performance of surveillance Un-vaccinated
cattle at 28—100 days post infection village-level sensitivity (HSe),
village-level sensitivity assuming perfect specificity (HSe2) and village-level
specificity (HSp)
Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.86 0.12 0.16
2 Design 5% prevalence 0.96 0.76 0.16
3 Binomial 5% probability 0.96 0.75 0.17
4 Beta-binomial ~5% probability 0.95 0.69 0.16
Table 3.8: Estimation of village-level performance of surveillance Un-vaccinated cat¬
tle at 100+ days post infectionvillage-level sensitivity (HSe), village-
level sensitivity assuming perfect specificity (HSe2) and village-level speci¬
ficity (HSp)
Tables 3.7 and 3.8 show the estimated performance at a village-level in unvaccinated
animals using estimates of diagnostic test performance from Brocchi et al. [2006]. These
diagnostic test performance parameters give specificity corrected village-level sensitivity
of 96-98% for design and binomial scenarios in 28-100 days post infection animals. In the
beta-binomial model the sensitivity in these animals is lower at 90%. In the worst case
scenario of single animal infections the village-level performance is only 24%. Village-
level specificity reflects the lower diagnostic test specificity and is approximately 16%
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with 5 out of 6 villages being reported as exposed after the initial application of the
testing strategy.
The village-level sensitivity results in animals 100+ days post infection are all low. This
is a consequence of the low estimate of diagnostic test sensitivity in this group (point
estimate 50% but with large uncertainty as a very small group was used to estimate the
parameters). In these animals the highest village-level sensitivity is 76% in the design
scenario.
Vaccinated cattle using estimates from Brocchi 2006 study — detecting
carriers at 28-100 days
Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.49 0.20 0.67
2 Design 5% prevalence 0.97 0.96 0.66
3 Binomial 5% probability 0.96 0.94 0.66
4 Beta-binomial ~5% probability 0.92 0.88 0.65
Table 3.9: Estimation of village-level performance of surveillance Vaccinated cattle
at 28-100 days post infection to identify carrier state Village-level
sensitivity (HSe), village-level sensitivity assuming perfect specificity (HSe2)
and village-level specificity (HSp)
As an alternative to assessing the surveillance scheme in its ability to detect exposed
animals (using experimentally infected animals as a proxy for this in the diagnostic
test evaluation data selection) we can consider detection of carrier animals. Brocchi
et al. [2006] classified an animal as a carrier if there was evidence of persistent infection
more than 28 days post initial infection. Virus isolation or positive RT-PCR were
considered signs of infection. The data for carrier detection performance were modelled
in vaccinated animals at 28-100 post infection and is shown in table 3.9. The specificity
corrected village-level sensitivity is close to the target 95% level for the design and
binomial scenarios and below (88%) for the beta-binomial scenario. In the single case
scenario the expected performance is 20%.
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Vaccinated cattle using estimates from Brocchi 2006 study — detecting
carriers at 100+ days
Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.48 0.21 0.65
2 Design 5% prevalence 0.97 0.96 0.66
3 Binomial 5% probability 0.96 0.94 0.65
4 Beta-binomial ~5% probability 0.92 0.88 0.66
Table 3.10: Estimation of village-level performance of surveillance Vaccinated cat¬
tle at 100+ days post infection to identify carrier stateVillage-
level sensitivity (HSe), village-level sensitivity assuming perfect specificity
(HSe2) and village-level specificity (HSp)
The results for carrier detection at 100 days+ are shown in table 3.10. The CEDITEST
diagnostic test performance is slightly higher in these animals at 87%. The village-level
results for specificity corrected sensitivity are similar to the 28-100 day post infection
carriers.
Vaccinated cattle using estimates from Brocchi 2006 study — detecting
carriers at 28-100 days using serial testing
Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.47 0.20 0.66
2 Design 5% prevalence 0.96 0.95 0.66
3 Binomial 5% probability 0.95 0.93 0.66
4 Beta-binomial ~5% probability 0.91 0.87 0.66
Table 3.11: Estimation of village-level performance of surveillance Vaccinated cattle
at 100+ days post infection to identify carrier state with serial
testing. Village-level sensitivity (HSe), village-level sensitivity assuming
perfect specificity (HSe2) and village-level specificity (HSp)
Serial testing is where any positive results on an initial CEDITEST are followed up
with a second test which must also be positive to declare an animal infected. This will
theoretically increase specificity and reduce sensitivity [Gardner et ah, 2000]. Unless
the tests are completely conditionally dependent, disease-free animals testing positive
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to the first test will have a some probability of testing negative to the second test —
increasing specificity. Diseased animals testing positive to the first test will likewise,
as long as the tests are not conditionally dependent, have some possibility of testing
negative to the second test — reducing sensitivity. In the Brocchi et al. [2006] evalu¬
ations the CEDITEST diagnostic test specificity estimate remained the same (within
the evaluation precision) at 99.5% and sensitivity was reduced to 81%. The village-level
results are shown in table 3.11. Specificity corrected village-level sensitivity was hence
reduced by approximately 1% point for each scenario.
Unvaccinated cattle using estimates from Engel 2008 study
Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.87 0.24 0.16
2 Design 5% prevalence 1.00 0.97 0.16
3 Binomial 5% probability 0.99 0.96 0.16
4 Beta-binonrial ~5% probability 0.99 0.91 0.16
Table 3.12: Estimation of village-level performance of surveillance Unvaccinated
cattle using Engel Bayesian estimates of diagnostic test per-
formanceVillage-level sensitivity (HSe), village-level sensitivity assuming
perfect specificity (HSe2) and village-level specificity (HSp)
Using the estimates of diagnostic test performance from Engel et al. [2008] the corrected
village-level sensitivity exceeded the target level for the design and binomial scenarios.
It dropped to 91% for the beta binomial scenario and was 21% for the single case
scenario. Village-level specificity was approximately 16%.
Vaccinated cattle using estimates from Engel 2008 study
Using the estimates of diagnostic test performance from [Engel et ah, 2008] the cor¬
rected village-level sensitivity was close to the target level for the design and binomial
scenarios. It dropped to 88% for the beta binomial scenario and was 21% for the single
case scenario. Village-level specificity was approximately 51%.
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Epidemiology HSe HSe2 HSp
1 Worst case - single infected 0.58 0.21 0.50
2 Design 5% prevalence 0.98 0.95 0.51
3 Binomial 5% probability 0.97 0.94 0.50
4 Beta-binomial ~5% probability 0.94 0.88 0.51
Table 3.13: Estimation of village-level performance of surveillance Vaccinated cattle
using Engel Bayesian estimates of diagnostic test performance.
Village-level sensitivity (HSe), village-level sensitivity assuming perfect
specificity (HSe2) and village-level specificity (HSp)
3.4.1 Summary
The results are also shown sorted by epidemiology model for corrected village-level
sensitivity in table 3.14 and in figure 3.8.
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Epidemiology Vaccination/Testing Days post infection Study HSe2
Single animal - design 21.92
un-vacc 28-100 brocchi 23.58
un-vacc 100+ brocchi 12.24
un-vacc engel 23.69
vacc 28-100 brocchi 16.61
vacc 100+ brocchi 17.98
vacc engel 20.75
vacc carrier 28-100 brocchi 20.76
vacc carrier 100+ brocchi 21.30
vacc carrier serial test 28-100 brocchi 19.78
5% deterministic - design 96.34
un-vacc 28-100 brocchi 97.18
un-vacc 100+ brocchi 76.18
vacc engel 95.43
vacc 28-100 brocchi 90.84
vacc 100+ brocchi 92.64
un-vacc engel 97.28
vacc carrier 28-100 brocchi 95.50
vacc carrier 100+ brocchi 95.81
vacc carrier serial test 28-100 brocchi 94.63
5% Binomial - design 94.96
un-vacc 28-100 brocchi 95.92
un-vacc 100+ brocchi 74.63
un-vacc engel 96.06
vacc 28-100 brocchi 89.03
vacc 100+ brocchi 90.90
vacc engel 93.95
vacc carrier 28-100 brocchi 93.98
vacc carrier 100+ brocchi 94.39
vacc carrier serial test 28100 brocchi 93.04
5% Beta-binomial - design 89.15
un-vacc 28-100 brocchi 90.37
un-vacc 100+ brocchi 69.83
un-vacc engel 90.47
vacc 28-100 brocchi 82.81
vacc 100+ brocchi 84.72
vacc engel 87.96
vacc carrier 28-100 brocchi 88.00
vacc carrier 100+ brocchi 88.46
vacc carrier serial test 28-100 brocchi 86.88
Table 3.14: Summary estimates of village-level sensitivity (assuming diagnostic test
has perfect specificity) grouped by epidemiology model and ordered by sen¬
sitivity. Study refers to source data for diagnostic test performance(design
- 90% Se and 100% Sp, Brocchi - [Brocchi et al., 2006], Engel - [Engel
et al., 2008]. Vaccination/testing refers to vaccination status and addition¬
ally if ability to detect carriers was the assessment criterion (with single














Figure3.8:Village-levels nsitivityassumingpe f ctdi nos ct tspecific ty.95%villagee ls nsi vityhownwi hdott d horizontalline.(Statussv ccination/carriertypedetect dbyest.t yisourcefCEDITESTerfo manceda . Plotsaretiledv rticallybyd ypo tinfec ionandhorizontallypid miologysc n rio)
oo
Chapter 3. Thrace Introduction and survey performance 87
3.5 Discussion
The performance of a disease surveillance system is contingent on the true epidemiology
of the disease, the sampling strategy, the diagnostic test performance and the decision
rule for the interpretation of the consequent results. In this analysis I have used worst
case and design based estimates of epidemiology. The sampling strategy is that previ¬
ously used in the Thrace sero-surveillance exercises. The diagnostic test performance
estimates are those available from a large, quality controlled test evaluation in addition
to using the values of test performance used to design the sero-surveillance in Thrace.
For all estimates of test performance other than the design test performance (with 100%
test specificity) the imperfect specificity of the diagnostic test gave an apparent increase
in the village-level sensitivity. False positive animal results in villages where no diseased
animals were sampled and diagnosed diseased resulted in correct diagnosis of village
status but for an incorrect reason. This form of increased sensitivity is not valuable as
the confirmatory testing of test positive animals would tend to demonstrate their true,
non-diseased, status and the initial higher estimate of village-level sensitivity would
be very optimistic. Hence for the remainder of this discussion I will only consider
the specificity corrected sensitivity (i.e. assuming that any test positive animals are
followed up with tests of perfect sensitivity and specificity). This value gives a realistic
upper bound for the overall system sensitivity with followup.
3.5.1 Sampling from smaller villages
In this evaluation I have restricted the simulation to villages holding 64 or more cows.
In the Thrace field surveys if a randomly selected village has less than 64 cows sampled
a neighbouring village will be used to make up the sample numbers to 64. Disease
freedom surveillance in smaller animal groups has been described in detail by Greiner
and Dekker [2005]. The main design issue occurs when the diagnostic test sensitivity is
lower than the target sensitivity require at the group (in this case village) level. With a
sufficiently large group enough samples can be taken to reach the target sensitivity for
the group. However, with villages smaller than 64 animals there will be a compensatory
effect as all animals will be sampled in the primary sampling group; even in a worse
case where there is only one diseased animal, it will be tested. This advantage will
not be true of the subsequent villages selected to top-up the samples to 64. It is likely
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that the presence of disease in these, 'top-up' villages used to supplement the small
villages will be correlated with the presence in the primary sampling village as foot-
and-mouth disease will spread readily by local movements, airborne spread and fomite
spread [Alexandersen et ah, 2003]. Villages with less than 64 cattle represent 5.6%
of the 2005 sampling frame (52 of 924 villages) so in the absence of adequate spatial
models of disease in Thrace and limited knowledge of the sampling behaviour I consider
the exclusion of these smaller villages provides a reasonable estimate of overall expected
village-level performance.
3.5.2 Performance in worst case scenarios
The current surveillance design does not achieve a village-level sensitivity of 95% when a
single animal is diseased under any of the plausible diagnostic test estimates. Although
this is not surprising given the design prevalence for the survey it is potentially of
concern as the Thrace cattle population is largely vaccinated. Vaccination will reduce
the transmission probability of foot-and-mouth disease [Orsel et ah, 2005, 2007a] and
hence result, on average, in smaller within group prevalences. Furthermore, clinical
detection may be less likely due to reduced clinical signs in vaccinated animals. Hence
to use a sampling based approach to make strong statements about disease status at
a village-level will require convincing evidence about likely village-level prevalences (if
disease were present) in the face of the current vaccination coverage.
3.5.3 Performance in 5% prevalence scenarios
In the scenario with within-village prevalence modelled as a deterministic 5% the sur¬
veys will generally detect disease in unvaccinated animals with a sensitivity close to or
greater than 95% with the exception of detection in unvaccinated animals 100+ days
post infection. The CEDITEST evaluation data for this particular group was based on
a sample of only 3 animals. The stochastic evaluation results reflect this uncertainty
but it is possible that the performance estimates for this group would improve with
more precise CEDITEST evaluation data. Indeed the estimates using the data from
Engel et al. [2008] the performance for unvaccinated cattle using the 5% deterministic
scenario is approximately 97%.
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In vaccinated cattle the village-level sensitivity was consistently below the OIE target
figure of 95% using the estimates of test performance from the Brocchi et al. [2006]
studies. Using data test performance estimates from the Engel et al. [2008] evaluation
the village-level performance generally reached 95% apart from in the beta-binomial
prevalence model scenario. These results in vaccinated cattle are of particular concern
as prevalence of foot-and-mouth disease may be lower in vaccinated villages due to
reduced transmission probability.
The beta-binomial epidemiology scenario gave an expected village-level sensitivity of
less than 95%. This is a concern as this scenario may be more likely to model the real
life situation with inter-village variation of prevalence. As the village-level sensitivity
is a non-linear function of prevalence an average prevalence of 5% within villages using
a design for deterministic prevalence of 5% does not give a design performance.
3.5.4 Concluding remarks
In all but the worse case scenarios and the use in unvaccinated animals more than 100
days post infection the village-level sensitivity was greater than 80%. Over the 152 or
more village-level samples taken each year this will still give a regional level sensitiv¬
ity performance of at least 92.3% (estimated using FreeCalc [Cameron and Baldock,
1998a,b]) however although this allows region level decisions to be made with high con¬
fidence the survey system may be less sensitive at a village-level than intended. The
survey has practical issues related to the village-level specificity. This will result in
a high rate of false positive villages if a single positive animal is used as a cut-point.
Although confirmatory testing will ultimately allow a large proportion of these villages
to be correctly classified this procedure is costly, time consuming and will not remove
all false positive villages. An alternative strategy is to increase focus on disease control
with efforts to achieve uniformly high coverage vaccination and to increase biosecurity
thus reducing the frequency and magnitude of foot-and-mouth disease outbreaks. Sero¬
logical surveillance could focus on estimation of outbreak magnitude by application of
NSP tests and confirmatory testing of whole animal groups only after clinical detec¬
tion. This would consume fewer resources allowing precise estimation of the benefits of





Survey data are available for three surveys (one carried out in 2005 and two in 2006).
In this chapter I describe the structure of these surveys and summarise the results.
The number of animals testing positive over the whole survey increased from 2005 to
2006. This is coincident with a number of village outbreaks of foot-and-mouth disease
which occurred in Spring and Summer of 2006 starting at about the time of the second
survey. The diagnostic test used in these surveys for initial testing (the CEDITEST
NSP) produces a continuous numerical result for each test which is dichotomised into a
positive or negative classification by comparison to a cut-off value. In this exploratory
analysis there is evidence of a shift in the continuous results between the two surveys
in 2006. This may result in misclassification of animals disease exposure status. I
suggest reasons for this and propose a method by which the test can be retrospectively
re-calibrated to attempt to correct for the shift.
4.2 Introduction
The background to the foot-and-mouth disease situation in Thrace is described in
chapter 3. In this chapter the data from three serological surveys is described and
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reported through exploratory data analysis prior to the modelling of these data-sets in
chapter 5. The data-sets describe the laboratory results from three serological surveys
carried out in 2005 and 2006. The timing of the three surveys and the approximate
times of the Thrace foot-and-mouth disease outbreaks are shown in figure 4.1.
outbreaks
2005 survey spring 2006 survey autumn 2006 survey
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2005 2006
Figure 4.1: A summary of the timing of sero-surveillance in Thrace (2005 and 2006)
showing approximate timing of Thrace foot-and-mouth disease outbreaks
4.3 Methodology
Survey data and sample frame data were obtained from Excel spreadsheets supplied
by the §AP foot-and-mouth disease institute in Ankara Turkey. The spread sheet data
was cleaned by:
• Removal of blank lines and additional fields
• Removal of any records with null or zero results - assumed to be non-analysed
• Re-coding of test results from Turkish to English (pos/neg etc)
• Relabelling of field headers from Turkish to English
The spreadsheet data was then manually imported into a Microsoft Access database
(Microsoft. Redmond CA). SQL queries were then used to aggregate and summarise
the data by provinces, villages and surveys as required for the exploratory analysis.
Query results were then exported into the R statistical system [R Development Core
Team, 2007] for exploratory data analysis and plotting.
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4.4 Results
4.4.1 Data Sources
Animal health and surveillance records for the Thrace region are structured within the
following administrative/stock holding hierarchy:
1. Province (5 total)
2. District (30 total)
3. Village (926 total)
4. Farm (approximately 1-10 per village)
5. Stock (Cattle/Sheep/Goats)
4.4.2 Key to tables and figures
2005 Spring 2005 Survey
2006A Spring 2006 Survey
2006B Autumn 2006 Survey
4.4.3 Sample frame - Thrace demography
In the 2005 sample frame data there are 5 provinces (Edi'rne, Kirklarefi, Teki'rdag,
Qannakale and Istanbul). These provinces are composed of administrative districts
within which are villages which will have a number of farmers owning livestock. The
numbers of districts, villages and cattle within each province are shown in table 4.1 to¬
gether with the mean and standard deviation of the cattle populations in each province's
villages. The distribution of recorded cattle populations within these villages is shown,
by province, in figure 4.2. The agricultural census records do not contain data describ¬
ing the distribution of livestock holdings at an owner/farm level.
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Table 4.1: Number of districts, number of villages, number of cattle, mean and stan¬
dard deviation of village cattle population in each province as recorded in
2005 census
Ed'irne Kirklareli Tekirdag Qannakale Istanbul
Population
Districts 9 8 9 2 4
Villages 278 202 288 42 116
Cattle 128,953 80,035 105,640 10,807 56,641
Cattle per village
Mean 463.86 396.21 365.54 257.31 488.28
SD 330.80 286.81 357.12 281.49 404.61
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Figure 4.2: Village cattle population sizes (2005 census data) by province. Each vil¬
lage's cattle population is represented by a black dot. Villages with similar
cattle populations in each province have their dots stacked in this plot.
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4.4.4 Dichotomous results from sero-surveillance
Sero-surveillance results are available from three separate surveys conducted in 2005,
Spring 2006 and Autumn 2006 as shown in figure 4.1. The number of villages visited in
each survey are shown in table 4.2. In all surveys the survey design required 64 animals
to be sampled in each village. However some villages did not have 64 cattle available for
testing so the district veterinary surgeons occasionally needed to sample animals from
neighbouring villages. The resulting distribution of cattle numbers sampled by village
is shown in 4.3. Occasionally villages were over-sampled with 6 villages in Spring 2006
being double sampled. In all surveys some villages had more than 64 samples taken.
There are no field records or documentation available to give background to this over-
sampling behaviour.





Table 4.3: Samples taken by village in each survey
Samples 4 6 8 11 13 14 25 26 38 39 50 53 63 64 65
2005 1 1 2 2 1 2 1 1 1 1 1 1 1 145 1
Samples 8 10 12 17 34 41 47 60 64 87 128
2006 Spring 1 1 1 1 1 1 1 1 224 1 6
Samples 23 26 28 38 64 77
2006 Autumn 1 1 1 1 191 1
Samples were initially analysed by the §AP institute in Ankara with a single CEDITEST
NSP test [Sorensen et al., 1998] using a 50% cut-off in in the percentage inhibition re¬
sult to classify the cattle as positive or negative. The results from this initial analysis
for each animal sampled are summarised by province in table 4.4. In 2005 68 or ap¬
proximately 0.7% of samples initially tested positive with the majority in the Istanbul
and Teki'rdag provinces. The number of test positive animals increased dramatically
in the Spring 2006 survey (sampled at about the time of the Spring 2006 outbreaks -
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see figure 4.1) to 252 or approximately 2% of samples. Again the highest provincial
prevalences were in Istanbul and Teki'rdag but there was also marked increase in the
positive samples in Ed'irne and Kirklareh. By Autumn 2006 the number of positive
samples was further increased to 358 or nearly 3% of samples. The proportion of test
positive samples in Edirne had decreased with the majority of positive samples being
from cattle in Istanbul, Kirklarel'i and Tek'irdag. In both 2006 surveys there were no
positive samples reported in the 1088 taken altogether in Qanakkale.
Table 4.4: Dichotomous test results for initial CEDITEST (overall and by province for
each survey)
2005 survey
Edirne Kirklareli Teki'rdag Qannakale Istanbul Overall
Test positive 6 1 18 2 41 68
Samples 2624 2304 2880 320 1600 9,728
% 0.23 0.04 0.62 0.62 2.56 0.70
2006 Spring survey
Edirne Kirklareli' Teki'rdag Qannakale Istanbul Overall
Test positive 39 25 95 0 93 252
Samples 3,008 2,364 3,392 512 3,072 12,348
% 1.30 1.06 2.80 0.00 3.03 2.04
2006 Autumn survey
Edirne Kirklareli' Tek'irdag Qannakale Istanbul Overall
Test positive 16 53 158 0 131 358
Samples 3,712 2,688 3,840 576 1,600 12,416
% 0.43 1.97 4.11 0.00 8.19 2.88
As each survey has at least one test positive sample the initial conclusion would be
that the results do not provide evidence to demonstrate freedom from foot-and-mouth
disease. In the Thrace surveillance system any test positive samples are re-tested with
a further CEDITEST NSP kit and subsequently negative samples are classified as nega¬
tive (not exposed). Additionally any initially positive samples are tested using a liquid
phase blocking ELISA test for "O" and "A" structural protein antibodies . Animals
with relatively low "O" and "A" antibodies are classified as negative (not exposed) on
the basis that an exposed animal would have a higher "O" or "A" titre than a vacci¬
nated animal. Whilst these confirmatory test procedures may give a marked increase
in the specificity of the surveillance system (by removing falsely positive classified an¬
imals) they will also reduce the overall system sensitivity as some animals that were
correctly classified as exposed by the first CEDITEST NSP will be erroneously classi¬
fied as not exposed by the confirmatory tests. Furthermore, as there is sparse evidence
describing the overall performance of this confirmatory system use of final classification
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for estimation of disease prevalence is difficult. Hence I will confine the remainder of
this exploratory analysis to the results from the initial CEDITEST NSP test.
The aggregated provincial data can not be used to draw detailed inferences about
the prevalence of exposure to foot-and-mouth disease as it is derived from clustered
sampling (at a province and village-level) with differing sample sizes in some villages.
Simple estimates of regional prevalence would be biased and would underestimate the
uncertainty (confidence interval) around point prevalence estimates. In the next chapter
I apply a multilevel mixture model to these surveillance data to estimate the disease
prevalence at the different levels of the population.
The dichotomous test results by village are shown for all villages in figure 4.3 and for
villages with 64 samples per village in table 4.5. The numerical results for villages with
samples sizes different from 64 are shown in table 4.6. These results are suggestive
that the prevalence in the samples from each village comes from a zero-inflated process
i.e. there are more zero value records than would be expected from common statistical
distributions. This is common in infectious disease prevalence data in clustered groups
of individuals — the prevalence in groups will be a mixture of zeros for unexposed
groups and a distribution or a mixture of distributions reflecting results from exposed
groups.
Table 4.5: The number of test positive animals in each village where 64 samples were
taken (by survey)
0 1 2 3 4 5 6 7 8 9 12 13 14 16 19 20 21 26 28 32 42
2005 122 14 4 2 1 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
2006A 103 38 17 10 9 3 2 1 0 0 0 1 0 0 1 0 0 0 1 0 0
2006B 143 7 10 5 5 2 1 4 2 2 1 1 1 1 1 1 1 1 0 1 1
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Table 4.6: The number of test positive animals in each village where other than 64
samples were taken (by survey)
2005 2006A 2006B
positive samples positive samples positive samples
2 63 13 128 3 38
1 39 3 60 0 23
0 13 3 87 0 77
0 14 1 41 0 28
0 6 0 8 0 26
0 4 0 34
0 11 0 12
0 8 0 10
0 8 0 17
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Proportion of positive animals in villages with any positives
Figure 4.3: The proportion of CEDITEST NSP positive animals in each sampled vil¬
lage by survey. The major x-axis is the proportion with the minor x-axis
indicating the number of animals positive to give that proportion if 64 an¬
imals were sampled. Each village's result is rounded to two decimal places
of proportion and identical rounded results are stacked.
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4.4.5 Continuous results from CEDITEST NSP testing
As described in the introduction to this chapter the selected animals in Thrace for
sero-surveillance are tested using a CEDITEST NSP test kit. This ELISA based test
produces an optical density result which is then standardised by use of a control serum
result to give a percentage inhibition result. The percentage inhibition result is then
used to classify animals as exposed or not-exposed using a simple dichotomous decision
rule whereby animals with percentage inhibition results greater than or equal to 50%
are classified as exposed. The continuous percentage inhibition results for all sampled
animals by each survey are summarised in figure 4.4. The majority of percentage
inhibition results are distributed in roughly symmetrical "bell-shaped" distributions
with long upper and lower tails. Inspection of this figure suggests a shift in the location
of the percentage inhibition results between the Spring 2006 (2006A) and Autumn 2006
(2006B) surveys. This is more easily appreciated by examining an empirical cumulative
distribution plot shown in figure 4.5 or a kernel density smoothed plot of the individual
results (figure 4.6). The mean percentage inhibition for all animals sampled and tested
with the first CEDITEST in 2005 is 9.44 and Spring 2006 is 9.83 as compared to 21.41
in Autumn 2006.
A
Figure 4.4: Histogram of percentage inhibition results of all sampled animals in Thrace
for survey in 2005 & both surveys in 2006. Histogram bins are 1 percentage
inhibition unit wide. The vertical dotted line indicated the manufacturers
cut-off value of 50 %.
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Figure 4.5: Empirical cumulative distribution function of CEDITEST NSP percentage
inhibition results by survey. Vertical dotted line at 50 represents manufac¬
turer's cut-off value.
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This shift may represent a genuine change in the NSP antibody levels in the sampled
livestock or may represent an artefact arising from the analytical methods. Possible
analytical causes include:
Control Sera The percentage inhibition result is mathematically derived from the
measured optical density of the ELISA test well for the sample scaled by the mean
observed optical density of two control wells per ELISA plate (96 well plates). If
the control sera reactivity changes between batches the sample results will shift
in baseline.
Incubation temperature A change in the processing of the ELISA plates may cause
a shift in the resultant optical density readings and if these aren't symmetrically
distributed around the control readings could cause a shift in the mean value/lo¬
cation of the results.
ELISA reagents hardware As with incubation temperature
Laboratory technique As above although the CEDITEST NSP appears to be rela¬
tively robust to changes in the protocol such as washing techniques [VPH Test
standardisation group, DEFRA, 2007].
Only partial data were available describing the raw results used to calculate the per¬
centage inhibition results. For the initial CEDITEST NSP there are 90 control values
available (means of paired control sera) for the Spring 2006 survey and 138 values for
the Autumn 2006. The surveys require 138 plates suggesting that 48 control sera/plate
records are unavailable for the Spring survey. However assuming that the data are
missing completely at random these results can be used to estimate any shift in control
sera/analysis characteristics. The summary statistics for the available control data are
shown in table 4.7 and figure 4.8
Table 4.7: Mean and standard deviation from available CEDITEST control wells pair
means for 2006 surveys
mean sd n
2006 Spring 1.28 0.22 90
2006 Autumn 1.25 0.19 138
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Figure 4.8: A smoothed kernel density plot of the mean paired ELISA control sera
results (optical density) for both 2006 surveys
These results show a small (mean 3%) decrease in control well optical density between
the Spring and Autumn 2006 surveys. A simulation study shifting the Spring 2006
control values by this magnitude and calculating the resulting percentage inhibition for
the samples did not reproduce the observed shift. So although only partial data were
available for control sera I consider it unlikely that a change in control sera explains
the shift in results between surveys.
No data are available to explore the effects of changes in laboratory technique on the
test results although the calculation of percentage inhibition relative to a control sample
may negate the effects of gross changes to the reaction or its reading.
Alternatively the observed shift in percentage inhibition results between Spring and
Autumn 2006 may represent a shift in the NSP antibody levels in the sampled cattle or
another biological factor present in the serum that mimics the NSP antibodies in the
ELISA assay. A spontaneous shift in natural proteins is biologically unlikely. However
an increase in NSP antibody levels due to increased exposure of the livestock is possible
through either increased exposure to foot-and-mouth disease or as a consequence of
vaccination although the former is unlikely.
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A possible cause of increased exposure of the population would be a shift in the demo¬
graphic across the surveys with a higher proportion of older cattle in the Autumn 2006
survey. This would give more time for the cumulative effects of repeated vaccination
to increase the serum NSP antibody levels in the cattle population. Demographic data
were available for the majority of animals sampled although a variety of recording sys¬
tems were used including estimated date of birth and estimated age. The distribution
of cattle ages by survey are shown in figures 4.8 and 4.9.















Figure 4.9: The distribution of reported cattle ages (Months) by survey for cattle with
a reported age. The data are smoothed with a Gaussian kernel smoother.
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The age distributions are broadly similar for the three surveys with the most notable
difference being a predominance of cattle aged 0-3 months in the 2005 when compared
to the 2006 surveys. The effect of cattle age on the shift of percentage inhibition of the
NSP ELISA test is shown in figure 4.10. The Autumn 2006 survey appears to produce
consistently higher percentage inhibition values across all age classes suggesting that
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Figure 4.10: The NSP ELISA percentage inhibition results stratified by cattle age class
including the cattle with no age records (shown in the 'NA' category). The
percentage inhibition results for each class are plotted using a gaussian
kernel smoother to show the summary distribution of results.
It is possible that the foot-and-mouth disease vaccinations used in Thrace are not
completely free of non structural proteins (EUFMD research group, personal commu¬
nications 2006). Hence it is possible that the vaccine will potentially elicit an NSP
antibody host response (Satya Parida, IAH Pirbright, personal communication 2008).
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The shift in percentage inhibition results may have important consequences regarding
the interpretation of the test results from Thrace sero-surveillance. For all surveys
the manufacturer based cut off value of 50 % was used whereby any animal having a
percentage inhibition result greater than or equal to 50 % is classified as exposed. If the
shift is common across all animals this will result in animals that would have be classified
as unexposed being classified as exposed. Alternatively this could be considered as
increasing the sensitivity of the test but dramatically reducing its specificity.
The exact nature of this shift is unknown but by assuming it is an additive effect it is
possible to estimate the results that would be seen without the shift.
Visual re-examination of figure 4.6 suggests that rather than a skewing or kurtosis
the distribution has shifted largely due to a rightwards translation of the majority
of the samples — mathematically each sample's percentage inhibition value is about
12 percentage units higher than it would be without the shift effect. To correct the
shift the additive component needs to be estimated and subtracted from the Autumn
2006 results. To use the mean result from each survey to estimate the shift may
overly bias the results as it is possible that there has been a true change in sero-
prevelance/exposure between the surveys. Hence I have estimated the shift by using
the mean of an empirically judged subset of the percentage inhibition results from each
survey — the data lying between the 35th and 65th quantiles. This range contains 30%
of the data but is unlikely to contain an substantial proportion of exposed animals and
hence should be robust to changes in natural exposure of the population. This approach
gives a calibration of +0.124 and -12.076 to the Spring 2006 and Autumn 2006 surveys
relative to the 2005 survey taking 2005 as a reference state (which is reasonable if
the effect is, for example, a consequence of repeat vaccine exposure). The resulting
continuous re-calibrated percentage inhibitor results are shown in the density plots in
figure 4.11 and the empirical distribution function plots in figure 4.12. Table 4.9 shows
the consequent dichotomous results by survey if these values are used with a cut-off
of 50 to classify animals exposure status. Three more animals are classed as exposed
in 2006 Spring and one hundred less in Autumn 2006 compared to the un-calibrated
results.
The effect of the re-calibration of the test results on the Autumn 2006 survey is shown
in figure 4.13. Although the number of test positive animals in 30 villages was reduced
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Figure 4.11: Kernel density plot of percentage inhibition results by survey — after
CEDITEST re-calibration as described in text
Table 4.9: Dichotomous results of CEDITEST NSP by survey before and after adjust¬
ment of percentage inhibition results from Autumn 2006 survey.
Negative Positive Negative (re-calibrated) Positive(re-calibrated)
2005 9660 68 9660 68
2006 Spring 12096 252 12093 255
2006 Autumn 12058 358 12158 258
only 2 villages were reclassified from having more than one test-positives animals to
having no test-positive animals.
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Percentage Inhibition
Figure 4.12: Empirical cumulative density plot of percentage inhibition results by sur¬
vey — after CEDITEST re-calibration as described in text









150 160 170 180
Index number of farm
190 200
Figure 4.13: The effect of percentage inhibition re-calibration and re classification of
CEDITEST results on the Autumn 2006 survey results. The majority of
villages have zero test positive animals and are truncated on this figure.
The dots show the number of test positive animals in each village before
(BLACK dots) and after (RED dots) re-calibration.
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4.5 Discussion
Each of the three surveys has produced initial CEDITEST NSP results with a marked
number of test positive results suggesting exposure of villages to foot-and-mouth dis¬
ease. There appears to be a higher level of exposure in the surveys of 2006 compared
to 2005. Most villages with test positive results have low rates of positive results but
in each survey there are a small number of villages with a markedly high proportion
of positive results. These results may represent a background noise of false positives
due to imperfect test specificity combined with a few truly exposed villages having high
rates of positive tests. Alternatively there may be an epidemiology where many villages
are exposed but in only a few do outbreaks become large.
The apparent shift in continuous test results between the two surveys of 2006 may have
either an analytical or epidemiological explanation. Determination of this would require
investigation of laboratory processes and possibly experimental studies or assessment
of multiple vaccination effects on diagnostic test specificity. In the absence of these
facilities the results may be re-calibrated using the described approach. Although this
re-calibration changes the status of approximately 100 animals in the last survey the
consequences regarding village status are minor.
As the survey tests results arise from a complex sampling process and are the con¬
sequence of analysis with a diagnostic test that will have imperfect sensitivity and
specificity simple, unbiased, estimates of village and animal-level prevalence can not
be made from the data. In the next chapter I take these data sets and use them to
parameterise a multilevel model of village and animal results to estimate the change in





In all three foot-and-mouth disease surveys over the period 2005-2006 in Thrace a
marked proportion of villages contained test positive animals. Classical interpretation
of these surveys requires follow-up testing of test positive animals to confirm their
serological status. If test-positive animals remain after this follow-up it is considered
that there is not evidence to substantiate freedom from disease [OIE, 2005b]. Here
I use an alternative multilevel mixture model approach to estimate the underlying
epidemiology of disease in the Thrace region over the three surveys and to update
estimates of the diagnostic test performance. Previously, zero inflated beta binomial
prevalence models have been used for these analyses; with the Thrace data a zero
inflated mixture of two beta-binomial prevalence models provides a better fit to the
data. Using this model the apparent conclusion is one of high village-level prevalence of
disease exposure across the three surveys. Alternatively it may be that disease exposure
is relatively low and that the major, low prevalence mixture component, represents
animals that are test positive due to antibody responses to the foot-and-mouth disease
vaccination programme in Thrace.
Ill
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5.2 Introduction
Traditionally, disease freedom surveys are designed such that if any animal in the survey
tests positive the region should no longer be considered disease-free. In this approach
any animals initially testing positive are re-evaluated using confirmatory tests, of high
specificity and sensitivity, so that initial false-positive results can be excluded. This
interpretation, that one or more confirmed positive animal allows rejection of the hy¬
pothesis of disease freedom, derives from the paradigm of traditional survey design
where the survey is designed to sample at least one exposed herd given a stated herd
prevalence with a stated confidence. And sample at least one exposed animal with a
stated confidence in each sampled herd given a stated animal-level prevalence [Cameron,
1997].
An alternative approach to examining the results of sero-surveillance data is to adopt
a Bayesian approach to probability and knowledge by representing our belief about
exposure status with a probability using the results from the survey to update our beliefs
about the region and its animal groups disease status [Suess et ah, 2002; Branscum et ah,
2004],
This approach allows probabilistic statements to be made about the disease status of the
region that give a finer degree of information than the simple disease free or not disease
free statements of traditional approaches. In the case of a region, such as Thrace, where
it is likely that disease freedom has not been achieved the results of a Bayesian analysis
may reveal trends in prevalence and probability of disease freedom. For example it may
be possible to demonstrate a decreasing prevalence at a village-level demonstrating an
improved disease-control/incursion situation.
In this section the available sero-surveillance data from the 2005 and two 2006 surveys is
used to parameterise a Bayesian model describing the epidemiology and diagnostic test
performance in the Thrace region. This model provides estimates of test performance
which may be used for design and analysis of surveys and estimates of epidemiology
which may also be used for survey design and to assess the trend of disease control.
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5.3 Methodology
The animal husbandry and disease surveillance structure within Thrace is inherently
multi-level hierarchical; cattle exist in groups owned by an individual farmer, these
farmers live and manage their cattle within villages and the villages are located within
the Thrace region. A priori it is reasonable to assume that presence or absence of
exposure to disease will be more highly correlated within the village/survey groupings
than between them. Hence to obtain unbiased estimates of the prevalence of exposure to
disease and to correctly apportion uncertainty in these estimates it is desirable to apply
a hierarchical multi-level model for the analysis of the surveillance data-sets [Goldstein
and McDonald, 1988].
Conceptually a three level model would appear appropriate to capture the village/own¬
er/animal survey levels of the data. However owners within Thrace villages will tend to
graze their animals communally (Nick Honhold, personal communication, May 2007).
Consequentially it may be reasonable to assume that a two-level (village/animal) struc¬
ture is adequate to describe disease in Thrace whereby the probability that an individual
animal is exposed is constant across an entire village rather than being clustered by
owner/group. This simplification reduces the number of parameters estimated by the
model (the hyper-parameters for the distribution of within owner/group prevalence)
and further means that the model will only be estimating the latent status of about
150 villages per survey rather than the latent status of many hundreds of owner's herds
if a three level model is used. This will increase computation speed and potentially
reduce parameter uncertainty if the model is appropriate compared to a three level
model.
I apply a Bayesian multi-level model to three sets of sequential surveillance data using
dichotomous test results (positive/negative CEDITEST ELISA results). To reduce
bias in the estimates the model includes the observational uncertainty by modelling the
CEDITEST diagnostic test as imperfect using priors for its sensitivity and specificity.
Data were used from the 2005 and two 2006 sero-surveillance exercises. These data-sets
include province, district, village, owner and animal records together with the contin¬
uous, percentage inhibition and dichotomised results of the first CEDITEST applied
to each animals serum sample. Additionally the data-sets include repeat CEDITEST
and liquid-phase blocking ELISA tests for structural protein antigens tests for all sera
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positive at the first CEDITEST. For this analysis the first CEDITEST result was used
as data are readily available for the diagnostic sensitivity and specificity of this test
used singly as opposed to limited data for its use in a serial testing scheme where only
performance with regard to carrier detection is available [Paton et ah, 2006].
5.3.1 Detailed model structure - base model
Table 5.1: Nomenclature for Bayesian model descriptions and code
posi Number of positive animals in sample from village i
api Apparent prevalence in sample from village i
rii Number of samples taken in village i
se Sensitivity of diagnostic test
sp Specificity of diagnostic test
Pi True prevalence in sample from village i
Pi Prevalence in village i if it is has any exposed animals
Vstatus,i Exposure status of village i (0=unexposed, l=exposed)
&a,k ba,k Beta coefficients of animal-level prevalence distribution class k
clciSSi Prevalence class (1 or 2) of village i
Vprev,s Prevalence of village exposure in survey s
V*uprev,s Prevalence of village exposure if the region is exposed
m & <j>\ Mean and variability measures of animal-level prevalence distribution for class 1
P2 & 4>2 Mean and variability measures of animal-level prevalence distribution for class 2
a & (3 Parameters of vague gamma distribution for phi
rstatus ,s Region exposure status in survey s
rprob,s Probability that the region is exposed in survey s
Pv & fv Mean and variability measures of village-level prevalence distribution
p.a.sim. 1 Simulated distribution of within village prevalence for distribution class 1
p.a.sim. 2 Simulated distribution of within village prevalence for distribution class 2
v.prev.sim Simulated distribution of village-level prevalence
The base model structure uses the hierarchical model of Branscum et al. [2006] which
uses a two-level (group and individual) structure: in this case villages and animals.
The observed data are the counts of test positive animals in the sample from a given
village. These are conditional on the unobserved prevalence of exposure in each village
and the diagnostic performance of the CEDITEST. The count of test positive animals
in each village is modelled as:
posi ~ binom [rii,pi x se + (1 — pf) x (1 — sp)]
Where posi is the number of test positive animals in village i, rii is the sample size in
the village i, se is the CEDITEST sensitivity, sp is the CEDITEST specificity and pi
is the prevalence of exposed animals in the sample from village i.
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The analysis makes the assumption that the number of test positives in the sample is
the result of a simple binomial process, i.e. the sampling and testing is performed with
replacement [Cameron, 1997]. In reality this is not the case. To accurately capture
the sampling mechanism requires an intermediate modelling step using a hypergeomet-
ric distribution whereby a village containing animals exposed with a prevalence pi is
sampled without replacement to generate a sample with a number of exposed animals
distributed hypergeometrically. Unfortunately it is not technically possible to include
this form of model and whilst modelling the diagnostic test as imperfect within the
WinBUGS /JAGS [Plummer, 2003] environment used to analyse these data. The hy-
pergeometric step is only important when sample sizes are large relative to village sizes
- in this case although the village sizes for each sample are not recorded inspection of
the demographic data (2005 sample frame) and manual matching suggest that the vil¬
lages are generally much larger than the modal sample size of 64 (see chapter 4 section
4.4.3).
The true prevalence in each village is not constant across all of the villages in the
survey. It will be zero in unexposed villages and variable (due to the dynamics of
infection and variability in biology/husbandry) in exposed villages. In the base model
Pi, the prevalence in village i is modelled as a mixture distribution of zeros (for non-
exposed villages) and a beta distribution (for exposed villages). The beta-binomial
distribution attempts to capture the over dispersion (above a binomial) in prevalence
seen in exposed villages [Johnson et al., 2004; Cameron and Baldock, 1998b].
Pi ~ beta(aa}i,baji) village exposed
= 0 village NOT exposed
The status of a village, vstatus,i of village i as exposed or not exposed is modelled as a
bernoulli variable:
vstatus,i ~ bem(ypreV)S)
Where vpreVtS is the prevalence of exposed villages (in survey s).
The prevalence of village exposure (i.e. the probability that a randomly selected village
is exposed) given that the region is exposed is not fixed from survey to survey and is
modelled as a beta distribution:
vPrev,s ~ beta(v.prev.a,v.prev.b)
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Where v.prev.a and v.prev.b describe the distribution of village-level prevalence across
surveys. If the region is not exposed the village prevalence vprev,s is zero.
The regional status (exposed or not exposed) for survey s, rstatus,s> is modelled as a
bernoulli variable:
fstatus,s ~ berniypj-Qb g)
Where rprob,s is the probability that the region is exposed at the time of survey s.
5.3.2 Model modification — three distribution mixture
The base model, as derived from Branscum et al. [2006] was modified to attempt to cap¬
ture the apparent heterogeneity in within village prevalence observed in the exploratory
data analysis 4.4.4. Examination of the prevalence data suggested that the prevalence
in exposed villages may be over-dispersed beyond even a beta-binomial distribution
and was bi-modal. Hence in this chapter I have redefined the Bayesian model to use a
mixture of three distributions for within village prevalence:
Vprev ~ beta(aa^i,ba) village exposed and low prevalence
Vprev ~ beta{aa^,ba) village exposed and high prevalence
= 0 village NOT exposed
Where aaj 6aj and aaj2 ba,2 are the beta parameters of the low and high prevalence
villages respectively. The parameter p. 2 represents the probability that an exposed
village has a prevalence drawn from the high rather than low prevalence group. In the
JAGS model code the mean village prevalence for the high group is modelled as the
mean from the low group with an additional scaling increment to ensure identifiability
of the parameters Stephens [2000].
5.3.3 Data requirements
The model uses the number of test positive animals and the sample size for each village
sampled in each of the three surveys. The data were re-structured for analysis using
Microsoft Access (Redmond, USA) and R [R Development Core Team, 2007]. The
models were run with both the original data and also with 'corrected' data where the
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continuous CEDITEST results were shifted and reclassified to correct for the apparent
change in percentage inhibition values observed between the two surveys in 2006 as
discussed in chapter 4.
5.3.4 Choice of prior distributions
As the model is fully Bayesian it is necessary to provide prior distributions for all
parameters in the model. Part of the development and evaluation of such models is
assessing the results conditional on different prior distributions so for some parameters
a number of different prior distributions were tested.
The diagnostic test sensitivity and specificity, se and sp were assigned beta distribution
priors using diagnostic test evaluation data from Engel et al. [2008] derived from Brocchi
et al. [2006]. These results estimate the sensitivity and specificity of the diagnostic
tests in vaccinated animals as the majority of cattle in Thrace are vaccinated (based
on preliminary vaccination coverage data examined at EUFMD research group meeting
May 2006). The Bayesian analysis from [Engel et al., 2008] removes the assumption
that a perfect gold standard is available to validate the estimation and provides an
uncertainty distribution for the sensitivity and specificity (described for efficiency with
a beta distribution using the parameters estimated for the stochastic simulation model
in Chapter 3). As these sensitivity and specificity priors were relatively precise the
model's sensitivity to prior information was assessed using less informative 'vague'
priors. The approximate form of these distributions is shown in figure 5.1. With a
Bayesian analysis it is critical that the prior distributions are not informed by the data.
As there were no available studies estimating prevalence distributions in the villages and
animals (other than expert opinion that would inevitably be informed by the survey
results) vague priors were used for animal and village prevalence distributions. The
parameterisation derived from Branscum et al. [2004] was used where the two beta
distribution parameters for each prevalence distribution were represented thus:




(f ~ Gamma( 1,0.001)
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Where fx is the mean of the prevalence distribution with a hyper-prior distribution
between almost zero and one (actual limits just within this improve numerical stability).
And 4> is related to the variability of the prevalence and has a Gamma distribution
hyper-prior with a mean of 100 and a standard deviation of 100.
0.0 0.2 0.4 0.6 0.8 1.0
Figure 5.1: Density of prior distributions for diagnostic test performance: 'Se' and 'Sp'
from Bayesian estimation of NSP performance by [Engel et al., 2008] and
two theoretical, less informative distributions used for both Se and Sp as
vague priors. (The prior 'Sp' from is highly informative and the plot has
been truncated in the y-axis on this plot)
5.3.5 Model estimation
The model was estimated using Bayesian MCMC with JAGS [Plummer, 2003] software
called from R [R Development Core Team, 2007] using the Runjags package [Denwood,
2008]. The JAGS software uses a similar model description language to the more com¬
monly used WinBUGS software Spiegelhalter et al. [1999] but gave faster and more
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stable results on initial testing. An MCMC burn-in period of at least 100,000 iterations
was used followed by a capture period of at least 100,000 iterations. In cases of poor
convergence the burn-in and capture periods were increased up to 500,000 each. Model
runs took approximately 6 hours for a total of 200,000 iterations. Results were tabu¬
lated and graphed using the R statistical system [R Development Core Team, 2007].
Each JAGS simulation used three chains with highly dispersed starting points for the
MCMC chain (i.e. 0.1, 0.5 and 0.9 for diagnostic test parameters and prevalences).
Convergence of the MCMC process was assessed by use of the Gelman-Rubin conver¬
gence statistic, as modified by Brooks and Gelman [1998]. Model selection between
the zero/single beta binomial mixture model and zero/double beta binomial mixture
model was primarily based on the deviance information criteria [Spiegelhalter et ah,
2002; Celeux et al., 2006]. This is a measure of model fit based on the likelihood in¬
tegrated over the posterior parameter density with an added penalty derived from the
number of parameters estimated by the model to adjust for the normal improved fit
of less parsimonious models [MRC Cambridge]. Model selection was further informed
by the convergence behaviour of the models assessed by examination of the trace plot
of the samples from the posterior distributions and calculation of the Gelman statis¬
tic [Brooks and Gelman, 1998] calculated using the R library 'coda' [Plummer et al.,
2006]. This is a measure of posterior sample chain stability and provides an estimate
of how well the parameter estimates from the posterior samples will capture the true
uncertainty in the parameters [Cowles and Carlin, 1996].
5.3.6 Model Diagnostics
For a given model, data-set and prior parameter distributions the Bayesian approach
provides posterior parameter distributions that precisely reflect how the evidence from
the data and model should update our beliefs about the parameter values Lee [1997].
However it is frequently impossible to determine an analytical form for the posterior
distributions in anything other than a simple model. Hence it is necessary to use
numerical methods to obtain samples from the posterior distributions and hence derive
statistic and probability plots. In the WinBUGS / JAGS software these samples are
draw using Monte Carlo markov-chain (MCMC) methods. As the number of samples
drawn tends towards infinity the distribution of the samples will tend towards that of
the posterior distribution of the parameters. Practical speed with which simulations
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approach a close approximation to the posterior will vary from model to model and
with data and priors. As sample sizes are limited it is necessary to perform a number
of diagnostic procedures to demonstrate that the posterior samples used do not have
any properties that suggest their distribution does not model the Bayesian posteriors
[Raftery and Lewis, 1992], These methods include use of three or more simulation chains
with different starting values for each parameter; visual examination of the simulation
history for each simulation chain for each parameter; examination of autocorrelation
of each chain; examination of the form of each parameter's posterior distribution and
application of formal convergence and effective size statistics. The individual methods
will be discussed with reference to the model output in the results section.
5.4 Results
5.4.1 Model selection
The Bayesian model was estimated using both a single and double beta-binomial mix¬
ture model with raw and re-calibrated data. Priors derived from Engel et al. [2008]
and less informative priors were used. The models that successfully converged on a rel¬
atively stable posterior MCMC series are listed in table 5.2. The models are compared
by deviance information criteria (DIC) in the table. For a given prior distribution and
data set the zero + double beta-binomial models consistently had a lower DIC sug¬
gesting a 'better' model fit. With mixture models the number of effective parameters
used in the calculation of the DIC is not rigorously defined and hence there are issues
regarding the use of DIC for model selection [Celeux et al., 2006]. However the double
mixture model in this case had a DIC markedly lower than that for the single mixture
models so small effects of DIC estimation methodology were considered unlikely to be
significant. For further discussion here the zero/double model based on Engel et al.
[2008]'s estimation of the CEDITEST diagnostic test sensitivity and specificity applied
to the re-calibrated data set is selected as it demonstrated good convergence, a low
DIC and uses literature informed prior information for the CEDITEST. This model's
DIC was only marginally higher than a similar model using vague priors and produced
similar posterior estimates.
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model data sea seb SPa SPb DIC
single re-calibrated 141.30 25.30 593.90 6.60 1019.05
single raw 9.00 1.00 9.00 1.00 1025.19
single raw 6.00 2.00 6.00 2.00 1027.47
double raw 141.30 25.30 593.90 6.60 1015.50
double re-calibrated 141.30 25.30 593.90 6.60 998.46
double raw 8.00 2.00 8.00 2.00 1015.72
double re-calibrated 8.00 2.00 8.00 2.00 997.95
Table 5.2: Summary of model runs that ultimately showed stable posterior simulation
histories. Deviance information criteria (calculated using pD method Plum-
mer [2003]). The model selected for discussion is shown in bold font. sea &
seb, & spa & spb are the pairs of parameters of the sensitivity and specificity
beta distribution priors describing the performance of the CEDITEST NSP
diagnostic test.
5.4.2 Model Diagnostics
As the posterior distribution statistics in the JAGS software are calculated from MCMC
samples it is necessary to confirm that the MCMC simulations have adequately con¬
verged onto stable time series Plummer et al. [2006]. Initial visual inspection of the
selected model trace output (see figure 5.9) showed apparently stationary MCMC chains
with no apparent time related drift or divergence.
Visual inspection of the smoothed posterior density plots for the three simulation chains
(each having different starting points) showed reasonable agreement between the form
of each chain (see figures 5.3 and 5.4) and with the majority of parameters smooth,
uni-modal posterior distributions. The exceptions are p.a.sim.2 and mu.2 representing
the mean and distribution of the animal-level prevalence in high prevalence exposed
villages. This bi-modality will be considered in the discussion section.
The Gelman statistic [Brooks and Gelman, 1998] for each parameter is shown in table
5.3 as calculated in R using the coda package [Plummer et al., 2006]. A potential scale
reduction factor (PSRF) is estimated using the between and within chain variance
estimates for chains with over-dispersed starting points. A converged model will have
similar variance within a chain as between values in different chains. The resulting
PSRF value for each parameter represents an estimate of degree of posterior variance
inflation arising from non-convergence — the posterior estimates will have a higher
variance than if the model had converged and the chains were mixing. A converged set
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of chains should have a PSRF close to unity. In this model each parameter's PSRF is
within 5% of 1.0 providing further reassurance that the MCMC chains have adequately
converged.














Table 5.3: Gelman convergence diagnostics for zero/double model fitted to re¬
calibrated surveillance data using se and sp priors from [Engel et al., 2008]
The R coda package also provides a method by which the effective size of a sample
set may be estimated [Plummer et ah, 2006] based on spectral analysis of the pos¬
terior samples Heidelberger and Welch [1981]. This method estimates the number of
independent samples that would have the same information content as the (possibly
autocorrelated) full posterior sample set. A large reduction would suggest high auto¬
correlation and redundancy. If the results set is small it is suggestive that a larger set
of simulations is required. The effective sample sizes are shown in table 5.4. Even the
smallest effective sample size of 927 (for parameter p.2) will provide a useful point and
distribution estimate. This was confirmed using simulated sampling from a variety of
plausible distributions for parameters with a sample size set to 927.
5.4.3 Results from posterior distribution samples
Table 5.5 and figures 5.3 and 5.4 show the results of the posterior distribution samples
from the selected model. For all three surveys the r.status parameter which captures
the estimated exposure status of the Thrace region on each model iteration consistently
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Table 5.4: Effective simulation set sizes calculated in R using empheffectiveSize see
Heidelberger and Welch [1981]
classified the region as exposed with no uncertainty. The v.prev.sim parameter repre¬
sents the distribution of village-level prevalence if the area is exposed i.e. if, in a given
survey, the region is exposed how probable is a given village-level prevalence. This dis¬
tribution has a mean of approximately 0.3 with a wide variation — the model and data
suggest that if the Thrace area is exposed the village-level prevalence will be variable
from survey to survey. For each survey the model estimates the specific village-level
prevalence (parameter v.prev[1..3]). These estimates all have a large uncertainty but
the mean increases from 0.12 in 2005 to 0.46 in Spring 2006 then drops to 0.28 in
Autumn 2006.
Parameters pa.sim. 1 and pa.sim.2 represent the distribution of animal-level prevalence
found in low and high prevalence exposed villages. Parameter p.2 is the probability
that an exposed village is in the high prevalence class (2). mu and phi are hyper-
parameters that define pa.siml and pa.sim.2. The results suggest that about 16% of
exposed villages are in the high prevalence class. The low prevalence class has a mean
of approximately 0.04 with some uncertainty although likely to be less than 0.1. The
prevalence in the high prevalence class is less well defined with a mean of 0.24 and a
credible interval from 0 to approximately 0.75.
The CEDITEST diagnostic sensitivity and specificity in this model were given informa¬
tive priors. These priors are shown plotted against the estimated posterior distributions
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Parameter Mean SD 2.5% 97.5%
mu.l 0.037 0.006 0.025 0.049
mu.2 0.242 0.091 0.069 0.403
p.2 0.167 0.107 0.048 0.465
p.a.sim.l 0.037 0.021 0.006 0.086
p.a.sim.2 0.238 0.166 0.001 0.599
phi.l 140.484 97.303 30.005 396.264




se 0.8467 0.028 0.788 0.897
sp 0.999 0.000 0.998 0.999
v.prevfl] 0.124 0.046 0.052 0.229
v.prev[2] 0.458 0.090 0.310 0.665
v.prev[3] 0.276 0.054 0.190 0.406
v.prev.sim 0.298 0.180 0.024 0.749
Table 5.5: Summary of posterior distributions for parameters of zero/double model
fitted to re-calibrated surveillance data using priors from [Engel et al., 2008]
in figure 5.2. The results suggest that the model and data do not add any information
to the prior estimates of the diagnostic test sensitivity. However the location and un¬
certainty regarding the diagnostic test specificity is changed with a mean of 98.9% to
a mean of 99.8%.
It is likely that the parameter estimates from this model will be correlated as, for
example, a particular apparent prevalence in the data may be explained by high true
prevalence and low test sensitivity or the converse. Figure 5.5 shows the approximate
degree of parameter cross correlation. The highest correlations are between p.2 (the
probability that an exposed village has a prevalence in the high prevalence group)
and mu.2 the mean prevalence of this group; and between v.prev[2] (the prevalence
at village-level in Spring 2006) and mu. 1 the mean prevalence of the low prevalence
group of villages. The form of these correlations are shown in figures 5.6 and 5.7. Both
pairs of parameters are negatively correlated such that, for example, a high estimate
of prevalence in the higher prevalence villages is associated with a lower probability of
an exposed village being in this group. The correlation of CEDITEST sensitivity and
specificity estimates is shown in figure 5.8.
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Sensitivity
Specificity
Figure 5.2: Density plots of the prior(shown with a dotted line) and kernel smoothed
posterior(shown with a solid line) distributions for the CED1TEST sensi¬
tivity and specificity.
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higure 5.3: Posterior density plot of prevalences using zero/double mixture model with
re-calibrated data — priors from Engel et al. [2008] for sensitivity and
specificity — coloured lines in each panel show results of each of the three
MCMC simulation chains (smoothed using a gaussian kernel window)
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Figure 5.4: Posterior density plot of other parameters using zero/double mixture model
with re-calibrated data— priors from Engel et al. [2008] for sensitivity and
specificity coloured lines in each panel show results of each of the three
MCMC simulation chains (smoothed using a gaussian kernel window)
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Figure 5.5: Cross correlation of parameter posterior distributions — zero/double mix¬
ture model with re-calibrated data using priors from Engel et al. [2008] for
sensitivity and specificity
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Figure 5.6: Correlation plot of p.2 (probability that an exposed village is from the high
prevalence group) against mu.2 (the mean prevalence of the high prevalence
group)
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Figure 5.7: Correlation plot of v.prev[2] (the village-level prevalence in Spring 2006)
against mu.l (the mean prevalence in the low prevalence group of villages)
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Figure 5.8: Correlation plot of estimated sensitivity of CEDITEST against against
estimated specificity of CEDITEST
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5.5 Discussion
This analysis classified the Thrace region as exposed at all three surveys given the
model, the prior assumptions and the data used to parameterise the model. This result
is compatible with ad hoc analysis of the survey data — even in the survey with the
fewest test positive animals (2005 survey) there were two villages with high positive
counts of 14 and 19 test positive animals out of 64 sampled. Even with a relatively
non-specific test (of, for illustration, only 90 or 99 % specificity) to observe this many
or more false positive test results in an unexposed sample of 64 animals is extremely
unlikely — see table 5.6.
Specificity = 0.90 Specificity = 0.99
P{x >= 14) 0.00136 1.01 x e"16
P{x >= 19) 2.5 x e~06 1.29 x e~24
Table 5.6: The probability of observing at least 14 or 19 false positive test results
in a sample of 64 animals for two different test specificity's (calculated as
Prob(x < X) where X ~ Binom{64,1 — Sp)) with x false positives and Sp
the test specificity)
The model also estimates the posterior distribution of village-level prevalence of expo¬
sure for each survey. This is the probability that each individual village is exposed in
each survey given that the region is infected. With the time profile of NSP antibodies
this is equivalent to infection and serological response within the previous 6-12 months.
Over the three surveys the village exposure probability increased from 0.12 in the 2005
survey to 0.46 in the Spring 2006 survey (at the time of the Thrace multiple outbreaks)
and then reduced to 0.28 in the Autumn 2006 Survey. The trend of these results are
compatible with the qualitative observations of the time considering the likely persis¬
tence of NSP antibody seroconversion and given that the target age for sampled animals
was 4 months to 2 years. This result should be critically interpreted as the probabil¬
ity that a village sample is drawn from either of the two beta-binomial distributions
of sample group prevalence (as opposed to being a zero-prevalence village). As there
is a non-zero probability that the beta-binomial distributions have a zero prevalence
these village-level prevalence results will over-estimate the actual village-level preva¬
lence. Simulated results suggest that with the animal-level prevalences in question this
error is of the order of 10%. I have explored models that required an exposed village
Chapter 5. Bayesian mixture model of Thrace Data 133
to have at least one exposed animal and rigorously replicate the sampling process. Un¬
fortunately these models were not computationally tractable. Even with the correction
for the beta-binomial modelling assumption the resulting village-level prevalences are
higher than expected from clinical reporting of observed foot-and-mouth disease cases
(none in 2005 and the outbreaks in Spring/Summer 2006). There are several possible
explanations for the discrepancy:
The posterior estimates of the three village prevalences may be correctly estimating
the village-level exposures. The distributions are very uncertain so estimate relatively
low village-level prevalences each year with finite probability. As the Thrace popula¬
tion is vaccinated it is possible that cattle movements and trading could result in a
high proportion of villages having a low animal-level prevalence of exposed animals —
vaccination preventing disease from taking off to create numerous outbreaks.
Alternatively the model may be correctly estimating the expected test status in the
Thrace villages but this may not reflect the animal-level exposure and hence may over-
represent the village-level prevalence of true foot-and-mouth disease exposure. I propose
two possible mechanisms for this:
The CEDITEST diagnostic test may not be as specific as estimated in this analysis
(and by previous evaluations). Hence false positive test results will be classified as
truly positive and result in mis-classification of animals and villages thereby inflating
the village-level prevalence. However, the model estimated the test to be very specific
(and this specificity estimate was robust to changes in the diagnostic test specificity
priors from the informative priors from Engel et al. [2008] to vague Beta(8,2) priors).
Alternatively: The cattle in Thrace are vaccinated using a trivalent foot-and-mouth dis¬
ease vaccine. It is possible that this vaccine may contain traces of 3 ABC non-structural
protein (NSP) which would result in an immune response creating NSP antibodies as de¬
tected by the CEDITEST ELISA (Satya Parida (IAH), personal communication 2008].
This would mean that the survey is, in many cases, estimating high levels of village
prevalence of NSP antibodies as a consequence of vaccination artefacts rather than as
a result of foot-and-mouth disease exposure. This hypothesis would require vaccina¬
tion coverage or response to be highly variable between villages. Unfortunately there
are only limited data available to estimate coverage. Current coverage estimates are
based on the number of vaccination doses supplied and demography data from live¬
stock censuses. These estimate coverage at between 80% and 123%. The estimates in
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excess of 100% are likely to arise from differences between cattle presented/recorded
at census and cattle presented at vaccination although clerical errors are also possible.
Investigation of the vaccination-related hypothesis would initially require comparison of
animal-level test results with animal-level vaccination results to look for an association.
If this was indicated then estimation of the effect may permit some correction. Current
surveys are targeted at animals between 4 months old and 24 months old to reduce
the effects of repeated vaccination. If sufficient young cattle numbers are available it
may be appropriate in future surveys to reduce the upper age limit to 12-18 months,
although this will then reduce the overall sensitivity of the system as cattle on average
will be less likely to be present during a previous village outbreak.
5.5.1 Mixture and animal-level prevalence parameters
Parameter p. 2 in the model — the probability that an exposed village was in the higher
prevalence group — was estimated with high uncertainty. This parameter was also
negatively associated with another uncertain parameter, mu.2, the mean prevalence in
the high prevalence villages. This is likely to be a consequence of the low numbers of
high prevalence results and the inherent problems of identifying parameters of mixture
models particularly when one distribution of the mixture has a much lower member¬
ship that the other distribution. The information required to parameterise the smaller
distribution is effectively reduced by noise in the tail of the larger distribution that
overlies it.
The interpretation of the estimates for parameters p.2 (defined above), pa.sim. 1 (the
animal-level prevalence distribution in low prevalence villages) and pa.sim.2 (the animal-
level prevalence distribution in high prevalence villages) is considered jointly. The se¬
lected model estimates each exposed village as having an animal-level prevalence com¬
ing from one of two distributions {pa.sim. 1 or pa.sim.2) with conditional probability
of coming from pa.sim2 being p.2. The results suggest that the majority (approxi¬
mately 63 %) of villages are in the low prevalence group (mean prevalence 0.037) with
the remainder in the high prevalence group (mean prevalence 0.24). Three possible
explanations are:
That these results represent the normal, stochastic behaviour of an infectious disease,
like foot-and-mouth disease, in a population. In the many cases, following the introduc¬
tion of one or a small number of infected individuals, there will be subsequent onwards
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transmission of disease to susceptible individuals. In a naive population the typical
number of direct onwards cases would be represented by the epidemiological parameter
Ro — the basic reproduction number [Anderson and May, 1992]. If Rq is close to unity
in a naive population or if the effective reproduction number resulting from, for exam¬
ple vaccination, is close to unity, some infection events may result in marked spread of
disease within the group of animals but the majority will result in only low numbers
of subsequent infections. Hence the two components of the mixture model represent
take-off of disease and low transmission with extinction.
An alternative hypothesis is that the mixture arises not, primarily, as a result of stochas-
ticity but that the effective reproduction number differs between groups of villages. The
effective reproduction number in a Thrace village will vary according to vaccination cov¬
erage, virus strains, environment and many features of husbandry practice. It is thus
possible to hypothesise that the mixture distribution of prevalence within villages is a
consequence of, for example, high and low vaccination coverage or differing husbandry
practices.
It is also possible that the mixtures actually represent a high prevalence distribution
of truly exposed villages where infection has taken off and a low apparent prevalence
distribution which arises due to poor specificity of the diagnostic test. This explanation,
however, is not supported by the parameter estimates for the test specificity which were,
as noted previously, robust to diagnostic test prior assumptions.
To identify the process behind the apparent mixture distribution requires accurate, vil¬
lage by village vaccination coverage estimates and in situ evaluations of the CEDITEST
diagnostic performance parameters when used in the Turkish laboratories on sera from
Turkish (vaccinated and unvaccinated) cattle.
5.5.2 Diagnostic test performance
The diagnostic test was estimated as slightly less sensitive (85%) than the design sen¬
sitivity used in the Thrace surveys (90%) but was highly specific (99.85%) and close to
the design specificity of 100%. Figure 5.2 shows that the posterior distribution of the
sensitivity was largely driven by the prior from Engel et al. [2008] whereas the posterior
for specificity was updated by the model/data to be more specific with less uncertainty.
Qualitatively the sensitivity and specificity estimates arise because for a given model
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the likelihood of observing a given data-set will be dependent on the sensitivity and
specificity of the diagnostic test (just as it is dependent on the village and animal-level
prevalence). Thus given a prior distribution, the Bayesian approach potentially allows
estimation of the test parameters. However there almost no information to inform the
sensitivity of the diagnostic test as this parameter will be negatively correlated with
prevalence estimates and there are low numbers of test positive animals. Hence the pos¬
terior for the diagnostic test sensitivity is almost identical to the prior. The specificity
is more strongly identified by the model as a marked departure from perfect specificity
will effectively introduce a third mixture distribution into the model (animals will test
positive because they are falsely positive or because they are genuinely positive in a
village of one of the two animal-level prevalence groups).
5.5.3 General assumptions
The model was constrained to fix diagnostic test sensitivity and specificity as constant
across all three surveys and to be fixed within each survey. The earlier analysis of per¬
centage inhibition results (in chapter 4) suggested that this is not necessarily the case.
The apparent drift in location of percentage inhibition was corrected by re-calibration
of the test (effectively moving the cut-off point) as previously discussed. However, it is
possible that other effects that do not move the overall location of the percentage inhi¬
bition test results may occur between and within surveys and would cause a between
survey variation in test performance. Unfortunately there are insufficient observations
to attempt to estimate sensitivity and specificity on a survey by survey basis. Trial
attempts at this resulted in non-convergent models. This is unsurprising as the infor¬
mation content of the data regarding test sensitivity will be very low with the low rate
of positive test results.
Also as previously discussed the model uses a simplification that the prevalence within
a sample is the prevalence within a village. This assumes that the sample is a represen¬
tative sample from the village cattle population. This is not the case. In order to reduce
the risk that cattle having multiple previous foot-and-mouth disease vaccinations will
be tested positive, due to vaccines containing small amounts of non-structural proteins,
animals for surveillance are selected from those between 4 months and 24 months old.
Thus the prevalence estimates for foot-and-mouth disease exposure will be biased rep¬
resenting the prevalence in this age group which may have a different exposure risk and
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behaviour to the average over the whole population a village. It is also possible that
sampling will not occur perfectly at each site as sampling is locally delegated (Naci
Bulut, §AP Institute, personal communication 2006) and hence may occasionally be
on a convenience basis from single farms rather than randomly across a whole village
sample frame.
Follow up CEDITEST diagnostic tests were performed by the §AP institute on positive
animals with then further follow up using the Bommeli CHEKIT test. I have elected
to only analyse the initial test results rather than use the results of the follow up test¬
ing. This was because only limited information is available describing the conditional
interpretation of these tests [Paton et al., 2006]. Hence inclusion would require joint
estimation of these parameters in the Turkish setting and would be unlikely to add to
the precision of the epidemiology estimates.
5.5.4 Implications for sero-surveillance in Thrace
As shown in Chapter 3, surveys to demonstrate freedom from disease using tests with
significantly imperfect specificity will almost always fail to demonstrate freedom on
initial interpretation of the primary test results. The simple pass/fail results from the
raw data of the 2005 and 2006 surveys in Thrace surveys has no utility for charting the
progression of a region from endemic or epidemic status to disease freedom as, by strict
interpretation, the region would be considered 'not-free' at each survey. Quantitative
analysis, such as the Bayesian mixture model approach, may permit a finer grained
examination of the primary NSP ELISA test data, before application of confirmatory
tests, and allow inference about the epidemiology of disease and its trends. The key
results from such analyses are the estimates of village-level prevalence of exposure
('u.preu' in this study) and the estimates of within village prevalence. These describe
the village-level of incursion of disease or previously exposed livestock and the within-
village characteristics of these incursions.
The analysis of the three surveys from Thrace suggests that in all surveys some villages
contained animals that were previously exposed to foot-and-mouth disease virus. It
can not be definitively ascertained from the data if this represents exposure of animals
within the village or movement into the village of previously exposed livestock. There
appeared to be a trend in estimated village-level prevalence of exposure compatible with
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reported disease history although higher in magnitude. This may represent undetected
disease, may be a result of vaccination related effects on test specificity or be a direct
result of diagnostic test performance. It would be important to identify which, by
further evaluation of the diagnostic test in the relevant vaccinated cattle, before a
region under vaccination control could be demonstrated to be free of FMD solely by
NSP test based sero-surveillance without further confirmatory testing.
More generally, the use of quantitative results in charting the progression to disease
freedom is likely to require careful refinement of the epidemiological model to reflect
the mechanics of incursion, movement, sampling and diagnosis. In the Thrace setting
a low level of seropositivity at a village level may be unavoidable due to purchase of
previously exposed livestock and the effect of residual traces of NSP material in vaccines.
Quantitative models need to explicitly include these processes otherwise villages may
be estimated as exposed to FMD when they are not.
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5.6 Appendix
5.6.1 Model code
5.6.1.1 Base two-level model
poSj ~ dbin(apj, samplesJ
apj = se-pi + (1 -sp) • (1 -pi)
Pi = Pi ' '"status,!
Pi ~ dbeta(aa>i, ba>i)
""status,! ~ dbern(uprev,surveyi)
aa, l = P~ 1 • 0-1















1 < i < N
~ dbern(rprobs)
~ dbeta(u.prev.a, u.prev.6)
— ^prev*,s ' "status,s
- dunif(0.001,0.999)
= p,y ' (f)V







1 < s < 3
a = 1
P = 0.01
5.6.1.2 Two level model with beta mixture of exposed village's prevalence
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pOS; ~ dbin(ap;, samples;)
aPi = se -pi + (1 - sp) • (1 -pi)
Pi = Pi ' '"status,!
Pt ~ dbeta(aa>c]asg., &Q ciass.)
class; = class* + 1
class* ~ dbern(p.2)
"status,* ~ dbern(uprev,surveyi)
p. 2 ~ dunif(0.001,0.999)
Oa, 1 = p.l • 4>.l
p.2 = (scale.2 + p.l)/{\ + scale.2)
«a,2 = p.2 ■ 4>.2
scale.2 ~ dbeta(l, 1)
K,i = </>. 1 • (1 - p.l)
ba,2 = (f>.2 • (1 - p.2)
p.l ~ dunif(0.001,0.999)
<f>. 1 ~ dgamma(a, /3)
(f>.2 ~ dgamma(a, (3)
"status,s ~ dbern(rprobjS)
"prev*,.s ~ dbeta(u.prev.o, v.prev.b)
"prev,s = "prev*,s ' "status,s
rprob,s ~ dunif(0.001,0.999)
u.prev.a = pv ■ (j)v
u.prev.6 = 'Au ' (1 hv)
hv ~ dunif(0.001,0.999)
<Al> ~ dgamma(a, (3)
se ~ dbeta(sea, se^)
sp - dbeta(spa, sp6)
p.a.sim. 1 ~ dbeta(aaji, bap)
p.a.sim. 2 ~ dbeta(aa>2,6a>2)
u.prev.sim ~ dbeta(u.prev.a, u.prev.fr)
1 < i < N






Uses data from Excel spreadsheets from Naci Bulut SAP Institute, Ankara, Turkey
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TRAKYA SEROSURVEY 2005.xls 2005 Survey
TRAKYA SEROSURVEY final 12.07.2006.xls Spring 2006 Survey
TRAKYA SEROSURVEY 2006 sonbaharx.xls Autumn 2006 Survey
CEDI SONBAHAR 2006 POSITIVE.xls Positive results from Autumn 2006
villages list and animal pop. size.xls Sampling Frame for 2005 Surveillance
vaccination_report.xls Planned and executed vaccination numbers by district dated
March 2006
villages list and animal pop. size.xls List by province, district and village of cattle
population census
5.6.3 Trace of model output from JAGS
See following page ...
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Figure 5.9: Posterior density trace using zero/double mixture model with re-calibrated
data— priors from Engel 2008 for sensitivity and specificity. Three chains
are show for each parameters (coloured red, green and black). The samples














Current legislation and animal health codes require that after an animal disease epi¬
demic, in a previously free region, several steps are taken to demonstrate that the disease
has been controlled and that external trade with the region no longer poses a risk. The
two main surveillance activities required are clinical and serological surveillance. Clin¬
ical surveillance entails the periodic examination of remaining livestock by stockmen
and veterinary surgeons on farm and staff, inspectors and official veterinary surgeons
at abattoirs, lairages and markets. Serological surveillance consists of survey-based
sampling of animals and subsequent testing with a diagnostic test to identify infected
or previously exposed animals. In this chapter I will estimate the diagnostic benefits
of the two approaches and estimate the additional value of serological surveillance over
clinical surveillance.
Clinical surveillance provides information on the basis that every time stock in a region
are examined and signs of infection/disease are not observed the subjective probability
that the region is disease-free is greater than before the observation occurred. In this
chapter I use this idea formally, applying Bayes theorem, to estimate over the post
epidemic period how the probability of disease freedom in a group of livestock increases
with time given that stock are inspected from time-to-time and no disease is detected.
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I apply this model to post epidemic scenarios using livestock demography data from
Devon and Surrey.
The estimation requires a model of observer detection of disease in an affected group
of animals. There are three components to this:
• A model of disease epidemiology within the group of animals: I use a stochastic
SEIR model with parameters obtained from a literature review and discussion
with experts. This captures the stochastic behaviour of foot-and-mouth disease
in livestock groups.
• A model of clinical signs of disease: I use a literature review and expert consolation
based disease profile which describes the development and resolution of clinical
signs throughout the disease course. This is used to approximate the probability
with which signs will be detected if an animal is observed.
• A model of stockholder and animal health professional observation: This simulates
the periodic and partial observation behaviours that apply to different husbandry
systems e.g. beef and dairy cows. A stochastic model was used. This model was
informed by estimates of human observation behaviour provided by interviews
with veterinary surgeons, stockmen and university clinicians involved in livestock
management and disease control activities during the UK 2001 foot-and-mouth
disease epidemic.
The performance of serological surveillance has previously been estimated by using rel¬
atively simple models of within-group epidemiology and point or distributional models
of diagnostic test sensitivity. In my analysis I am particularly interested in the time
dependent effects of surveillance so I have explicitly modelled the antibody response of
exposed animals against time to give an estimate of diagnostic test sensitivity against
time for each animal. Using standard sero-surveillance sampling designs and the same
stochastic disease model that I used for clinical modelling allows me to construct a
model of serological detection at any time during the post epidemic period.
With the above models I can estimate (for a given prior probability of disease in the
region at the start of the surveillance period) the daily probability of disease given that
no clinical signs are seen. Application of the serological model to the herd or flock
simulation on a given date allows me to estimate the further reduction in probability of
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disease given that the survey was negative. From these results summary measures can
be calculated estimating the time saved by performing serological surveillance after a
period of clinical surveillance rather than waiting for a longer period doing just clinical
surveillance.
6.2 Introduction and background
After a foot-and-mouth disease epidemic in a previously disease free country interna¬
tional trade regulations [OIE, 2005b] require that evidence is provided to demonstrate
that the disease has been successfully controlled and that trade will not represent
a significant risk. Conventionally this evidence consists of several components: the
methodology of disease control, the epidemiology of the disease, the demography of the
affected region, a suitable period of clinical surveillance and a systematically planned
and executed sero-surveillance study. This chapter focuses on the last two, surveillance-
based, components. Surveillance studies operate by having some, non-zero, probability
of detecting disease if it is present in the study population. This is the system sensitiv¬
ity [Martin et ah, 2007b]. Completion of the surveillance activity without detection of
disease effectively increases confidence that there is no disease present. I use the term
disease in this study to include all clinical and serological manifestations of disease
having potential consequences either clinically or economically. A serologically positive
animal may have recovered from clinical disease. Detection of such an animal in the
post epidemic period would at the very least require its slaughter, may delay declara¬
tion of disease freedom and would instigate further diagnostic procedures. Hence for
the purposes of this study on post-epidemic surveillance disease will include serological
as well as clinical signs. Every time an animal, farm or region is examined and disease
is not found the probability that the animal, farm or region is disease free increases
(assuming the examinations are not completely statistically dependent).
Currently both clinical surveillance — the time to time examination of standing live¬
stock by keepers and veterinary surgeons — and serological surveillance are required
as evidence to substantiate freedom from foot-and-mouth disease OIE [2005b]. In this
chapter I estimate the surveillance benefits of clinical surveillance in post foot-and-
mouth disease outbreak scenarios and then estimate the additional surveillance benefits
of serological surveillance.
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The post epidemic period has a retrospective start. Towards the tail end of an infectious
disease epidemic cases will arise, on average, less and less frequently. The post epidemic
period starts with the last recorded case. Notification of a new case effectively 'resets
the clock' with a new start of post epidemic period. This process repeats until no
new cases are notified. With foot-and-mouth disease, livestock in a previously infected
area will normally remain under full or partial movement restrictions until there is
strong evidence that there is no longer infectious disease present [Anderson, 2002].
Traditionally, post-epidemic surveillance is a period of high vigilance on the part of
farmers, stockmen, government veterinary officers and private veterinary clinicians.
There is a high societal pressure within the agricultural community neither to start a
new outbreak nor to fail to report existing infection according to a livestock veterinary
surgeon active during the UK 2001 epidemic (David Black personal communication,
August 2008). Any suspected cases on farms will be reported by stockmen or veterinary
surgeons to the local animal health office or disease control centre for subsequent clinical
investigation and laboratory diagnostic tests.
6.2.1 Previous studies
McLaws et al. [2007, 2006] estimated the farm level sensitivity of clinical surveillance
during the active phase of the UK 2001 foot-and-mouth disease epidemic at approx¬
imately 97% by comparison of clinically detected farms with serologically identified
farms. However, these studies do not estimate the incremental sensitivity of clinical
surveillance with repeated daily examination that will be present in the post epidemic
period and do not address the issue of post epidemic serological surveillance. Arnold
et al. [2007] uses a stochastic model to simulate foot-and-mouth disease epidemics with
clinical identification of infected premises and a culling and vaccination strategy. The
study estimates the number of residual carrier animals after an epidemic and con¬
siders the efficacy of a non-structural protein based diagnostic test in post epidemic
surveillance in vaccinated herds. Carpenter et al. [2004] describe a model for a large
dairy herd simulating intra-herd spread of disease and clinical detection. The model
is designed to estimate events in a large herd North American setting and uses a very
conservative estimate of 10 clinical cases before disease is detected. This and the lack
of serological surveillance makes the results of this model unsuitable for estimation of
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benefits of serological surveillance in a UK setting. Bates et al. [2003] describe a re¬
gional intra and inter herd model of foot-and-mouth disease. This model is used for
subsequent evaluation of control strategies including culling and vaccination. As with
the other studies described in this section there is no implicit consideration of how the
performance of clinical surveillance varies over time and the comparative advantage of
serological surveillance at the end of a period.
6.3 Methodology
6.3.1 Overview
The aim of this chapter is to estimate the post epidemic surveillance benefits of clinical
surveillance and the additional benefits of serological surveillance. In this study the
benefits will be calculated as a daily system sensitivity [Martin et ah, 2007b] — the
probability that a diseased group or collection of groups of animals would be identified
by the survey on a given day. This is then cumulated over the post epidemic period for
clinical surveillance to give the probability that a diseased group of animals would be
detected on any day up to that point. This can then be combined with a prior belief
in the probability of disease in the group to give a posterior probability of disease if
surveillance has not detected disease.
There are four components to this analysis; a model of epidemiology in infected groups,
a model of clinical surveillance, a model of serological surveillance and the integration
of these components into the cumulative results. These are addressed in turn in the
following sections.
6.3.2 Model of epidemiology within an animal group
Figure 6.1 shows a simplified schematic for the clinical and epidemiological stages of an
infectious disease in an individual.
The performance of clinical or serological surveillance will be contingent on the un¬
derlying epidemiology of the disease that it aims to detect. As change in surveillance
performance over time is a key focus of this analysis an individually based mechanistic
model is used to simulate progress of disease through an exposed group of animals. Use








Figure 6.1: Timeline showing pathogen load (e.g. viraemia) and immune response
(e.g. antibody levels) of a typical infectious disease in an individual. The
coloured bars show the different clinical and epidemiological statuses, (re¬
drawn from [Keeling and Rohani, 2007])
of an individually based model captures both the temporal changes in disease status
of animals and the stochastic variability of disease patterns. The model is an SEIR
(susceptible, exposed, infectious, recovered) frequency dependent model [Keeling and
Rohani, 2007] — a structure which approximates the clinical behaviour of foot-and-
mouth disease virus in a dispersed group — where the number of effective contacts
between individuals will be approximately independent of the group size i.e. Ro does
not increase as herd or flock size increases [Sobrino, 2004, p 362].
Figure 6.2: Structure of within-group SEIR model showing probabilities that an in¬
dividual changes state. (S=susceptible, E=exposed, I=infectious and
R=recovered.) Where [3 is the product of an individual's average num¬
ber of contacts per day and the probability of a contact with an infected
individual resulting in a successful transmission event, a and 7 are the
reciprocals of the latent period and infectious period durations.
At the start of the outbreak the group of animals is assumed to consist of N animals of
which E have been exposed to foot-and-mouth disease (by contact, fomite transmission
or otherwise) and S = N — E are unexposed i.e. susceptible. The SEIR formulation
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uses probabilities that an individual in each class will change state (in the case of the
transition from susceptible to exposed this is also dependent on the number of infectious
individuals in the whole group). As the transition is represented as a probability rather
than a deterministic rate the model is stochastic and the number of individuals in
each class with time cannot be determined analytically. A number of methodologies
exist to realise this model and generate sets of simulated outbreaks. For efficiency and
simplicity I use Gillespie's direct algorithm (Gillespie [1977] described in Keeling and
Rohani [2007]). The algorithm uses the following method to exactly simulate the SEIR
process:
1. Identify all possible events (e.g. a susceptible individual becomes exposed)
2. Set a time variable to the start time for the simulation
3. Calculate the mean rate at which each possible transition event occurs (e.g.
0SI/N for 5 -► E)
4. Calculate the rate at which any event occurs (The sum of the individual rates)
5. Draw the time to the next event from the negative exponential distribution using
the above rate.
6. Using the individual event rates as weighting choose one of the possible events to
perform
7. Do the chosen event and increment the time variable
8. Repeat steps 3-7 until the time variable reaches the chosen end of simulation
time
The model uses animal group sizes drawn from the agricultural census data for the
counties of Devon and Surrey in 2006. Both of these areas have experienced foot-and-
mouth disease outbreaks; in 2001 in Devon and in 2007 in Surrey [Anderson, 2002,
2008]. For each simulation of a within-group epidemic the group size is drawn from
the empirical distribution of group sizes for the selected county and animal type. The
initial number of exposed animals was drawn from a Poisson distribution with a mean
of 4.1 + 0.0049/r where h is the number of individuals in the group. This was based on
the initial size estimates of Arnold et al. [2007] in cattle herds in the UK 2001 epidemic.
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For my study draws from this distribution that resulted in a zero sized outbreak were
discarded. Animal types were divided into sheep, dairy cattle and non-dairy cattle
using the census classification data. A farm with dairy animals and non-dairy animals
was considered to have two independent groups. The dairy, non-dairy and sheep classes
were selected to mirror likely differences in disease epidemiology and clinical observation
behaviour between the classes. The distribution of group sizes in the two study counties
are shown in the results section. Each within-group outbreak was simulated for 120
days as preliminary simulation studies identified that this period would capture the
important differences between sampling methods, scenarios and animal groups. During
each simulation the dates of each new transition from susceptible class to exposed class
were captured for input into the subsequent stages of the analysis. Illustrative results
from the SEIR model are shown in the results section 6.4.2.5.
The SEIR transmission model requires parameters to describe the following: the proba¬
bility that two individuals contact and that if an individual is infectious a transmission
occurs in a unit time (/?); the mean duration of the latent period (1/cr) and the mean
infectious period (I/7). These parameters were estimated by reviewing the available
literature describing the epidemiology of foot-and-mouth disease (see section 6.4.2) and
discussion with experts. As there was a large uncertainty associated with these param¬
eters deterministic sensitivity analysis was carried out using different values of /3, a and
7 as detailed in the results section.
Limited data were available to validate the SEIR model of within-group infection. One
source was the records of post-epidemic serology following the UK 2001 foot-and-mouth
disease epidemic. Data were recorded in a report to the OIE for official declaration of
disease freedom [DEFRA, 2002]. The records contain details of samples taken from
sero-positive farms and the number of animals testing positive. These are summarised
in the results section and compared with the outputs of the SEIR model.
6.3.3 Model of clinical surveillance
Clinical surveillance may consist of the visual and physical examination of the livestock
in a particular group of animals. This occurs either during their day to day husbandry
or additionally as disease control measures. For this study only the observations of
livestock keepers were considered. This was both for simulation simplicity and also
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as it was considered that livestock keepers were significantly more likely to identify
disease in their stock than external veterinary surgeons or animal health officers as it
was suggested by David Black (personal communication August 2008) that they were
more familiar with the normal behaviour of their stock and had more opportunity to
observe them. A simple model of livestock owner clinical examination was proposed
and discussed with an expert panel comprising a foot-and-mouth disease specialist, a
production animal clinician, a farm manager, a shepherd and two animal husbandry
lecturers.
For each animal type (broadly, their husbandry system):
• On a particular day the group of animals may be observed, en masse, with a
probability Pgr0uV-
• If the group was observed each individual would be observed with a probability
Pindiv ■
• If an individual was observed there was a maximum probability of diagnosing
foot-and-mouth disease if present Pmax-
• The relative probability of diagnosis of a foot-and-mouth diseased individual was
not constant but followed a clinical disease profile with perhaps subtle signs of
disease after an incubation period, then increased signs to a maximum with then
a gradual decrease and resolution of signs with recovery and healing.
The parameters for this model were estimated by discussion with the expert panel in the
case of the first three parameters and by literature review and discussion with a foot-
and-mouth disease epidemiologist in the case of the clinical disease profile parameters.
The process of clinical observation was simulated by assuming that each exposed animal
in a group progresses through a deterministic clinical profile (see figure 6.3(a)). On
each day of the epidemic the probability that the group and an individual within the
group was observed was used to create a stochastic (varied on each simulation instance)
observation window (see figure 6.3(b)). This observation window was then applied to
the clinical profile for the group to give a day by day and animal by animal output of
observed clinical signs (see figure 6.3(c)).
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Days post intial Exposure Days post intial Exposure
(a) Clinical profiles (graded from red-orange- (b) Stochastic observation window (white = animal
yellow-white in increasing ease of detection) observed on that day)
0 10 20 30 40 50
Days post intial Exposure
(c) Observed clinical profiles
Figure 6.3: Clinical observation model showing progression of 20 animals through a 60
day outbreak to illustrate use of clinical profiles and observation window.
In figure 6.3(a) the colours represent the severity of clinical signs with blue
being no signs, orange being low grade signs and white representing severe
signs. Figure 6.3(c) represents the outbreak in figure 6.3(a) as observed
through the white gaps in the observation windows in figure 6.3(b).
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For each animal type (husbandry system) the resulting observed clinical profiles are
scaled. For discussion and literature review purposes the clinical presentation of foot-
and-mouth disease was estimated on an ordinal scale from 0 (not detectable) to 4
(maximum probability of detection in that animal type/ husbandry system). This
scale was assumed to represent a continuous scale. It was standardised so that for each
animal type the highest score was Pmax (the maximum probability of detection in that
animal type).
The output of the clinical observation model, applied to simulated epidemic can be
represented as a matrix C where Ca,t represents the probability that clinical signs will
be seen on day t in animal a. An outbreak in a group will be considered detected if
clinical signs are detected in any animal in the group. Thus the probability of detection
of disease in a group of n animals on a particular day t can be estimated as:
Pt = l-n:=l(l -Ct,a)
Clinical post-epidemic surveillance will begin, by definition, on the first day after an
epidemic or outbreak is putatively ended so we are generally interested in the cumulative
effect of continued clinical surveillance — i.e. the probability that a diseased group of
animals will be detected by a given day. This may be estimated at day t by:
Pt = i-nua-fl)
Pt may increase or decrease from day to day and in infrequently observed groups of
animals may often be zero. Pf will always increase or remain constant as time passes.
6.3.4 Model of serological surveillance
Serological surveillance normally consists of the sampling of blood from all or a ran¬
domly selected subset of the group of animals for biological testing to identify antibodies
to foot-and-mouth disease and hence infer exposure to the virus [Baron, 1996]. In this
study I assume that either a random sample of the animal group is selected for sero¬
logical testing or the entire group is tested. Random sampling is the approach outlined
in the DEFRA, EU and OIE guidelines and echoes the procedures carried out in the
foot-and-mouth disease epidemic in many regions of the UK in 2001 [DEFRA, 2002].
The mechanism of sample size calculations for such surveys is discussed elsewhere in
this thesis and in depth by Cameron [1997]. A standard approach is to calculate a
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sample size to give a 95% confidence or probability of the serological test identifying
at least one diseased, sampled individual given an assumed within-group prevalence
of disease (if it is present) and assumed serological test performance characteristics.
In this simulation of serological surveillance I assume that the cELISA diagnostic test
[Paiba et al., 2004] (as used in the UK in 2001) is employed. This is a solid phase
competitive ELISA test with a theoretical 100% sensitivity in cattle and sheep.
In the simulation model the sample size for the random sample required to meet the
above 95% confidence criteria was generated for each simulated epidemic using a look
up table of herd/flock size and sample size. The look-up table was created using the
software program 'FreeCalc' [Cameron and Baldock, 1998a] with the above diagnostic
test parameters and an expected herd prevalence of foot-and-mouth disease (if infected)
of 5% as used for serological survey design in 2001 [Thrusfield et ah, 2005a].
In this study the diagnostic benefits of clinical surveillance are assessed from the first day
of the post epidemic period through to 120 days. It is possible that an animal may be
tested with the cELISA test that has not mounted a full serological response and hence
the diagnostic test will not operate at maximum sensitivity. Animals exposed to foot-
and-mouth disease develop antibodies after a delay and effectively have a serological
profile, with time varying probability of detection. The effect of this serological profile
on the test performance was estimated using data from the cELISA evaluation in Paiba
et al. [2004], In Paiba et al. [2004] two groups of four cows and two groups of four
sheep were inoculated with foot-and-mouth disease. One group in each species was
inoculated directly, the other by contact with foot-and-mouth disease infected donor
animals. Blood samples were drawn from the exposed animals and the percentage
inhibition results of a cELISA assay were recorded. For the evaluation of the variation
of diagnostic test sensitivity with time after exposure I have used the data from the
group that were indirectly exposed via a donor animal as this is more likely to represent
the response of exposed animals in a field setting. The original data from this study
were not available so percentage inhibition values for each of the animals were measured
from the published figures using digitisation software [Arizona-Software, 2008]. Blood
samples were recorded as taken at 0, 2, 4, 6, 8, 10 and 12 days in the sheep and 0, 1, 2,
3, 4, 5, 7, 9, 11, 15 and 30 days in cattle. In order to impute the test behaviour in the
intervening days and to estimate the variability of the cELISA response an empirical
model was fitted to the recorded data. A four parameter logistic model [Crawley, 2007,
page 203] was used to capture the asymptotic and sigmoid features of the antibody
Chapter 6 Benefits of Serological Surveillance over Clinical Surveillance 155
response with time. The four parameter logistic model was chosen as it allows fit
to lower and upper asymptotes with flexibility of location and scale of the sigmoid
component of the curve. The variance of percentage inhibition results was obviously
heteroscedastic with time so process error was modelled as an exponential polynomial
function. The percentage inhibition response at time t (Pit) was modelled:
Pit ~ N(nt, at)
B~A
~ +1 +eC-(D + t)
= 1/y/ri
Tt = exp(E + F ■ t + G ■ t2)
The model was parameterised using Bayesian MCMC with JAGS software [Plummer,
2003] called using the R statistical environment [R Development Core Team, 2007] us¬
ing the Runjags package [Denwood, 2008]. The model formulation is shown in appendix
6.6. Vague gamma priors were used for the parameters A..G. The model (see section
6.3.4) was run for a burn-in period of 100,000 simulations and sampled for 100,000
iterations. At each day post exposure over the range of the evaluation data the per¬
centage inhibition values were simulated (within the MCMC code) and compared to
the manufacturer's cut-off value of 60% (the value that would be used to classify results
in an outbreak). This permitted an estimation of the diagnostic test sensitivity at each
day post exposure. Convergence of the MCMC process was assessed by running three
simulation chains and examining the posterior traces of these chains and calculating the
Gelman convergence diagnostic [Brooks and Gelman, 1998]. As this model was simply
to smooth the underlying cELISA data and capture its uncertainty no additional model
diagnostics or alternative models were assessed.
The model estimates the sensitivity of the cELISA test applied to indirectly infected
cattle and sheep for each day after their initial exposure. These results are used, in a
similar manner to the clinical sign profiles in the previous section, to give a serological
detection probability profile (sensitivity) to each animal in the group as it becomes
exposed. The exposure times are exactly the same times as simulated by the stochastic
SEIR model. This whole group profile is then randomly sampled on each day (using
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the sample size determined by FreeCalc) or selected in full depending on the sampling
strategy being simulated to give a simulated set of blood results for each, post-epidemic,
day. The probability that one or more of these animals will test positive is given by:
P(T+) = 1 - n-=1 (1 - Sef)
where P{T+) is the probability of at least one animal testing positive and Sei is the
estimated sensitivity of the test in the ith animal in the sample of s animals.
Serology is unlikely to be repeated so a cumulative sensitivity of testing the group is
not calculated.
For both the serological surveillance and the clinical surveillance only the survey sensi¬
tivity is estimated. With both modes of surveillance there may be false positive results
as neither surveillance mode will have perfect specificity. This is not considered in
this analysis as I am concerned with the relative ability of the different survey modes
to detect potentially diseased animal groups. False positive results will be screened
out after clinical or serological surveys by further clinical, serological and virological
investigations involving examination by experts and additional diagnostic tests.
6.3.5 Estimate the posterior probability of disease
The above methods allow the estimation of the cumulative, day-by-day sensitivity of
clinical surveillance P*(T+)t and the sensitivity of serological surveillance P{T+)t at
day t. Given a prior belief of the probability that a group of animals is infected the
clinical surveillance sensitivity results can be used to estimate the probability that the
group is infected day by day during the post epidemic period given that no signs are
clinically detected. Additionally the further reduction in probability of disease given a
negative serological survey result can also be estimated on a day at the end of a period
of clinical surveillance. In qualitative terms: for every day that disease is not detected
we become more sure that it is not present and if we additionally perform serology we
are further reassured that the group of animals is not infected.
Prob(D+lT_) _ ProKT-ID^ProKD-) (6.1)
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So an initial prior belief that a group of animals is infected of Prob(D+) is updated
using the probability of clinical detection up to day t to give a posterior belief that a
group of animals is infected (given no clinical disease was observed) of Prob(D+\T^in).
If on a particular day clinical surveillance is done the posterior estimate of the prob¬
ability of disease to that point (Prob(D+\Tfilin)) can be used as the prior estimate for
a similar equation to 6.1. This gives the probability of disease in the group given that
no clinical signs of disease have been observed up to that day and that serological
surveillance on that day was negative.
6.3.6 Summary metrics
For each simulation set summary measures are calculated. Generally the posterior
probability of disease will approach an asymptote whereby further clinical surveillance
with no disease detected does not further decrease the posterior probability of disease.
This point is estimated numerically by identifying the first date at which the posterior
probability of disease is within a specified tolerance (1% of the prior probability of
disease). This probability of disease or confidence of disease freedom could also be
achieved by doing serological surveillance at the end of a period of clinical surveillance.
The date of this can be identified and hence a number of 'days saved' estimated to
achieve the same confidence of disease freedom. An alternative measure is to take the
asymptote point of the clinical surveillance result and estimate the benefits of additional
serological surveillance at this date giving 'probability of disease reduction'. See figure
6.4 for an illustration of these measures. The robustness of the summary measures to
the tolerance method was assessed using deterministic sensitivity analysis setting the
asymptote detection tolerance to 2% and 0.5%.
6.3.7 Prior probability of disease
The previous section requires a prior probability of disease for the calculation (using
Bayes theorem) of the posterior probability of disease each day given negative survey
results. This probability will be informed on an individual basis by factors including
epidemic history and control strategy. The base figure used for this analysis is 0.0002.
This is the equivalent of one farm in Devon being diseased (there being approximately
5000 cattle/sheep groups in Devon). DEFRA's report to the OIE claiming disease
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Figure 6.4: Illustration of measures derived from the model outputs. The red (upper)
line represents the decreasing probability of disease as time passes with no
clinical detection. The orange (lower) line represents the additional benefits
of carrying out serological surveillance at the end of a given period of clinical
surveillance. Points (a), (b) and (c) are estimated numerically to calculate
the two metrics - 'time (or days) saved' and 'probability reduction'.
freedom after the UK 2001 foot-and-mouth disease epidemic [DEFRA, 2002] identified
that 0.03 % of farms that were serologically tested were test positive. This estimate
may represent an upper limit of diseased farms after that epidemic as some of these
farms will have been old infections missed during the main epidemic control period.
The values 0.001 and 0.0001 were used for sensitivity analysis.
6.4 Results
6.4.1 Demography of study areas
The 2006 agricultural census records 8,796 holdings in Devon and 2,265 in Surrey. These
are classified by presence of any cattle or sheep in tables 6.1 and 6.2. The agricultural
census classifies animals on a holding into categories, distribution of group sizes in
the two counties within these categories is shown in figures 6.5. For the simulation
models of outbreaks and surveillance cattle were considered to be either in dairy or
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non-dairy (hereafter referred to as 'beef'). This grouping was chosen as it reflected
the broad difference in stockman observation behaviours between the twice daily close
observation of milking dairy cattle and the less frequent, longer range observation of
non-milking cattle. Dry cows, heifers, bulls, calves and other non-milking stock on








Table 6.2: Number of farms in Surrey with either any cattle, any sheep or both
There is a marked difference in the total numbers of cattle and sheep holdings in the
two counties. Additionally there are relatively fewer dairy herds in the 1-200 animal
herd size range in Devon compared to Surrey. The distributions of classified group sizes
in the two counties are shown in figure 6.6.




Figure 6.5: Box plot showing the distribution of herd and flock sizes as classified by
demography records in the 2006 Agricultural census. Herd and flock sizes
are shown on the y-axis with group classification on the x-axis
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Figure 6.6: Distribution of dairy, beef (non-dairy cattle) and sheep groups in Devon
and Surrey scenario areas.
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6.4.2 Parameters for SEIR Epidemic Model
6.4.2.1 Transmission parameters
The majority of studies regarding foot-and-mouth disease epidemiology consider the
farm or animal holding to be the unit that may become infected ([Ferguson et al., 2001;
Keeling et al., 2001; Keeling et al., 2003; Keeling and Rohani, 2007; Tildesley et ah, 2006]
and others). This is appropriate from the point of view of farm based decision making
such as vaccination strategies, movement controls and culling policies. However my
model of within farm surveillance requires transmission parameters describing animal
to animal transmission characteristics. These are generally estimated experimentally
[Velthuis et ah, 2007] for reasons of control and reproducibility although they may be
estimated from surveillance data obtained by clinical examination or diagnostic testing
of farm animal groups. Estimates from the literature review are summarised in table
6.3 with notes in section 6.7. There is great uncertainty in some published studies
regarding the transmission parameters of foot-and-mouth disease at an animal-level
in within-farm outbreaks. For example in Orsel et al. [2007a]'s study of transmission
between dairy cows the estimate for Ro in unvaccinated animals had a 95% confidence
interval of 1.2 to infinity.
6.4.2.2 Latent Period
Carpenter et al. [2004] provide estimates for the latent period and infectious period in
dairy cattle based on expert opinion and literature review. Bates et al. [2003] provide
an estimate for the latent period in sheep (see table 6.3).
6.4.2.3 Infectious Period
Alexandersen et al. [2003]'s analysis of virus concentration in excretions from infected
animals demonstrated virus excretion at least 10 days after exposure of cattle to infected
pigs. However they report a sharp decline in excreted virus load at day 4-5 of clinical
disease. Orsel et al. [2007b] estimated the infectious period (using an SIR model without
a latent period) as 21.1 days with a 95% confidence interval of 10.6-42.2. Parker [1971]
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Animal Type R0 latent period (1/cr) infectious period (l/q)
Sheep 0.5 2 3
Beef 2.0 2.5 5
Dairy 2.0 2.5 5
Table 6.4: Estimates used to parameterise SEIR model.
a mouse model to assess infectivity). Alexandersen et al. [2002b, 2003] consider sheep
to have a highly infectious period of 7-8 days followed by a period of 1-3 days when
trace amounts of viral RNA are excreted and subsequently a carrier state in 50% of
individuals. It is also noted that although themajority of animals are no longer secreting
by 10-14 days post infection environmental virus survival will effectively prolong the
infectious period. This environmental survival can be up to 6 months in slurry although
there is a poor evidence base for this [Alexandersen et al., 2003].
6.4.2.4 Selection of parameter estimates for SEIR model
The previous estimates from the literature suggest a high level of uncertainty regard¬
ing the values of transmission parameters for foot-and-mouth disease within-groups of
animals. This will, in part, reflect the stochastic and husbandry system dependent
nature of transmission and clinical disease. The parameter ranges used for simulation
were informed by values found in the literature and discussion with an epidemiologist
experienced with foot-and-mouth disease. The base values are recorded in table 6.4.
Further scenarios were then developed using a range of basic reproduction numbers for
the outbreaks and also lengthening the duration of latent and infectious periods. These
scenarios are shown in table 6.5. They use values of i?o of 0.5, 1, 2 and 8 for all groups
and include extended scenarios with extended latent/infectious periods for all groups.
6.4.2.5 Validation of SEIR model
The SEIR model was internally validated by comparison of its outputs with those of
a deterministic SEIR. model using the same parameters. The deterministic model was
estimated with a numerical method [Woodrow Setzer, 2008] using the Isoda algorithm
[Hindmarsh, 1983]. The results of two simulation sets are shown in figures 6.7 and 6.8.
There appears to be good agreement between the results of the stochastic SEIR model
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Scenario Animal type RQ l/a 1/7
1 sheep 0.5 2 3
2 sheep 1.0 2 3
3 sheep 2.0 2 3
4 sheep 8.0 2 3
5 sheep 0.5 4 6
6 sheep 1.0 4 6
7 sheep 2.0 4 6
8 sheep 8.0 4 6
1 cattle 0.5 2.5 5
2 cattle 1.0 2.5 5
3 cattle 2.0 2.5 5
4 cattle 8.0 2.5 5
5 cattle 0.5 5 10
6 cattle 1.0 5 10
7 cattle 2.0 5 10
8 cattle 8.0 5 10
Table 6.5: The transmission, latent period and infectious period parameters used for
the 8 epidemiological scenarios for each animal type in the SEIR model.
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and the deterministic SEIR model suggesting that, for the purposes of this analysis,
the stochastic model is correctly simulating the intended transmission process.
Susceptible Exposed
~T~ ~T~ T- ~T~ ~V
20 40 60 80 100
Days after initial exposure
Infected
20 40 60 80 100
Days after initial exposure
Days after initial exposure
Recovered ( mean = 15.2 % )
40 60 80 100
Days after initial exposure
Figure 6.7: An example result set from the SEIR simulation model in a sheep flock of
100 animals. The plots show the results of 50000 simulations using initial
exposed numbers as described in section 6.3.2. Ro is 0.8, the latent period
is 4 days and the infectious period is 8 days. The plots show the density
of the different outbreak trajectories (trajectories shown white-light grey-
dark grey as more frequent). The black dashed line on each plot shows the
result of a deterministic outbreak model with the same parameters as the
stochastic model.
Ideally, external validation would compare the stochastic SEIR simulation output with
detailed records of comparable on-farm epidemics where animals were sampled and
tested for foot-and-mouth disease with the husbandry system unaltered. Unfortunately
the highly infectious nature, economic importance and regulatory issues surrounding
foot-and-mouth disease make such experiments impractical. Whenever foot-and-mouth
disease is detected in a herd or flock controls will be applied and normally the animal




~T~ ~T~ ~T~ ~T~ ~T~
20 40 60 80 100
Days after initial exposure
Infected
20 40 60 80 100
Days after initial exposure
60 80 100
Days after initial exposure
Recovered ( mean = 81.3 % )
40 60 80 100
Days after initial exposure
Figure 6.8: An example result set from the SEIR simulation model in a cattle herd of
100 animals. The plots show the results of 50000 simulations using initial
exposed numbers as described in section 6.3.2. Ro is 2.4, the latent period
is 4 days and the infectious period is 8 days. The plots show the density
of the different epidemic trajectories (trajectories shown white-light grey-
dark grey as more frequent). The black dashed line on each plot shows the
result of a deterministic epidemic model with the same parameters as the
stochastic model.
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group will be culled as soon as possible. The DEFRA report to the OIE for demon¬
stration of disease freedom lists records of 45 sero-positive sheep premises identified in
the post epidemic surveillance [DEFRA, 2002], These farms escaped clinical detection
through signs not being observed due to poor observation, chance or a less obvious
clinical manifestation of disease. These results provide an estimate of epidemic final
size without external controls. The estimate may be biased as farms where disease is
harder to detect are more likely to contribute to the sample e.g. smaller farms with
less experienced stockmen. The point estimates of on farm prevalence are shown in
figure 6.9. The mean within farm prevalence was 10.9%. Of the 45 sampled farms 22
had a single serologically positive animal. These results are loosely compatible with
the estimated final size prevalence of 8.36% in sheep flocks using the base epidemic
parameters as shown in table 6.6
Several studies document prevalence of foot-and-mouth disease within herds of vac¬
cinated cattle [Kitching et ah, 2005; Woolhouse et ah, 1996] and in endemic settings
[Bronsvoort et ah, 2006]. Woolhouse et ah [1996] estimated Rq to be between 2.1 and
72.8 in 5 different herds with a median of 21.1. These were large(1732-2834 head) cattle
herds with outbreaks 71-114 days after vaccination. Bronsvoort et ah [2006] reports
within-group prevalence estimates for cattle of 34.2%, 83.6% and 91.1% for serotypes
O, A and SAT2 respectively. For sheep and goats estimates were 61.1% and 5.6% for
serotypes SAT2 and O respectively. These estimates are based on serology of Cameroo-
nian livestock in the absence of vaccination or culling based control. These estimates
are of limited value in validating the SEIR model but do illustrate the high, within herd
prevalences that can be seen with foot-and-mouth disease in the absence of control.
For illustration of the different epidemiology scenarios used for sensitivity analysis the
results from 10000 simulations of an epidemic in a group of 100 sheep and 100 cows are
shown in figures 6.10 and 6.11. The results show the wide variation in both the tim¬
ings of exposure and the final numbers of exposed animals estimated by the stochastic
simulation. Table 6.6 shows the estimated final prevalences under eight different epi¬
demiological scenarios.
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Figure 6.9: Point estimates of within farm sero-prevalence obtained from the 45 sero
positive farms recorded in annexe 5 of [DEFRA, 2002]





















Table 6.6: Mean final prevalence at 120 days after initial infection in six transmission
parameter scenarios (deterministic sensitivity analysis) for sheep and cows.
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6.4.3 Parameters to describe clinical profile of disease
There are four sets of parameters needed for the clinical detection model:
• A description of the relative likelihood of detection from infection to resolution
of clinical signs
• An estimate of the maximum probability that disease would be detected in an
infected animal if the animal is observed
• An estimate of the probability that an individual animal is observed if the group
is observed
• An estimate of the probability that the group of animals is observed on a random
day
The clinical profile is composed of a symptomless incubation period (see figure 6.1)
followed by a period of clinical signs.
6.4.3.1 Incubation Period
Alexandersen et al. [2003] suggest that the within farm incubation period is generally 2-
14 days but that it can be as low as 24 hours in pigs or in high challenge scenarios. They
record the typical incubation period in sheep and cows as 2-6 days. In experimental
conditions they report the mean incubation period as 3.5 days for direct cow to cow
infection and 2 days for intensive sheep to sheep infection. For the model I have assumed
a deterministic incubation period of 2 days for sheep and 3 days for cattle (the model
structure does not allow fractional incubation periods)
6.4.3.2 Clinical Signs
The time profile of clinical signs was informed by literature based data from [Alexan¬
dersen et ah, 2003; AVIS Consortium, 2002; Kitching, 2002; Kitching and Hughes, 2002]
and discussion with a foot-and-mouth disease expert. The result was table 6.7 giving
an ordinal clinical detection profile shown in table 6.8.
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Day of clinical signs Clinical score Clinical signs
1 1 Pyrexia
Hot painful feet
Reluctance to stand or walk
Inappetence
Reduced milk production
2 2-3 Nasal discharge
Early vesicles in mouth
Increased salivation and drooling
3 3-4 Mucopurulent nasal discharge
Further vesicles formed in mouth
Vesicles on coronary band,
Inter-digital cleft and bulb of heel
Teeth grinding due to pain
Acute lameness
3-4 4 Ruptured vesicles
4-5 4 Lesions show fibrin deposition
Epithelial re-growth
5-7 3-2 Scar tissue formation and healing
Normal body temperature restored
7-14 2-1 Healing of lesions
Table 6.7: Approximate clinical progression of foot-and-mouth disease in cattle by day
since appearance of clinical signs. An ordinal clinical detection score is
estimated from these signs and adapted for sheep with discussion with an
epidemiologist and a clinician (Mark Bronsvoort and David Black (Personal
communication 2008)).
Day 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Cattle 0 1 1 2.5 3.5 4 4 3 2.5 2 2 1 1 1 1 1 1 1
Sheep 1 2.5 3.5 4 4 2 1 1 0 0 0 0 0 0 0 0 0 0
Table 6.8: Daily clinical detection score based on table 6.7. (Day is days since infection)
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Animal Probability Estimate Notes
Sheep Observe flock 0.14 Weekly observation on average
Observe individual 0.40 Spatial dispersion
Detect if diseased 0.10 Subtle clinical signs
Beef Observe herd 0.66 Every 1.5 days
Observe individual 0.90 Majority of herd cluster
Detect if diseased 0.80 Some animals observed at distance
Dairy Observe herd 1.00 Twice daily milking
Observe individual 1.00 Milking animals
Detect if diseased 0.95 Obvious signs and close observation
Table 6.9: Estimates of observation parameters used to inform the clinical detection
model.
6.4.3.3 Remaining clinical detection parameters
These estimates were based on the interviews summarised in appendix 6.8. The prob¬
abilities and justifications are shown in table 6.9
6.4.4 cELISA Sensitivity estimates over time
The estimated parameters for the four parameter logistic model of cELISA test response
are shown in tables 6.10 and 6.11 for cattle and sheep respectively. These parameters
are used to simulate cELISA percentage inhibition measurements for cattle and sheep
as shown in figures 6.12(a) and 6.12(b) together with the observed cELISA results from
Paiba et al. [2004].









Table 6.10: Estimates from JAGS model of parameters for logistic model of cELISA
test response in cattle. Results are from study where animals were infected









Table 6.11: Estimates from JAGS model of parameters for 4 parameter logistic model
of cELISA test response in sheep. Results are from study where animals
were infected by contact with inoculated animals.












Table 6.12: Estimates of cELISA test sensitivity in cattle with time using data from
[Paiba et al., 2004] estimated with JAGS Bayesian model. Estimates are
shown by day until approximate convergence with 100% sensitivity (esti¬
mated to 30 days). Results are from a study where animals were infected
by contact with inoculated animals. Simple proportion empirical estimate
from the raw Paiba et al. [2004] data are also shown for indirect inocula¬
tion results. The empirical results are the simple proportion of test animals
whose percentage inhibition results were above cut-off value of 60%.














Table 6.13: Estimates of cELISA test sensitivity in sheep with time using data from
[Paiba et al., 2004] estimated with JAGS Bayesian model. Estimates are
shown by day until approximate convergence with 100% sensitivity (esti¬
mated to 30 days). Results are from a study where animals were infected
by contact with inoculated animals. Simple proportion empirical estimate
from the raw Paiba et al. [2004] data are also shown for indirect inocula¬
tion results. The empirical results are the simple proportion of test animals
whose percentage inhibition results were above cut-off value of 60%.
The resulting estimates of cELISA diagnostic sensitivity versus time after exposure are
shown in figure 6.13 and in tables 6.12 and 6.13 where they are shown with correspond¬
ing simple estimates from the raw data. Sensitivity in cattle and sheep is virtually zero
until 5 days post exposure in sheep and 7 days post exposure in cattle. It then increases
rapidly to effectively 100 % by 8-9 days after exposure.
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Figure 6.12: Observed percentage inhibition from cELISA [Paiba et al., 2004] (red
dots) and simulated values (jittered black points) for cattle and sheep
with indirect foot-and-mouth disease virus inoculation. Standard cut-off
shown with horizontal dotted line.













Figure 6.13: Sensitivity estimates of cELISA [Paiba et al., 2004] versus time using
JAGS model for indirect inoculation
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6.4.5 Simulation Results
Figure 6.14 shows illustrative output of the model estimating posterior probability of
disease for a selection of scenarios. This decreases from a starting, prior probability, as
time passes with repeated clinical surveillance given that no clinical disease is detected.
In these results there is a lag in the probability decrease due to the incubation period of
foot-and-mouth disease during which no clinical signs will be detectable. Once clinical
signs of foot-and-mouth disease would have appeared there is a relatively rapid decrease
in posterior probability of disease until the probability approaches an asymptote. The
asymptotic probability is reached when the outbreak of disease within the herd or
flock has extinguished and all clinical signs have resolved. In the case of sheep and
beef animals the asymptote is reached relatively slowly as the observation pattern and
probability of detection of clinical signs in a diseased individual are relatively low so,
on average, only a small amount of information is gained each day. In a dairy herd
the close and frequent observation of the animals and rapid appearance of clinical signs
means that in a diseased herd clinical signs will be rapidly detected so most information
is gained in the first few days of observation. Serological surveillance at the end of a
given period of clinical surveillance decreased the time to reach a particular posterior
probability of disease and decreased the asymptotic posterior probability of disease in
sheep and beef animals. In dairy animals there were no significant sensitivity gains by
using serological surveillance.
Figures 6.15 and 6.16 show the asymptotic posterior probabilities for clinical surveil¬
lance alone and clinical surveillance followed by a serological survey at the end of the
clinical surveillance period (i.e. when clinical surveillance has reached its asymptote).
As would be expected the posterior probability is lower with higher final prevalence
(higher Rq) epidemics in beef and sheep groups. In dairy animals clinical observation
is highly effective in all epidemiological scenarios almost instantaneously giving a near
zero posterior probability of disease given no clinical signs are observed. In contrast
in sheep and beef groups serological surveillance gives a marked reduction in posterior
probability of disease, given all animals test negative. Serological surveillance when the
whole group is sampled is particularly effective. Performance of sample based serology
compared to whole herd serology decreases as an adjunct to clinical surveillance in
sparse outbreaks, (i.e. gives a higher posterior probability of disease in sparse outbreak
scenarios)














Days post infection Days post infection Days post infection
Figure 6.14: Selected output from model showing estimated posterior probability of
disease decreasing with time from potential exposure give no clinical signs
are detected (red line). The instantaneous benefits of serological surveil¬
lance are shown with the orange line representing the posterior probability
of disease with time given no clinical signs of disease and a negative serol¬
ogy survey on the date in question. Point (a) is an estimated probability
and date at which clinical surveillance offers no significant reduction in
probability of disease within the tolerance parameter. Point (b) show that
this probability may be achieved (often earlier) by combining serological
surveillance and clinical surveillance. Point (c) shows the improvement in
confidence of disease freedom available by doing serological surveillance
at the date at which clinical surveillance ceases to have benefits. In these
examples the serological surveillance was based on a random sample of
the animals in the group (sample size designed using FreeCalc) and the
prior probability of disease was set to 0.0001. In the case of dairy cattle
the clinical detection is sufficient good to give no gain when serological
surveillance is added — the orange and red lines are coincident.
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Figure 6.15: Asymptotic posterior probability of disease following repeated clinical
surveillance. Shown for each Ro, generation time (base or long), for each
husbandry system and county.
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Figure 6.16: Asymptotic posterior probability of disease following repeated clinical
surveillance with serological surveillance at the end of the period. Shown
for each Ro, generation time (base or long), for each husbandry system
and county. Results are shown for complete animal group sampling and
FreeCalc based sampling.
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Figures 6.18 and 6.17 show summary results of simulations over a range of epidemio¬
logical scenarios, animal types, sampling strategies and demographics. These results
were robust to the tolerance used to determine the asymptote for posterior probability
as discussed in section 6.3.5 so are reported using an asymptote detection tolerance of
1%.
Figure 6.17 shows the relative effect of whole herd/flock sampling versus random sam¬
pling where the random sampling is designed to meet a pre-determined within herd/flock
sensitivity criteria (in this case 95% sensitivity assuming 5% within-group prevalence).
In the high Ro (high final prevalence scenarios) there are no marked benefits to whole
herd sampling. However as final prevalence decreases (still remaining above 5% on
average) there are marked benefits (i.e. reductions in posterior disease probability) to
be gained by sampling the entire group of animals for sero-surveillance. These gains
are slightly greater in sheep flocks in the simulations using Devon based demography
than Surrey based demography. The gains are a consequence of the improved detec¬
tion of low prevalence disease with full group sampling. Full group sampling using a
sensitive test (like the cELISA test used in this simulation study [Paiba et ah, 2004]) is
almost 100% sensitive at a group level as shown in figure 6.16 which shows the absolute
asymptotic performance when serology is performed additionally to clinical surveillance
— probabilities of disease being reduced from a prior of 0.0002 to a posterior of 1 x 10-6.
The figure (6.17) shows the posterior probability of disease reduction obtained by per¬
forming serological surveillance at the end of a period of clinical surveillance. The
absolute value of this reduction will be dependent on the prior probability of disease
chosen. However, the prior probability of disease was found only to influence the
scale of the probability reduction metrics so the results are discussed using the single
prior probability of disease of 0.0002. The posterior probability reduction by adding
sero-surveillance decreased in sheep and beef groups across the eight epidemiological
scenarios as Rq and final prevalence increased (the final prevalences are shown in table
6.6).
Figure 6.18 shows the number of days saved by adding end of period serological surveil¬
lance. Assuming the asymptotic posterior probability of clinical surveillance is a target
performance, this probability can be obtained much earlier in beef and sheep groups
by adding serological surveillance after a shorter period of clinical surveillance. No
significant time is saved in dairy cattle as clinical surveillance achieves low posterior
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probabilities very quickly due to twice daily observation and high detection probabili¬
ties. In beef (non-dairy) groups the saving is approximately 15-30 days (assuming Ro is
2.0) and in sheep flocks approximately 20-33 (assuming Ro is 0.5). The greater saving
in sheep flocks is a consequence of the poorer clinical detection in these groups. Over the
range of Ro scenarios in sheep flocks the time saved increases, at first, with decreasing
final prevalence then decreases over the last two to three scenarios. This effect is consis¬
tent over the range of prior probabilities of disease, tolerances of asymptote detection
and demographic scenarios. This apparently paradoxical effect is a consequence of the
measure used which is, in full, the number of days saved by using serology to achieve
the asymptotic clinical only probability. In the Ro = 0.5 scenario the asymptotic prob¬
ability with clinical surveillance is markedly higher than in the other scenarios. The
asymptote is reached relatively quickly so although serology is still beneficial in these
scenarios the apparent time saved is less.
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Figure 6.17: Estimated estimated reduction in posterior probability of disease in an an¬
imal group by doing sero-surveillance as an adjunct to day-by-day clinical
surveillance assessed at the date after exposure when clinical surveillance
ceases to give significant additional information. Shown for each i?0, gen¬
eration time (base or long), for each husbandry system and county. Re¬
sults are shown for complete animal group sampling and FYeeCalc based
sampling.
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Figure 6.18: Estimated number of days saved to achieve a similar posterior probability
of disease in an animal group by doing sero-surveillance as an adjunct
to day-by-day clinical surveillance. Shown for each R0, generation time
(base or long), for each husbandry system and count}'. Results are shown
for complete animal group sampling and FreeCalc based sampling.
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6.5 Discussion
6.5.1 General discussion
This study has estimated, for a set of scenarios, the daily probability that a group of
animals is diseased given a starting belief and absence of clinical signs during continuous
clinical surveillance. The decrease in the probability, from an assumed time of exposure,
is rapid in the case of milking dairy cattle and markedly slower in the case of non-dairy
cattle and sheep. Traditionally, serology has been considered more important in sheep
than in cattle but these results emphasise that consideration should be given to the
potentially less effective detection in beef animals. The findings in the UK 2007 foot-
and-mouth disease outbreak where, at detection, clinical signs on the index beef farm
were thought to be up to 10 days old [Ryan et al., 2008] reinforce this. The ultimate
probability of disease, given no observed signs, is lower in dairy animals than in other
systems. Serological surveillance by partial or complete blood sampling of the animal
group may be performed at the end of a period of clinical surveillance. In dairy animals
this surveillance does not significantly improve either the ultimate confidence of disease
freedom or the speed with which that confidence is obtained. In non-dairy cattle and
sheep, serological surveillance will give marked improvements in confidence of disease
freedom and/or speed by which a required confidence is achieved. The same confidence
in disease status of a group may be reached approximately 2-4 weeks sooner using sero-
surveillance. The relative benefits of serology are greatest in sparse outbreaks with
poor clinical observation. Such settings will also increasingly reward more thorough
serological surveillance, with sampling proportions greater than the traditional design
requirements.
The decision to undertake serological surveillance in addition to clinical surveillance may
be solely driven by regulatory and political pressures; previously without serological
surveillance an affected country could not regain the status of disease-freedom and
resume international meat and livestock trade. OIE regulations have somewhat relaxed
and now require portfolios of evidence rather than prescriptive survey designs [OIE,
2009b]. It is unlikely that serological surveillance would disappear from such portfolios
but it is efficient to apply serology where it is most beneficial, i.e. where clinical
surveillance is least likely to provide sufficient evidence. This has always been the case
to an extent, this study helps to quantify these benefits.
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The simulation model has only dealt with a single group of animals where it is assumed
that a number of animals are instantaneously exposed at the start of the simulation
period. In a foot-and-mouth disease outbreak post epidemic surveillance will normally
have to consider the more epidemiologically and logistically complex problem of a het¬
erogeneous set of animal holdings which are all at some risk of exposure over a wide
time window. On a farm to farm basis serology will always have the benefit, in non-
dairy animals, of giving a marked improvement in confidence of disease freedom. The
benefit that serology reduces the time to declaring a group of animals disease-free is
harder to quantify in a heterogeneous multiple farm setting. If it is assumed that all
farms are exposed at the start of the post epidemic period the timing improvements
of serology will be similar to those of the single groups used in this study. However
foot-and-mouth disease virus is a challenging pathogen. In the UK 1967 epidemic sev¬
eral farms experienced outbreaks up to six weeks after infection was apparently under
control with no infected individuals [HMSO, 1969, page 41]. In the UK Surrey 2007
outbreak environmental contamination both initiated the outbreak and possibly re¬
sulted in a delayed secondary outbreak some distance from the index infected premises
[Anderson, 2008]. This was assumed to be due to environmental reservoirs of foot-and-
mouth disease virus. Uncertainty about the environmental reservoirs [Alexandersen
et ah, 2003] and 'silent-spread' [Blanco et ah, 2002] of foot-and-mouth disease will add
uncertainty to the precise benefits of serological surveillance. These issues are in part
managed by the regulatory guidelines that require serological surveillance to normally
commence only after a suitable delay (previously 2 months after the last notified case
of foot-and-mouth disease). Whilst this wait period makes it more difficult to precisely
value the time benefits of serology the time benefits are still potentially gained — if
environmental recrudescence effectively exposed a group of animals near to the end
of a 60 day wait period a decision about that group reinforced with prompt serology
potentially has much greater confidence than without it i.e. it is equivalent to waiting
60 days then an additional long period of clinical surveillance alone.
6.5.1.1 Assumptions and limitation
In this analysis I have chosen to only consider surveillance in cattle and sheep. Post
epidemic surveillance in both of the recent UK foot-and-mouth disease epidemics was
mainly an issue in these species. Whilst a poorly managed pig unit was the index farm
of the 2001 epidemic, the disease went on to be largely one of sheep and cows [Gibbens
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et al., 2001]. In areas of intensive pig production pig unit bio-security is high and
epidemiology of disease rapid so clinical detection would be likely to be effective and
rapid. The high value of large scale pig production units combined with the potential
for high volume virus excretion from diseased pigs means that strategic vaccination
combined with rapid culling of infected premises of pig units may be a possible response
in a future epidemic if the strain and location place the pig population at significant
risk [TAIEX, 2007],
This study has not considered surveillance in a vaccinated population. Vaccination
will have marked influences on the precise benefits of clinical and serological surveil¬
lance. Disease in a vaccinated or partially vaccinated population may have markedly
different epidemiological characteristics [Orsel et ah, 2007a]. Vaccination can suppress
clinical signs but may still permit virus replication and excretion [Paton et ah, 2006].
Also serological detection in vaccinated animals will require different non-structural
protein based diagnostic techniques [Sorensen et ah, 1998]. These tests are generally
less sensitive than the c-ELISA test used in un-vaccinated stock. Hence while clinical
and serological surveillance will both still have benefits after vaccination-based control
the relative quantitative value of these benefits may be quite different. More generally,
serology may have additional benefits, even in unvaccinated populations, if a foot-and-
mouth disease strain produces particularly subtle or absent clinical signs in a species
as clinical detection will be relatively less effective.
For modelling and descriptive simplicity I have artificially categorised the study pop¬
ulations into dairy, non-dairy (beef) and sheep. The epidemiological and surveillance
models estimate the surveillance performance in homogenous units. In reality a large
number of farms are mixed (see tables 6.1 and 6.2) and certainly all dairy farms will
have some degree of mixing between milking animals and replacement heifers, dry
(non-milking) cows, calves and bulls. On these farms there may well be epidemiological
mixing such that disease in one class of animal may spread to others. In this setting
there may be a local sentinel effect whereby, for example, a few dairy animals kept in
proximity to a large number of lowland sheep become infected with foot-and-mouth
disease after the sheep flock but will be detected first due to more pronounced clinical
signs and more attentive observation. These effects will be difficult to estimate as on
farm mixing will be highly variable from farm to farm. The overall effect would be
likely to improve clinical detection performance when sheep and cattle are mixed.
Chapter 6 Benefits of Serological Surveillance over Clinical Surveillance 191
On farm management behaviours change markedly throughout the year in the UK
cattle and sheep sectors. Grazing of animals is driven by grass production with, for
example in some systems, beef stock being moved from more remote pastures to indoors
housing for the winter months. The sheep industry is not homogenous with lowland
and highland sectors and extensive movement between pasture types throughout the
farming year. These movements mean that clinical observation of each animal type
will be highly contingent on the system and time of year when an epidemic strikes. It
is possible that these influences are partially self compensating; from an onwards risk
perspective, although clinical surveillance in extensively grazed hill sheep will be very
poor the scale of epidemics and onwards risk of infection to other systems will be low.
The serological detection model required estimates of day by day sensitivity of the
cELISA diagnostic test. The smoothing model used gives a small but non-zero sensi¬
tivity for the diagnostic test in the first few days after exposure. The results reported
use this model, setting the first two day's sensitivity to zero did not make a significant
change to the results. Also, in the model, the test was considered to have a specificity
of 100% i.e. there was a zero probability of classifying a herd as diseased if none of
the sampled animals were diseased. In reality all diagnostic tests will produce some
false positive results, whilst these results in themselves are diagnostically wrong they
do have the paradoxical side-effect of increasing herd level sensitivity of a serological
survey; i.e. a herd that is diseased may be flagged as diseased despite no animals with
disease being tested. The same is particularly true of clinical surveillance where there
are anecdotal reports of false positive results during the control phases of the UK 2001
epidemic. These results if thoroughly followed up with expert investigation and further
testing will increase the performance of the surveillance system but at potential consid¬
erable cost due to consumption of resources in the investigation potentially uninfected
farms.
When herds or flocks are blood sampled for serological surveillance the procedure will
inevitably involve close contact with the livestock. Hence there is a possibility of in¬
creased rates of clinical detection during serological surveillance. For the purposes of
analysis I have assumed this effect is negligible. In practice it may slightly increase
the benefits of serological surveillance when this is considered as a whole procedure
involving sampling and serological testing.
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In this study the detection systems are simply classified into clinical and serological.
Clinical detection will include visual and physical examination with perhaps the so¬
phistication of milk production measurements. Current research elsewhere is exploring
other modalities of detection. As these are introduced it would probably be necessary
to reclassify the approach used in my study into continuous and one-off surveillance.
For example the use of thermal imaging cameras [Rainwater-Lovett et ah, 2008] al¬
lows veterinary officers to visit a farm and identify animals with higher that normal
body/peripheral temperature areas as an early indication of clinical disease. Thurmond
and Perez [2006] model the use of bulk milk tank based detection systems with pooled
analysis of daily samples from dairy farms. Other longer term ideas include the use
of low cost embedded or ruminal temperature measuring probes that provide teleme¬
try back to the farm reporting an almost continuous record of body temperature. The
former thermal imaging observation may be used in a functionally similar way to a sero¬
logical survey — it takes place on a single occasion and provides a single opportunity
for detection. The temperature telemetry approach is more akin to clinical surveillance
where, with suitable analysis algorithms, it provides a continuous opportunity for a
disease alert trigger.
6.5.1.2 Concluding remarks
The simulation model has suggested, within the outbreak scenarios used, that serology
only has significant benefits in sheep and non-dairy settings. Serology at the end of a
period of clinical surveillance can be used to either markedly increase the sensitivity
of disease detection in the group or to bring detection (to a predetermined thresh¬
old) forward by perhaps 15-33 days. Serology is relatively more beneficial in sparse
epidemics with a low Rq and low final prevalence, such as upland sheep flocks, partic¬
ularly if applied to whole groups rather than small random samples. It also detects
historical infection more effectively than clinical surveillance, antibodies persist long
after foot-and-mouth disease lesions have healed.
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6.6 Appendix 1 — Formulation of JAGS model to estimate
cELISA test sensitivity
Pi ~ dnorm(/Xj, Ti
Hi
Ti ~
= A + (B-A)/(l + ec<D~t^) > 1 < i <
exp(E + F ■ ti + G ■ ff)
A rsj dgamma(l, 0.01)
B ~ dgamma(l, 0.01)
C ~ dgamma(l, 0.01)




Hi,j = A + (B-A)/( l + ec<D-fi)
n,j = exp{E + F ■ j + G ■ j2)
psim:j ~ dnorm(/rij, rij)
psim1* j = psiml j- — cutoff
sej = step(psim1* j)
> 1 < j < Nt
6.7 Appendix 2 — Transmission data from literature
1 — Young calves Karin Orsel [Orsel et al., 2005]
8-10 week old Holstein calves housed in free mingling groups
Challenged with O/NET/2001 [Bouma et ah, 2004]
Two each out of generally four calves inoculated with virus
Four fold increase in VN titre or clinical signs or PCR or NS-ELISA was diagnostic test
for foot-and-mouth disease
Experiment ended at 30 days post infection
Used final size analysis to estimate Ro by MLE
Vaccinated calves — Rv 0.18 (0.01-1.2)
Unvaccinated calves — Rq 2.52 (1.13-52.1)
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2 — Dairy cows Karin Orsel [Orsel et al., 2007a]
Two groups of 10 Holstein-Fresian dairy cows (2,3, and 4th parity 50-120 days post
partum) (in unvaccinated experiment)
Random milking routine and normal bio-security for milkers
Challenged with O/NET/2001 [Bouma et ah, 2004]
5 cows inoculated in each group of ten
Experiment lasted 31 days
Four fold increase in VN titre considered diagnostic
Used final size analysis to estimate Rq by MLE
Odd estimates from analysis - see paper - dependent on assumption of infectiousness
of inoculates
All contacts became infected after exposure to the inoculates in unvaccinated animals.
No transmission occurred to vaccinates.
Rv estimates were 0 for vaccinates and oo
for unvaccinated cows.
3 — Lambs Karin orsel [Orsel et al., 2007b]
52 weaned lambs — 10 weeks old
Assigned to 13 groups of 4. Two lambs per four were foot-and-mouth disease inocu¬
lated.
Four fold VN titre increased used as diagnosis.
Experiment ran for 30 days.
GLM as per Klinkenberg [Klinkenberg et ah, 2002] to estimated (3
Also estimated infectious period
/3 in unvaccinated lambs 0.105 per day (0.044 - 0.253)
T estimated as 21.1 (10.6 - 42.1)
Hence R as 2.22 (0.46 - 4.33)
In vaccinated lambs limited data but final size estimate of Rv as 1.14 (0.3 - 3.3)
4 — 1000 dairy cow simulation model [Carpenter et ah, 2004]
5 — Sheep [Streftaris and Gibson, 2004] Two experiments of 32 sheep each.
Sheep in groups of 8
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Naturally infected sheep used for parameter estimates
Bayesian estimates of parameters of SEIR model
Experiment 1
p 0.024 (0.005-0.048)
latent period 1.599 (0.440-1.507)
Experiment 2
(3 0.020 (0.004-0.063)
latent period 1.937 (0.836-3.403)
No record of infectious period estimates
6 — Cattle [Bankowski et ah, 2008] Four animal experiments using Holstein cattle.
Donor and recipient animals used to estimate latent period and infectious period.
Latent period:
Overlap method: Median 53.33 hours (95% interval 42.35-71.86) Entire period method:
Median 68.75 hours (95% interval 58.15-86.80) Infectious period: 106.99 hours (95%
interval 40.34-232.41)
7 — Cattle and small ruminants [Mardones et ah, 2008] Systematic review and
modelling of disease stage duration.
Incubation period:
Cattle: 6.1 days
Small ruminants: 4.7 days
Infectious period:
Cattle: 5.9 days
Small ruminants: 2.8 days
Latent period:
Cattle: 1.8 days
Small ruminants: 2.0 days
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6.8 Appendix 3 — Summary of interviews
Interviews were conducted with a sheep clinician/lecturer [Scott, 2008], a practising
sheep clinician (Black, David. Personal communication August 2008), a lecturer in ani¬
mal husbandry [Hodgson-Jones, 2008], a farm manager [Aitchison, 2008b] and shepherd
[Aitchison, 2008a]. The points made are listed in the following sections. These points
represent a summary of the interviews and in some case provide contradictory opinion.
6.8.1 Sheep
1. Sheep farmers are required to examine their stock on a daily basis
2. Hill flocks may actually only be examined with an interval of one week to several
months.
3. Sheep are inspected by shepherds during supplement feeding or maintenance ac¬
tivities
4. Inspection is more frequent during lambing, dipping and shearing.
5. When a flock is examined only some animals maybe seen due to wide spatial
dispersion.
6. In a post epidemic setting a government vet would probably inspect on weekly
basis.
7. During the UK 2001 epidemic veterinary inspections were daily
8. Veterinary officers rarely visited farms after the epidemic unless alerted by the
stock keepers or if they were in a high risk area.
9. During the UK 2001 epidemic some hill flocks were gathered and brought down
to lowland pastures for increased surveillance however there were concerns that
this activity could increase the risk of flock exposure to foot-and-mouth disease
and subsequent within-flock transmission.
Chapter 6 Benefits of Serological Surveillance over Clinical Surveillance 197
6.8.2 Cattle
1. Milking dairy cows will be observed at relatively close distance at least twice daily.
2. Dairy farmers will generally know milking cows individually and will be highly
likely to identify signs of clinical disease.
3. Current milking machine have the capacity to detect a drop in milk yield and
alert the stockman to the problem in an individual cow.
4. Dry-cows (not milking), bulls, calves and heifers (not milking) will be observed
at least once a day.
5. Beef cattle are observed less frequently than dairy cattle except during the calving
season. They would normally be observed once a day when housed in the winter
and every few days when outside during the summer.
6. Suckler cows are observed at least once a day during feeding.
7. In a post epidemic setting the government veterinary officers would rarely visit
unless alerted by the stockholder.
8. When a group of beef animals or non-milking dairy animals is observed most
(approximately 70%) of the group would be observed.
Chapter 7
Discussion
Demonstration of disease freedom after a disease outbreak or period of endemic dis¬
ease is important; without it regions and countries will often remain internationally
isolated in livestock and animal product trade. However the design of post epidemic
surveillance systems is complex, being contingent on the epidemiology of the disease,
including its control, the diagnostic test systems available to detect it, the structure and
management of the livestock population and the required levels of confidence needed to
satisfy stake-holders. Only an instantaneous survey of all livestock in a region with a
perfect test can give an unconditional and certain diagnosis of the presence or absence
of disease in a population. Real world surveillance systems will always use sampling
strategies with probabilistic interpretation of results where diagnostic accuracy of the
surveillance system is balanced against the overall cost of implementing the system. In
chapter 2, I proposed a targeted or risk based strategy for surveillance system design
that aims to reduce the time and resource cost of implementing a surveillance system
whilst maintaining a nominated level of diagnostic performance. Selection of sampling
units based on mathematical-model, statistical-empirical or expert-based estimates of
risk of infection will, if the models are generally predictive, save time and money. Re¬
cently, Williams et al. [2009a,b] also consider targeted surveillance using simulation
studies and an example scenario of scrapie in sheep. Their work further highlights po¬
tential benefits whilst reinforcing the points that targeted surveillance is more suitable
for the detection and estimation of prevalence in low prevalence settings than for the
estimation of prevalence and clustering in higher prevalence settings. Targeted surveil¬
lance is dependent on good models of disease. Good models are those that estimate
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risk of disease presence in sampled units with relatively low bias and ideally with useful
precision. The results in chapter 2 suggest that the benefits of targeted surveillance
are, however, relatively robust to model errors though better models will give greater
savings with a lower risk of poor survey performance. Targeted surveillance represents
an application of mathematical epidemiological modelling in disease control somewhat
removed from its previously contentious application in directing efforts at prevention
and control but still with potentially great benefits.
Exploring the application and design of animal disease surveillance systems is hindered
by the infrequent and episodic occurrence of epidemics and the limited availability of
the resulting surveillance designs and data. Access to the ongoing foot-and-mouth
disease surveillance work in Thrace, Turkey provided an opportunity in chapters 3
to 5 to estimate the performance of the current approach and to apply a Bayesian
methodology to estimate disease epidemiology and test performance from the available
survey data-sets.
The simulations in chapter 3 suggest that the classical, two stage, sampling strategy is
sufficiently sensitive to detect disease under a range of design epidemiological scenarios
to satisfy international trade regulations. However two challenges remain with this
approach:
Firstly the imperfect specificity of the current, non-structural protein based, diagnostic
tests potentially results in a large number of false-positive animal test results. These
results then require further confirmatory testing which delays final results, increases
costs and reduces the overall surveillance system sensitivity. These effects are made
worse in a vaccinated population where repeated vaccination may increase the rate of
false positives.
Secondly the estimate of adequate performance assumes that foot-and-mouth disease
will be present at a 'design' prevalence of 5% as per previous OIE regulations for
demonstration of disease freedom. In a vaccinated population with good vaccination
coverage disease prevalence may ultimately be much lower. For example, a model
by Arnold et al. [2007] suggests that in a reactively vaccinated population foot-and-
mouth disease carrier herds may be present at about 0.2% and would therefore require
census based sampling to adequately detect disease. Thus as a region like Thrace
moves by vaccination and other control measures towards disease freedom it may be
necessary to adjust serological surveillance techniques and use a wider range of evidence
Chapter 7. Discussion and Concluding Remarks 200
sources to adequately demonstrate freedom from disease. An alternative, as adopted
in South America, is to aim to cease vaccination in order to declare disease freedom,
permitting more liberal trade and easier demonstration of freedom by sero-surveillance
— on the basis that if foot-and-mouth disease were present full-blown outbreaks would
be observed.
In chapters 4 and 5 I explored the Thrace surveillance data and made inferences about
disease epidemiology and diagnostic test performance. Whilst disease freedom data
sets may be used to inform these estimates, the overarching conclusion has to be,
particularly with uncertain test performance data and the issue of vaccination related
false positives, that estimates of disease prevalence from these data sets are vague with
wide credible intervals. This is a consequence of the relatively low information content of
the survey for the number of parameters being estimated and the issue of identifiability;
it is difficult to jointly estimate, for example, diagnostic test sensitivity and disease
prevalence without suitable informative prior information for these parameters.
The Bayesian approach does, though, have definite advantages over the more classi¬
cal, frequentist interpretation of disease freedom surveys. As a region moves towards
disease freedom the probability of disease in the region and group (e.g. village) level
prevalence may be tracked to identify trends and improvements. The scenario-tree
based methodology of Martin et al. [2007b] explicitly uses Bayes theorem to update
previous estimates of the probability of disease with the results from new surveys. Also
the OIE phyto-sanitary measures agreement [World Trade Organisation, 2008] requires
that international trade of livestock and animal products are only restricted on the ba¬
sis of scientifically identified asymmetries of risk. Bayesian analysis provides estimates
of prevalence which may inform quantitative risk models providing finer grained infor¬
mation than classical disease freedom present/absent models.
Surveillance to gain or regain the status of disease freedom does not depend on sero¬
logical studies alone; clinical evidence based on observation of a region's livestock is
considered an important component but its relative merits are poorly defined. Chapter
6 identified the benefits of serological surveillance relative to clinical surveillance in
a range of post-epidemic settings. As with all post-epidemic surveillance the perfor¬
mance of the surveys is contingent on the underlying disease epidemiology. Serological
surveillance is at its most useful in production systems with otherwise low rates of
observation of stock. Clinical surveillance, as it is present to a degree in all animal
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holdings, provides a good surveillance system method when clinical disease is obvious
and has a relative advantage over probability-sample based sero-surveillance when dis¬
ease is sparsely clustered. Serological surveillance will detect subtle disease but only
when it is relatively widespread unless sampling is of a high density. The conclusions
from chapters 2 and 6 suggest that surveillance, given that suitable models of disease
exist, may be designed both in modality (clinical versus serological) and location (us¬
ing risk models) to give most efficient application of resources to providing prompt and
accurate decisions about disease status. Cannon [2009] provides a theoretical overview
of different disease detection and estimation methodologies considering efficient use of
resources. The article raises the important question that if we are to design surveys
efficiently we have to do this with respect to some measure, an objective function,
which may be cost, farms visited, samples taken or otherwise. Economically efficient
approaches and a careful definition of aims and objective criteria will become increas¬
ingly important if cost allocation of animal health moves, as is predicted [Alder, 2008],
towards the producer rather than the state.
While serological surveillance is likely to continue to be an important and necessary
component of post epidemic surveillance it is important to remember that it is only
one piece of a more complex system that collectively helps protect the disease status
of a region's livestock. This larger system includes good farming practices that reward
a high standard of animal health, appropriate biosecurity measures both in periods
of disease freedom and during epidemics and rapid and appropriate responses to new
epidemics limiting spread and impact and thus limiting the magnitude of subsequent
post-epidemic surveillance tasks. The hazard analysis critical control point (HACCP)
based approach of focusing on the high importance/visibility components of animal
production pathways may be as important as population based sampling in limiting
onwards disease risk in outbreak or epidemic events.
There continue to be further advances in analysis and techniques surrounding post-
epidemic surveillance. Past advances have been both theoretical, such as methodologies
of sample size calculation and evidence synthesis using scenario trees, and in diagnos¬
tics techniques such as the development of non-structural protein based diagnostic tests
capable of differentiating between vaccinated and previously infected animals. Future
developments may continue along the same threads. Increased computational speeds
permit simulation based methods allowing further extensions of risk based survey tar¬
geting and Bayesian estimation. New models allow real time estimation of epidemic
Chapter 7. Discussion and Concluding Remarks 202
parameters and prediction of high risk premises [Jewell et al., 2009a,b]. The devel¬
opment and parameterisation of these complex, individually based, models of disease
transmission can be used alongside suitable mechanistic and economic models of the
surveillance process to permit countries and regions to regain the status of disease-
freedom optimally — balancing costs and delays against the vital confidence in the
process needed to reassure stockholders, animal health workers, trading partners and
governments.
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